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Synaptic degeneration is currently the best biomarker correlate of cognitive decline in 
dementia. In the years prior to dementia onset, many neurophysiological changes are 
occurring hypothesised to preserve cognitive function, including alterations in synaptic 
and neuronal function. This thesis aims to characterise the early synaptic and 
neurophysiological alterations occurring in a mouse model of tauopathy-driven 
neurodegeneration (rTg4510). This work was performed in the somatosensory cortex, 
a well characterised region of the brain in the mouse, which serves as a prototypical 
model of the neocortex.  
The work presented in Chapters two and three revealed alterations in synaptic 
glutamatergic receptor function (reduced NMDA:AMPA receptor ratio) and intrinsic 
neuronal properties in prodromal tauopathy in rTg4510 mice, using in vitro whole-cell 
patch clamp electrophysiology. Increased dendritic branching proximal to the soma 
was seen in these recorded neurons following post hoc imaging of their structure. In 
more advanced stages of tauopathy, reductions in putative AMPA receptor-mediated 
spontaneous synaptic activity was observed. Significant reductions in glutamatergic 
receptor expression and synaptic markers was detected in both prodromal and more 
advanced tauopathy, quantified from isolated synaptosomes.  
To characterise how glutamatergic receptor dysfunction manifested in vivo, recording 
paradigms were optimised for in vivo two-photon targeted whole-cell patch clamp 
electrophysiology, outlined in Chapter four. This technique was used to simultaneously 
record subthreshold synaptic properties, network activity, and evoked synaptic 
responses in the rTg4510 model in early neurodegeneration in Chapter five. Whilst 
spontaneous network activity was similar between genotypes, there was an 
observable increase in the fast peak response of evoked activity.  
This work suggests that synaptic dysfunction is a feature of both prodromal and 
advanced tauopathy, with different functional and biochemical correlates manifesting 
at different stages of disease progression. Further characterisation of these 
processes, and how this contributes to symptomatic decline, can provide a basis to 
develop novel therapeutic strategies to alleviate tau-mediated synaptic and neuronal 
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1 GENERAL INTRODUCTION 
1.1 DEMENTIA 
Dementia is a clinical syndrome, characterised by substantial deterioration of one 
or more cognitive domains such as a decline in executive function, learning and 
memory, and social cognition (American Psychiatric Association, 2013; Hugo and 
Ganguli, 2014). There are an estimated 50 million cases worldwide, projected to 
increase to 152 million cases by 2050 (Alzheimer’s Association, 2020; Prince, 
2015). It was the 5th leading cause of death in the world in 2016 and causes 
unprecedented socioeconomic impact, with an estimated cost to society of £26 
billion a year in the UK alone (Alzheimer’s Association, 2020; Prince, 2015; Prince 
et al., 2013, 2014).   
The biggest cause of dementia is Alzheimer’s disease (AD) which accounts for 
60-80% of cases (Alzheimer’s Association, 2020). There are however, multiple 
other forms of dementia including but not limited to: vascular dementia, dementia 
with Lewy bodies, frontotemporal dementia (FTD) (Bang et al., 2015; O’Brien and 
Thomas, 2015; Walker et al., 2015). A common pathological feature of 
dementias, which are typically caused by neurodegenerative diseases, is the 
association with abnormal aggregation of a subset of proteins in the brain which 
can be used to confirm diagnosis post-mortem (Irvine et al., 2008; Lovestone and 
McLoughlin, 2002).  
1.1.1 Alzheimer’s Disease 
AD is a progressive neurodegenerative disease which affects approximately 1 in 
3 people over the age of 65 (Alzheimer’s Association, 2020; Herrup, 2015; Prince 
et al., 2014). The majority of cases (~99%) of AD are sporadic, with the greatest 
risk factor for AD being advanced age. The remainder are familial forms of AD 
(~1%) that are associated with genetic mutations in the amyloid precursor protein 
(APP) gene, and those that influence APP processing and cleavage 
(PSEN1/PSEN2) (Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell et al., 
1991; Randall et al., 2010; Tanzi and Bertram, 2005). The discovery of causal 
genetic mutations in the APP gene, led to the idea that amyloid was crucial in AD 
pathogenesis (St. George-Hyslop et al., 1987; Glenner and Wong, 1984; Levy et 
al., 1990; Tanzi and Bertram, 2005). This idea influenced the amyloid cascade 




was a causative pathological driver of AD, with the ensuing pathological cascade 
formed as a direct consequence of this deposition (Hardy and Higgins, 1992). 
Whilst a lot of research and disease modifying treatments have focussed on this 
hypothesis, targeting amyloid deposition, no effective therapeutics have been 
discovered to date (Hardy and Higgins, 1992; Herrup, 2015; Karran et al., 2011).  
AD has two core neuropathological hallmarks, amyloid plaques and 
neurofibrillary tangles (NFTs) (Alzheimer, 1911). These neuropathologies are 
evident early in the pathological timeline of the disease, and accumulate in a 
stereotypical and progressive fashion (Alzheimer, 1911; Braak and Braak, 1991; 
Montine et al., 2012; Figure 1.1). Amyloid protein aggregates, known as amyloid 
plaques, accumulate within the brain approximately 10-15 years prior to 
symptomatic onset (Jack  Jr et al., 2009; Villemagne et al., 2013; Figure 1.1). The 
second neuropathological hallmark are NFTs, formed of aggregated tau proteins, 
which is common to multiple dementias known as tauopathies (Braak et al., 2011; 
Grundke-Iqbal et al., 1986). The emergence of NFTs in the brain occurs 3-5 years 
prior to symptomatic onset, and this correlates well with synaptic and neuro- 
degeneration in AD and other dementia spectrum diseases (Bejanin et al., 2017; 
Vogel et al., 2020; Figure 1.1). The role of tau in the pathogenesis of AD has been 
emphasised within the past 10 years, with significant evidence now suggesting 
that tau accumulation is a key pathological driver of AD and other tauopathies 
(Busche et al., 2019; DeVos et al., 2018; Iqbal et al., 2010; Ittner and Götz, 2011; 







Figure 1.1 Alzheimer’s disease: A timeline of the onset of pathological 
changes and progression within the brain. Lines represent the state of 
pathological changes that occur within the brain (y-axis) with symptomatic 
impairment denoted on the x-axis. Amyloid pathology appears early in the brain 
(10-15 years prior to symptomatic onset), denoted as a red line. Tau pathology is 
next detectable (3-5 years prior to symptomatic onset), denoted as a blue line. 
Structural changes such as synaptic and neuro- degeneration occur in parallel 




Tauopathies are a group of neurodegenerative diseases characterised by 
abnormal tau protein inclusions within neurons or glia (Kovacs, 2015; Orr et al., 
2017). Familial forms of tauopathy are caused by mutations within the 
microtubule associated protein tau (MAPT) gene, which encodes the tau protein 
(Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998). One form of 
familial tauopathy, frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17), presents with severe behavioural deficits, dementia, 
and is accompanied by a parkinsonian syndrome (Foster et al., 1997). Brain 
autopsies performed on these patients revealed frontotemporal atrophy with the 
presence of tau inclusions (Foster et al., 1997). Causal missense mutations, such 
as the P301L mutation, were identified within the MAPT gene in FTDP-17 
(Hutton, 2001; Hutton et al., 1998; Wilhelmsen et al., 1994). This indicated that 
mutations in the MAPT gene were sufficient to cause the formation of tau 




pathology influences neurophysiological dysfunction, and synaptic and neuro- 
degeneration, is still a vital unanswered question in dementia research.  
1.1.3 Tau 
Tau is one of the major microtubule-associated proteins, encoded by the MAPT 
gene on chromosome 17 (Barbier et al., 2019; Weingarten et al., 1975). Six tau 
isoforms are detectable in the adult human brain, generated from alternate 
splicing of exon (E) 2, E3, and E10 regions of MAPT (Andreadis, 2005; Andreadis 
et al., 1992; Goedert et al., 1989). Alternate splicing of E10 results in tau isoforms 
which contain three (3R) or four microtubule binding repeats (4R), with differential 
and balanced expression of these two groups of isoforms found in normal 
physiology (D’Souza and Schellenberg, 2005; Liu and Gong, 2008). 
Dysregulation of balanced 3R/4R isoform expression has been implicated as a 
pathogenic mechanism in several tauopathies (D’Souza and Schellenberg, 2005; 
Liu and Gong, 2008). 
1.1.3.1 The physiological function of tau 
Tau is predominantly expressed in the axons of neurons following maturation, 
with some expression in other non-neuronal subtypes including oligodendocytes 
(Binder et al., 1985; Lopresti, 2002; Lopresti et al., 1995). The main physiological 
function of the tau protein is the stabilisation of microtubule bundles in axons 
(Barbier et al., 2019; Black et al., 1996; Weingarten et al., 1975; Witman et al., 
1976). However, recent work has found that endogenous tau is also present in 
dendrites and dendritic spines, and interacts with PSD95 at post-synaptic sites 
(Mondragón-Rodríguez et al., 2012; Xia et al., 2015). Endogenous tau may 
therefore facilitate normal synaptic function. For example, there is evidence that 
tau participates in structural reorganisation of dendritic spines following synaptic 
plasticity (Chen et al., 2012; Frandemiche et al., 2014). This suggests that tau 
plays diverse physiological roles in both axonal and dendritic neuronal 
compartments, and is directly involved in normal synaptic physiology.  
1.1.3.2 Tau pathology 
The degree by which tau promotes microtubule assembly and stability in normal 
physiological conditions is regulated by post translational modifications such as 
phosphorylation (Binder et al., 1985; Lindwall and Cole, 1984; Mandelkow et al., 
1995). Tau phosphorylation promotes the dissociation of tau from microtubules, 




as a precursor to the accumulation of tau aggregates (Alonso et al., 1994; Iqbal 
et al., 2005; Kopke et al., 1993; Lindwall and Cole, 1984). Abnormal 
hyperphosphorylation is also thought to promote the mislocalisation of the tau 
protein, with these hyperphosphorylated tau species found missorted to the 
somatodendritic compartment including within synapses (Hoover et al., 2010; 
Sohn et al., 2016).  
Following abnormal hyperphosphorylation, tau undergoes conformational 
changes prior to self-assembly into insoluble filaments (Serrano-Pozo et al., 
2011). These filaments eventually aggregate together to form NFTs (Serrano-
Pozo et al., 2011). Markers are used to determine the stage of tau pathology, with 
antibodies such as AT-8 targeting hyperphosphorylation of specific tau epitopes, 
and MC-1 detecting a conformational change in the structure of tau equivalent to 
an early pre-NFT stage (Goedert et al., 1995; Jicha et al., 1997). For the more 
mature, fibrillar NFTs, Thioflavin-S (ThioS) can be used to detect the β-pleated 
sheet structure of filaments or silver impregnation methods such as the Gallyas 
technique can be used for the argyrophilic inclusions (Braak and Braak, 1991; 
Braak et al., 2006; Serrano-Pozo et al., 2011). The different stages of tau 
pathology from early pre-NFT pathology to mature and fibrillar NFTs are thought 
to play different roles in the pathophysiology of tauopathies (Brunello et al., 2020; 
Dujardin et al., 2018; Spires-Jones et al., 2009). 
1.1.4 Animal models of dementia 
Historically, the most commonly used experimental models of dementia are 
transgenic mice that overexpress familial disease-associated mutations, which 
leads to the development of neuropathological inclusions seen in the disease 
(LaFerla and Green, 2012; Mullane and Williams, 2019). The generation of 
tauopathy models, typically by the expression of tau mutations, develop NFTs 
with associated neuronal dysfunction and degeneration (Götz and Ittner, 2008). 
These models also recapitulate other aspects of tauopathies such as 
neuroinflammation and synapse loss (Götz and Ittner, 2008).  
However, these models suffer from random integration of the transgene, either 
with inappropriate transgene disruption following insertion, overexpression 
effects, or other artificial phenotypes (Gamache et al., 2019; Goodwin et al., 
2017). This has led to difficulties in concluding whether the various phenotypes 




become the focus for the next generation of models, which express the transgene 
in a targeted manner to attempt to produce a more physiologically relevant model 
with less artifacts (Saito et al., 2014, 2019). Some of these newer models show 
limited disease phenotypes and so irrespective of artifact, the model should be 
chosen that best fits the experimental hypothesis and disease state in question. 
1.1.4.1 Mouse models of tauopathy 
Recapitulating tauopathy in mice is not simple as adult mice only express the 4R 
isoform of tau, compared to balanced 3R/4R expression found in humans. 
Interestingly, overexpression of all six isoforms of human tau in mice lacking 
mouse tau (knock-out (KO) for mouse tau) leads to the formation of pre-NFT tau 
pathology (Andorfer et al., 2003). Overexpression of mutations from familial 
tauopathies develop more mature NFT pathology and neurodegeneration. For 
example, the P301S mouse model overexpresses the P301S mutation found in 
FTDP-17, and develops progressive age-associated tau pathology and 
neurodegeneration (Allen et al., 2002). A novel tauopathy model, the tau knock-
in model, has attempted to overcome some of the mutant overexpression issues 
by direct and targeted replacement of the MAPT mouse gene with the human 
variant which is expressed at physiological concentrations (Saito et al., 2019). 
Other tauopathy models have been generated by infusing pathological species 
of tau into the mouse brain, to investigate the transsynaptic spread of tau (Ahmed 
et al., 2014; Clavaguera et al., 2013; Falcon et al., 2015). Whilst these models 
have been informative on the mechanisms of propagation of tau pathology, these 
models tend not to develop insoluble NFTs, and the pathology within these 
models is insufficient to induce neurodegeneration (Götz et al., 2018).  
1.1.4.2 The rTg4510 model of tauopathy 
The model used for the work in this thesis was the rTg4510 mouse model of 
tauopathy, generated in 2005 (Ramsden et al., 2005; SantaCruz et al., 2005). 
This bitransgenic model is generated by the crossing of two genetically modified 
mouse lines. The responder 4510 line carries a tetracycline operon-responsive 
element upstream of cDNA with encodes mutant human MAPTP301L on an 
FVB/NJ background. This is crossed with an activator line which expresses a 
tetracycline-controlled transactivator under the control of the calcium 
(Ca2+)/calmodulin kinase II α promoter on a 129S6 background. This leads to 




doxycycline treatment (Bailey et al., 2014; Blackmore et al., 2017; Ramsden et 
al., 2005; SantaCruz et al., 2005). Mutant transgene overexpression can be up 
to 13x the amount compared to typical murine tau expression (Ramsden et al., 
2005; SantaCruz et al., 2005). Recently, it was suggested that transgene 
insertion lead to insertion deletion artifacts at the site of insertion, disrupting a 
number of genes important for synaptic and neuronal development (Gamache et 
al., 2019; Goodwin et al., 2017). However, in comparison with other models 
including the more recent knock-in models, the rTg4510 model develops a robust 
and rapid neurodegenerative phenotype associated with tau pathology 
development. Therefore, for the experimental hypothesis tested within this thesis, 
this model better recapitulates some of the key aspects of interest. However, with 
the limitations of the model, conclusions drawn should be interpreted cautiously, 
with the appropriate transgene controls used when possible.  
The rTg4510 mouse model recapitulates some of the key neuropathological 
aspects of tauopathies including the manifestation of progressive age-associated 
tau pathology and neurodegeneration. Hyperphosphorylated tau is detectable 
from ~2.5 months of age, progressing to more mature NFTs at around 4-6 months 
of age (Blackmore et al., 2017; Ramsden et al., 2005; SantaCruz et al., 2005; 
Spires et al., 2006; Figure 1.2 A). One key feature of this model is the appearance 
of progressive and dramatic neurodegeneration which occurs between 6-7 
months (Ramsden et al., 2005; SantaCruz et al., 2005; Spires et al., 2006; Figure 
1.2 B), which is not seen in many other models of tauopathy. Interestingly, the 
pathological tau burden and neurodegeneration develop heterogeneously 
throughout the forebrain, with phenotypes emerging later in the cortex than in the 
hippocampus (Blackmore et al., 2017; Harrison et al., 2020; Ramsden et al., 
2005; SantaCruz et al., 2005). Therefore, this model can provide invaluable 







Figure 1.2 The rTg4510 mouse model of tauopathy. A pathological timeline 
across ages in the rTg4510 model is shown in panel A, marking the age of 
detection of different tau pathologies and neurodegeneration onset. A photograph 
of the gross anatomy of the brain is shown in B, demonstrating the severe 
neurodegeneration seen at 10 months in the forebrain in comparison to a wild-
type mouse brain at the same age. Two-photon images show the progressive 
loss of dendritic spines and axonal terminal boutons seen in the model (C), 
quantified with age (D). Abbreviations: M = months, W = weeks. Figure A & B is 
adapted from SantaCruz et al., 2005, Figure C is adapted from Jackson et al., 
2017, Figure D is adapted from Jackson et al., 2020. 
 
Alongside the development of pathology, neurophysiological dysfunction is 
evident in the rTg4510 model. There was a reduction in network activity 
(measured by imaging spontaneous Ca2+ transients) and changes in neuronal 
excitability (measured using whole-cell electrophysiology) prior to 
neurodegeneration in the rTg4510 model, suggesting that tau overexpression 
alone can alter neurophysiological function (Busche et al., 2019; Crimins et al., 
2012; Hatch et al., 2017; Jackson et al., 2017; Menkes-Caspi et al., 2015). 
Interestingly, some functional domains, such as visual processing in the visual 




2014). This implies that some pathways may be more resilient to the 
pathophysiological changes occurring in tauopathy and neurodegeneration. 
In addition, there are demonstratable alterations in synapse number, function, 
and structural plasticity in the rTg4510 model. Specifically, synapse density was 
decreased in early neurodegenerative phases of tauopathy, with a skew towards 
transient synaptic structures compared to more stable ones (Crimins et al., 2011, 
2012; Kopeikina et al., 2013a, 2013b). Synapse stability was also altered, with a 
transient increase in dendritic spine turnover followed by progressive spine loss 
prior to neurite and neuro- degeneration (~5.5M of age) (Jackson et al., 2017, 
2020; Figure 1.2 C & D). Together, this suggests the model displays a synaptic 
phenotype in early neurodegenerative phases of tauopathy that may mimic that 
seen in the disease. 
Therefore, the rTg4510 model was selected to examine synaptic and 
neurophysiological function at an age point equivalent to prodromal tauopathy. 
There are potentially transient and homeostatic functional changes at this age 
point that could account for observed deficits in cellular and network function prior 
to the emergence of frank neurodegeneration. These changes were investigated 
in a tractable and prototypical model of the neocortex, the somatosensory cortex.  
1.2 THE MAMMALIAN NEOCORTEX 
The outer most layers of the cerebral hemispheres, known as the neocortex, are 
involved in higher level function including sensory perception and integration, 
complex behaviours, and memory formation and preservation (Ghazanfar and 
Schroeder, 2006; Harris and Shepherd, 2015; Kandel et al., 2000). There is a 
striking degree of similarity across the neocortex with respect to its’ 
cytoarchitecture, microcircuitry, and reciprocal subcortical connectivity (Harris 
and Shepherd, 2015; Lübke and Feldmeyer, 2007; Mountcastle, 1997).  
The neocortex is organised into cortical columns, perpendicular to the pia, which 
are formed of six horizontal layers of cells based on the laminar structure within 
the cytoarchitecture (Brodmann, 1909; Heimer, 2012; Mountcastle, 1957, 1997). 
These cortical columns are thought of as discrete functional units, with cells within 
a column sharing similar properties such as receptive field tuning (Hubel and 




proposed to increase the efficiency of complex cognitive computations (Harris 
and Shepherd, 2015; Lübke and Feldmeyer, 2007).  
The canonical cortical circuit describes the flow of excitatory information within 
these columns, first described in the visual cortex (Douglas and Martin, 1991; 
Douglas et al., 1989, 1995). Whilst recent evidence suggests some subtle 
regional differences, the basic principles seem to be conserved and extend 
across cortical areas (Capone et al., 2016; Harris and Shepherd, 2015; Kaas, 
1987). Most subcortical information enters the column from the thalamus and 
undergoes local processing in more superficial cortical layers (Douglas and 
Martin, 2010; Guillery and Sherman, 2002). Reciprocal intralaminar connections 
allow for recurrent excitation, feedback inhibition and disinhibition, with local 
translaminar axonal and dendritic collaterals connecting the superficial to the 
deeper cortical layers (Lübke and Feldmeyer, 2007). Deeper cortical layers 
project cortical column output to neighbouring neocortical structures and other 
subcortical regions (Douglas and Martin, 2010).  
Overall, cortical columns are broadly similar in structure and connectivity across 
neocortical regions and species, with differences in cytoarchitecture likely related 
to differences in connectivity that allows for functional specialisation (Harris and 
Shepherd, 2015; Rockel et al., 1980). This gives confidence that these units may 
have similar fundamental roles within information processing, which can be 
generalised to understand more complex cognitive behaviours (Harris and 
Shepherd, 2015). As such, the somatosensory cortex has become an attractive 
model to study the neocortical system and has helped inform some common 
principles of neocortical function (Lübke and Feldmeyer, 2007; Miller et al., 2001).  
1.2.1 The somatosensory cortex 
Somatosensory information – sensory perception such as pressure, touch or 
temperature change felt anywhere on the body – is processed in the brain via the 
somatosensory pathway. The somatosensory cortex encodes this sensory 
perception, with areas across the entire body corresponding to specific regions 
within the brain (somatotopy). In humans, for example, there are specific regions 
of the brain that will respond to sensation at individual fingers, first described by 
Penfield and Rasmussen, 1950. The somatosensory cortex in mice was first 




clusters of neurons defined as barrels, with receptive fields that corresponded to 
single whiskers (vibrissae) in a somatotopic fashion.  
1.2.1.1 From whisker to the primary somatosensory cortex 
The typical pathway for conveying vibrissal information to the primary 
somatosensory (S1) cortex can be described as follows. A single whisker 
movement innervates distal axons of trigeminal ganglion in the infraorbital branch 
of the trigeminal nerve (Lee and Woolsey, 1975; Rice et al., 1986). This 
innervates trigeminal nuclei of the brain stem which are organised into discrete 
neuronal clusters termed barrelettes (Belford and Killackey, 1979; Erzurumlu et 
al., 1980; Veinante and Deschênes, 1999). These project to the thalamus, which 
is organised into barreloids (Land et al., 1995; Van Der Loos, 1976; Williams et 
al., 1994). Thalamic axons then project to the S1 cortex (Lee and Woolsey, 1975; 
Welker, 1971; Woolsey and Van der Loos, 1970). Each structure of this pathway 
preserves the information flow in a somatotopic fashion (Adibi, 2019; Petersen, 
2007). 
1.2.1.2 Primary somatosensory cortex cytoarchitecture and circuitry 
S1 cortex is separated into six layers as is typical of the neocortex. The majority 
of neurons within this region are excitatory, constituting 80-85% of all neurons 
within S1 (Lefort et al., 2009; Markram et al., 2015; Narayanan et al., 2017; 
Oberlaender et al., 2012). The remainder are a heterogeneous population of 
interneurons, thought to help shape excitation and define receptive field tuning 
(Harris and Shepherd, 2015; Markram et al., 2015). The most superficial layer of 
S1 (layer I) is exclusively comprised of inhibitory cell bodies in addition to apical 
dendritic arbors and axonal projections (Lefort et al., 2009; Markram et al., 2015; 
Oberlaender et al., 2012). The deeper layers (II – VI) consist of a mixture of 
excitatory and inhibitory cells with inter- and intra- laminar connections (Lefort et 
al., 2009; Markram et al., 2015). 
The inputs into S1 from the thalamus can be further split into different parallel 
pathways, which target distinct nuclei or layers within S1: the lemniscal, 
paralemniscal, and extralemniscal pathway (Petersen, 2007; Pierret et al., 2000; 
Yu et al., 2006; Figure 1.3). The well characterised lemniscal pathway is the 
primary glutamatergic pathway for vibrissal information, thought to convey 
whisking and touch. This projection enters S1 via the dorsal medial region of the 




innervate layer IV (barrels) in S1 with sparse projections to layer VIa 
(Chmielowska et al., 1989; Lu and Lin, 1993; Mo et al., 2017; Figure 1.3). The 
excitatory layer IV axons form prominent inputs to layer II/III within the same 
cortical column (Feldmeyer et al., 1999, 2002). These neurons form 
transcolumnar intralaminar connections, with axonal arborisations extending well 
beyond the confines of the cortical column (Petersen, 2007). These neurons form 
strong descending connections to cell bodies in layer V (Koralek et al., 1990; 
Reyes and Sakmann, 1999). These innervate layer VI cells, and also the thalamic 
VPM and the medial part of the posterior thalamic nuclear group (POm), closing 
the corticothalamic loop (Bourassa et al., 1995; Land et al., 1995; Lübke and 
Feldmeyer, 2007). 
Other whisking related information is conveyed from the paralemniscal pathway, 
which enters from the POm by forming axon collaterals with layer I and layer Va 
in S1 (Koralek et al., 1988; Lu and Lin, 1993; Figure 1.3). This pathway is 
suggested to play a role in active whisking and exploration, and sensorimotor 
coordination (Petersen, 2007; Yu et al., 2006). The most recently discovered 
extralemniscal pathway projects via the ventral lateral VPM in the thalamus, 
whose axons then innervate S1 (layer V) and the secondary somatosensory 
cortex equally (Pierret et al., 2000; Figure 1.3). This pathway is thought to convey 






Figure 1.3 The excitatory microcircuitry within the primary somatosensory 
cortex from thalamic input.  A schematic of excitatory information flow within a 
barrel column. The lemniscal, paralemniscal and extralemniscal pathways are 
highlighted in green, purple, and pink, respectively. Information enters the cortical 
column via the VPM and POm thalamic nuclei. Black arrows denote general 
column microcircuitry such as transcolumnar and descending connections, and 
includes recurrent connections as curly arrows. Cortical layers are shown as 
alternating white and shaded grey areas, labelled on the left. The column is 
marked as dashed vertical lines and the barrel fields are shown in layer IV as 
rounded rectangles. Adapted from Adibi, 2019. 
 
1.2.1.3 The somatosensory cortex as an experimental model system 
The rodent somatosensory cortex has been widely used as a neocortical model 
system. As the barrel fields are visible by eye, this allows for the identification of 
individual cortical columns within slice preparations that preserve the connections 
between the column and the thalamus, which is not possible with preparations 
from other cortical areas (Agmon and Connors, 1991; Lübke and Feldmeyer, 
2007; Lübke et al., 2000). The region is also easily accessible for recording and 
imaging experimentally, with the ability to drive evoked responses using whisker 
stimulation, which is a behaviourally relevant pathway. This allows the same 




given invaluable insight into cortical processing and plasticity, and has been well 
defined within the literature from cellular composition to functional circuity in 
behaving animals. 
Anatomical and functional characteristics of the barrel cortex therefore make it an 
ideal system to study cortical microcircuit dysfunction in pathophysiological 
conditions. Using a well-defined microcircuit such as S1 to study the impact of 
tauopathy allows for more precise characterisation of the specific locus of 
dysfunction occurring which could then be generalised to other, more complex, 
microcircuits. Within the rTg4510 mouse model, there is significant tau pathology 
accumulation from 4-6 months of age in S1, with alterations in synaptic stability 
from ~5.5 months of age and visible neurodegeneration from ~6 months of age 
(Blackmore et al., 2017; Harrison et al., 2020; Jackson et al., 2020; Ramsden et 
al., 2005; SantaCruz et al., 2005). Therefore, S1 in the rTg4510 model is a viable 
model for studying the effects of tauopathy-mediated dysfunction and 
degeneration in cortical networks. 
1.3 NEURONS 
Whilst there are highly diverse and heterogeneous populations of neurons within 
the brain, they share some common properties in regard to their basic structure 
and electrical functionality. Characterising how these properties are altered in 
disease can help guide us towards neurophysiological alterations that underpin 
complex network and behavioural phenotypes. 
1.3.1 The electrophysiology of the neuron  
Neurons are electrically specialised cells due to the inherent properties of the 
phospholipid bilayer membrane, which prevents ion movement between the 
intracellular and extracellular space producing an electrochemical gradient 
(Goldman, 1943; Kandel et al., 2000). This lack of ionic mobility can precipitate 
into an electrical charge, dependent on the extracellular and intracellular ion 
concentrations (Goldman, 1943; Hodgkin and Katz, 1949). This gradient is 
maintained by various ion channels embedded within the phospholipid 
membrane. Overall, the electrical excitability of neurons is dictated by a 
combination of membrane and ion channel properties, and how these integrate 




1.3.1.1 Neuronal excitability: passive properties 
The neuronal membrane can be considered as an electrical circuit, with ion 
channels embedded within the membrane modelled as resistors (Hodgkin and 
Huxley, 1952; Kandel et al., 2000). Therefore, the passive properties of a neuron 
refer to the capacitive and resistive functions of the neuronal membrane and the 
ion channels within this circuit. These properties influence how the neuron 
responds to voltage change, by altering how current flows across the membrane. 
This includes the time course, the size, and the amplitude of the response to 
incoming currents, shaping how this response flows through the neuron (Kandel 
et al., 2000; Rall, 2011). Together, these passive properties can influence 
neuronal excitability. Some of these electrical properties can be elucidated using 
whole-cell patch clamp electrophysiology recordings, by injecting hyperpolarising 
or subthreshold currents into the cell and measuring the corresponding voltage 
deflection response.  
1.3.1.2 Neuronal excitability: active properties 
Active properties refer to the dynamic response of membrane-embedded gated 
ion channels to a voltage or chemical change (Crill and Schwindt, 1983; Kandel 
et al., 2000). For example, when the neuron is depolarised past action potential 
(AP) threshold, the complexity of the response surpasses that of a simple circuit 
with a capacitance and resistance. Active properties of different voltage gated ion 
channels work in complement to drive the electrical potential away from the 
resting membrane potential to produce an all or nothing AP response (Kandel et 
al., 2000). Hyperpolarising voltage-gated channels also contribute to active 
properties of the neuron, altering the frequency of APs. Together, active 
properties influence neuronal excitability by altering the length and size of the AP 
response, and how often that response can occur.  
1.3.2 Neurophysiological dysfunction in tauopathy 
Whilst it is difficult to measure changes to passive and active electrical properties 
in human tauopathy due to cellular accessibility, alterations to the electrical 
properties of neurons have been seen in multiple models of tauopathy. Acute 
incubation with tau oligomers have a marked effect on the AP waveform and 
dynamics, leading to a slower, longer, and reduced amplitude AP (Hill et al., 
2019). In the chronic Tau35 model of tauopathy at 14-18M when tau pathology is 




phenotype with altered intrinsic neuronal properties such as an increased 
capacitance, decreased input resistance, and a decrease in AP firing rates 
(Tamagnini et al., 2017). In another chronic model of advanced tauopathy, the 
rTg4510 model, there was a hyperexcitable phenotype seen in neurons in the 
frontal cortex, with a depolarised resting membrane potential, increased input 
resistance, and increased AP firing rates at 8-9M of age (Crimins et al., 2012; 
Rocher et al., 2010). Interestingly, neurons recorded in the hippocampus within 
the rTg4510 model at a similar age (7-8M), also showed an altered 
neurophysiological phenotype (increased hyperpolarising activated currents and 
decreased membrane time constant), but this did not affect the core excitability 
of these cells in comparison (Booth et al., 2016a). Therefore, it seems that there 
are differential tauopathy-driven phenotypes, likely related to the pathological 
stage of the model and brain region studied, as the rTg4510 model has a more 
severe pathological phenotype in comparison to the Tau35 model. This suggests 
that there are differential mechanisms of dysfunction or compensation at different 
stages of tauopathy. Whilst the precise mechanisms by which these changes are 
occurring is unknown, it is obvious that there are likely multiple pathological 
processes by which tauopathy induces neurophysiological dysfunction. 
1.4 SYNAPSES 
The synapse is a term coined by Charles Sherrington in 1897, describing the non-
continuous contact between one neuron to another, which had been suggested 
as part of the neuron doctrine (Foster et al., 1897; Kandel et al., 2000; Ramon y 
Cajal, 1911). These specialised connections allow the transmission of signals, 
either electrical or more often chemical, between neurons. Typically, synapses 
are formed of the pre- and post-synapse and the synaptic cleft. Whilst this 
overview will focus on chemical synaptic connections solely between neurons, it 
should be noted that astrocytic endfeet are in close contact with the majority of 
synapses within the brain and play a role in modulating synaptic transmission 
(Dieterich and Kreutz, 2016; Kandel et al., 2000; Ventura and Harris, 1999). This 
overview will also focus on the more prevalent chemical synaptic transmission for 
brevity and relevance for this thesis. 
1.4.1 Synaptic structure  
The structure of synapses is specialised to ensure efficient and appropriate 




synaptic dysfunction. This specialisation occurs from a vast array of 
heterogeneous protein machinery, specific to the functional architecture of either 
the pre- or post-synapse that streamlines the process of synaptic transmission 
(Dieterich and Kreutz, 2016; O’Rourke et al., 2012). 
Proteins at the pre-synaptic terminal facilitate and regulate pre-synaptic 
transmission (Garner et al., 2000; Figure 1.4). This includes proteins to determine 
the localisation, tethering, and fusion of synaptic vesicles at the pre-synapse. For 
example, SNARE and SM proteins dock and prime vesicles at the cytomatrix 
active zone (Garner et al., 2000); the synaptic vesicle protein synaptophysin is 
suggested to play a role in the efficient endocytosis of synaptic vesicles (Kwon 
and Chapman, 2011). Other proteins also tightly regulate synthesis, storage and 
release of neurotransmitters (Schweizer and Ryan, 2006). Ion channels, such as 
voltage-gated Ca2+ channels, and other receptors are also embedded in the pre-
synaptic membrane (Kandel et al., 2000; Schweizer and Ryan, 2006).  
At the post-synaptic terminal, there are ~1500 proteins which are specialised to 
generate the response to neurotransmitter release (O’Rourke et al., 2012; 
Scannevin and Huganir, 2000; Figure 1.4). A number of these proteins form a 
complex yet critical structure known as the post-synaptic density (PSD). This 
dynamic protein lattice helps localise, organise, and traffic receptors and other 
required molecules within and to the PSD. Receptors and ion channels crucial for 
generating a response to neurotransmitter release are stabilised within the PSD 
by scaffold proteins. PSD95 is one such protein scaffold associated with synapse 






Figure 1.4 The structure of a chemical synapse.  An electron micrograph of a 
synapse (A), with the pre-synapse highlighted in purple and the post-synapse 
highlighted in green. Abbreviations: SV = synaptic vesicles, CAZ = cytomatrix at 
the active zone, PSD = post-synaptic density. Scale bar = 100 nm. Panel B shows 
a labelled cartoon schematic of a typical chemical synapse. A is adapted from 
Dieterich and Kreutz, 2016. 
 
1.4.1.1 Assessing the synaptic proteome: synaptosomes 
There is a large diversity in the downstream molecular mechanisms of synapses, 
which is likely a consequence of molecular composition within the synapse, even 
within traditional neurotransmitter categories (O’Rourke et al., 2012). 
Synaptosome preparations are the foundation of how we assess the molecular 
content of synapses, although development of newer technologies such as array 
tomography, are starting to be favoured for assessing single synapse diversity 
within small subregions (Busse and Smith, 2013; Dieterich and Kreutz, 2016; 
O’Rourke et al., 2012). Synaptosomes are sealed terminal ends which preserve 
the synaptic milieu including vesicles and synapse bound receptors (Evans, 
2015; Hebb and Whittaker, 1958; De Robertis et al., 1961; Whittaker, 1959, 
1993). Further purification methods such as discontinuous sucrose and percoll 
gradients can be used to improve purity of the preparations, and the pre- and 
post- synapse can be further isolated (Dunkley et al., 1986; Gray and Whittaker, 
1962; Huttner et al., 1983; Nagy and Delgado‐Escueta, 1984; Tenreiro et al., 
2017). This process allows for the identification and quantification of protein 




1.4.2 Synaptic transmission 
The general process of neuronal communication via chemical synapses occurs 
in a similar manner regardless of subtype (Kandel et al., 2000; Figure 1.5). An 
AP occurs at the pre-synaptic neuron, where this signal reaches and depolarises 
pre-synaptic terminals. This depolarisation activates voltage dependent Ca2+ 
channels, leading to a transient influx of Ca2+ within the pre-synaptic terminal 
(Dodge and Rahamimoff, 1967; Katz, 1969). These ions bind to calcium sensors 
on synaptic vesicles. Neurotransmitters are stored within these vesicles, and are 
released into the synaptic cleft by exocytosis at the active zone of the pre-
synapse (del Castillo and Katz, 1954; Fatt and Katz, 1951; Heuser and Reese, 
1973). Neurotransmitters diffuse across the synaptic cleft, to bind to ligand-gated 
post-synaptic ion channels (del Castillo and Katz, 1956b, 1956a). This binding 
causes a change in receptor conformation allowing the inflow of specific ions, 
leading to an electrical change at the post-synaptic neuron (Fatt and Katz, 1952).  
Post-synaptic responses to neurotransmitter release are said to be quantal, with 
“packets” of neurotransmitters released from vesicles activating post-synaptic 
receptors producing a change in current at the post-synapse (Fatt and Katz, 
1951, 1952). These responses can be expressed as a function of the number of 
active synapses, the probability of release, and the potency of the released 
neurotransmitter (del Castillo and Katz, 1954). If any of these properties are 
altered, this can alter the amplitude or frequency of post-synaptic responses. A 
reduction in the probability of release for example would likely lead to a lowered 






Figure 1.5 Synaptic transmission. An AP (shown in inset) occurs in the pre-
synaptic neuron (A). This depolarisation within the neuron causes the opening of 
voltage-gated Ca2+ ion channels. Ca2+ influx into the pre-synaptic terminal leads 
to neurotransmitter release (B). Then, independent of synapse type, 
neurotransmitters are released into the synaptic cleft (C & D). With glutamate 
release (C), post-synaptic glutamate receptors are particularly permeable to 
sodium (Na+), causing a depolarisation of the post-synapse at resting membrane 
potentials (shown in inset). With γ-aminobutyric acid (GABA) release (D), post-
synaptic GABA receptors are typically permeable to chloride (Cl-) causing a 
hyperpolarisation of the post-synapse at resting membrane potentials (shown in 
inset). Glutamatergic synapse shown in purple and green in C and GABAergic 
synapse shown in yellow and red in D. 
 
1.4.2.1 Excitatory and inhibitory synaptic transmission 
The major excitatory and inhibitory neurotransmitters in the brain are glutamate 
and γ-aminobutyric acid (GABA) respectively, formed from their precursor 
glutamine (Kandel et al., 2000; Sibson et al., 1998). Glutamate binds to glutamate 




potentials, thus increasing the probability of firing an AP (Figure 1.5 C). GABA 
and GABA receptors conversely decrease the probability of firing an AP by 
hyperpolarising membrane potential (Vm), classing it as an inhibitory 
neurotransmitter in most circumstances (Kandel et al., 2000; Krnjević and 
Schwartz, 1967; Figure 1.5 D). These electrical changes can be measured using 
whole-cell patch clamp electrophysiology, and are known as excitatory or 
inhibitory post-synaptic activity respectively. 
Whether an ion channel elicits excitatory or inhibitory activity is dictated by the 
equilibrium potential of the ion that is permeable through the channel (Kandel et 
al., 2000). The excitatory glutamate receptors are typically equally permeable to 
Na+ and potassium (K+) ions, with the reversal potential of glutamate receptors 
being ~0 mV. This results in a depolarisation (inward current) of the membrane 
at resting membrane potential (Figure 1.5 C). Inhibitory ionotropic GABA 
receptors are typically permeable to chloride (Cl-) ions, which have an equilibrium 
potential of ~-70 mV. Therefore, the influx of Cl- (outward current) leads to a 
hyperpolarisation of the membrane at resting membrane potential (Figure 1.5 D).  
1.4.2.2 Inhibition & GABA 
Whilst this thesis will mainly focus on excitatory neurotransmission, inhibitory 
neurotransmission is critical to the function of neuronal networks and therefore 
cannot be overlooked. In the mature brain, GABA is an inhibitory 
neurotransmitter, acting on both synaptic and extrasynaptic GABA receptors: 
GABAa, GABAb, GABAc (Owens and Kriegstein, 2002). These different receptors 
promote different GABAergic responses, with fast activity mediated by the 
ionotropic GABAa and GABAc receptors, and slower activity mediated by 
metabotropic GABAb receptors (Benardo, 1993; Dutar and Nicoll, 1988). GABA 
releasing neurons are typically classed as inhibitory interneurons. Inhibition within 
neuronal networks is of critical importance, as a network of pure excitation would 
only beget further excitation. This balanced network dynamic generates complex 
properties such as neuronal oscillations, increasing the computational ability of 
the brain (Haider et al., 2006; Isaacson and Scanziani, 2011).  
1.4.2.3 Excitation & Glutamate 
Focussing on excitatory neurotransmission, glutamate acts on ionotropic and 
metabotropic glutamate receptors. The ionotropic glutamate receptors are named 




methyl-4-isoxazolepropionic acid (AMPA), N-Methyl-d-aspartate (NMDA), 
kainate. Therefore, the receptors are termed AMPA, NMDA and kainate 
receptors respectively (Collingridge et al., 2009; Kew and Kemp, 2005; Traynelis 
et al., 2010). There are eight known metabotropic glutamate receptors, termed 
mGluR(1-8) (Kew and Kemp, 2005; Kunishima et al., 2000; Masu et al., 1991; 
Niswender and Conn, 2010). Ionotropic glutamate receptors are thought to 
mediate the majority of excitatory neurotransmission, whereas metabotropic 
receptors modulate neuronal excitation and neurotransmitter release via 
secondary messenger signalling cascades. 
1.4.2.3.1 Ionotropic glutamatergic receptors: AMPA receptors 
AMPA receptors (AMPAR) are heteromeric transmembrane ionotropic receptors 
that mediate the overwhelming majority of fast glutamatergic synaptic 
transmission. AMPARs are expressed mainly on neurons, and to a lesser extent 
glia, and along with NMDA receptors (NMDARs), are thought to dictate the 
majority of excitatory signalling (Ashby et al., 2008; Hollmann and Heinemann, 
1994; Kew and Kemp, 2005). They assemble as tetramers, formed of 
combinations of four subunits, GluA1-4 (Boulter et al., 1990; Collingridge et al., 
2009; Hollmann and Heinemann, 1994; Hollmann et al., 1989; Keinänen et al., 
1990). In addition, these receptors form stable complexes with auxillary AMPAR 
subunits, such as stargazin, and other transmembrane AMPAR regulatory 
proteins (TARPs). These facilitate appropriate AMPAR trafficking, stabilisation, 
maturation, and function (Bats et al., 2007; Chen et al., 2000; Opazo et al., 2010; 
Tomita et al., 2003).  
Upon glutamate binding to AMPARs, irrespective of membrane voltage, 
conformational change of the receptor occurs opening a central transmembrane 
pore. This leads to the influx of Na+ (with some K+ efflux) which depolarises the 
post-synaptic terminal at typical resting membrane potentials. In some cases, 
AMPARs are also Ca2+ permeable. This is either by alternate splicing and RNA 
editing of GluA2 containing AMPARs, or in those AMPARs that lack the GluA2 
subunit (Hollmann et al., 1991; Isaac et al., 2007; Jonas et al., 1994). Different 
AMPAR subunits variants can dictate the kinetics of the post-synaptic response. 
For example, splice variants of the GluA3/4 subunits lead to lowered 
desensitisation of AMPAR responses (Grosskreutz et al., 2003; Mosbacher et al., 




exclusion of the GluA2 subunit, can dictate the voltage dependence and 
conductance of AMPARs (Cecilia Angulo et al., 1997). Combinations of both 
different subunits and subunit splice variants alters activation, desensitisation and 
recovery of AMPAR responses (Grosskreutz et al., 2003). 
Heteromeric and homomeric receptor subunit conformation undergoes 
spatiotemporal regulation within the brain. From birth, GluA1-3 expression 
increases gradually and stabilises early in life (Henley and Wilkinson, 2013; Zhu 
et al., 2000). Conversely, GluA4 undergoes strict developmental regulation, with 
high expression in early development to low expression in the adult brain (Zhu et 
al., 2000). Subunit expression is also regulated within brain regions, with GluA3 
present at 10% of the levels of GluA1 and GluA2 in the adult brain (Lu et al., 
2009; Sans et al., 2003). There are also differential subunit conformations within 
different cell types. For example, the most abundant AMPAR subunit in pyramidal 
neurons in the neocortex is GluA2 with lesser expression of GluA1 and 3, which 
would likely form GluA1/GluA2 and GluA2/GluA3 heterodimers as seen in 
hippocampal pyramidal neurons (Jonas et al., 1994; Mansour et al., 2001; Sans 
et al., 2003; Wenthold et al., 1996).  However, other cell types such as inhibitory 
interneurons, predominantly express GluA2 lacking Ca2+ permeable AMPARs 
(Geiger et al., 1995; Jonas et al., 1994; Mahanty and Sah, 1998). Inhibitory 
interneurons also express GluA4 containing AMPARs which are key in regulating 
inhibitory circuit integration, whereas GluA4 is mostly absent in mature excitatory 
neurons (Pelkey et al., 2015; Zhu et al., 2000).  
AMPARs are highly dynamic proteins, that rapidly undergo constitutive and 
activity-dependent trafficking and recycling at the post-synapse. AMPAR 
trafficking is linked to subunit composition, with GluA2 containing AMPARs 
trafficked and recycled with a half-life in the order of minutes, compared to slower 
constitutive turnover over hours to days of other AMPAR assemblies (Henley, 
2003; Nishimune et al., 1998; Noel et al., 1999). The active and dynamic 
regulation of AMPARs is fundamental in learning and memory mechanisms 
(Henley and Wilkinson, 2013).  
1.4.2.3.2 Ionotropic glutamatergic receptors: Kainate receptors 
Along with AMPARs, kainate receptors were termed the non-NMDA glutamate 
receptors for many years, due to their sensitivity to NBQX, insensitivity  to D-APV, 




2006). Kainate receptors are tetrameric assemblies, formed from five possible 
subunits (GluK1-5) (Bettler et al., 1990; Collingridge et al., 2009; Hollmann and 
Heinemann, 1994). Kainate receptors are the less abundant glutamate ionotropic 
receptor and whilst they are structurally and functionally similar to AMPARs, their 
role in physiology is less clear (Lerma and Marques, 2013).  
Kainate receptors have varying affinities for both glutamate and kainate, 
conferred by subunit assembly. With this, the lack of selective agonists has 
hampered our understanding of the kainate receptor (Kew and Kemp, 2005; 
Pinheiro and Mulle, 2006). In contrast to the other ionotropic glutamate receptors, 
kainate receptors show diverse and non-conventional signalling mechanisms 
including activation of both canonical ionotropic and non-canonical metabotropic 
pathways (Lerma and Marques, 2013; Valbuena and Lerma, 2020). Whilst their 
physiological role is likely widespread, there is paradoxical evidence of their role 
at the pre- and post-synapse, with kainate receptor activation shown to modulate 
neuronal excitability and inhibition (Evans et al., 2019; Lerma and Marques, 2013; 
Pinheiro and Mulle, 2006). Within the brain, their expression is relatively low and 
restricted to specific pathways, and activation of post-synaptic kainate receptors 
mediates low amplitude slow currents compared to AMPARs (Castillo et al., 1997; 
Lerma and Marques, 2013). Thus, the role mediated by kainate receptors in 
canonical excitatory signalling is still uncertain compared to the other ionotropic 
glutamate receptors. 
1.4.2.3.3 Ionotropic glutamatergic receptors: NMDA receptors 
NMDARs are ionotropic glutamatergic receptors with multiple ligand binding 
sites. In contrast to the other ionotropic receptors, NMDAR activation requires the 
binding of both the endogenous ligand glutamate and glycine/D-serine as a 
cofactor (Hansen et al., 2018; Mcbain and Mayer, 1994; Traynelis et al., 2010). It 
is also unique amongst the other glutamatergic ionotropic receptors as it is a 
voltage-gated receptor. At hyperpolarised potentials, there is a magnesium 
(Mg2+) ion in the channel pore that blocks activation. Sufficient depolarisation (> 
-40 mV) is required to relieve the Mg2+ block. Therefore, this receptor has been 
described as a coincidence detector as it needs both glutamate activation and 
depolarisation to be maximally active. This also leads to typically slower activation 




are permeable to Na+, K+ and Ca2+, with Ca2+ influx triggering downstream 
signalling cascades. 
These heteromeric receptors are made up of the constitutive GluN1 subunit plus 
variants of GluN2 (GluN2A, GluN2B, GluN2C, GluN2D) or the more recently 
discovered GluN3 (GluN3A, GluN3B) subunits (Chatterton et al., 2002; Ciabarra 
et al., 1995; Collingridge et al., 2009; Hollmann and Heinemann, 1994; Meguro 
et al., 1992; Moriyoshi et al., 1991; Sucher et al., 1995). These receptors are 
typically formed of two glycine-binding GluN1 subunits with either two glutamate-
binding GluN2 subunits or less frequently two glycine-binding GluN3 subunits or 
a mixture of both GluN2/3 (Laube et al., 1998; Monyer et al., 1992; Pachernegg 
et al., 2012). The most widely expressed NMDARs are typically GluN1 with either 
GluN2A or 2B (Hollmann and Heinemann, 1994; Traynelis et al., 2010).  
Different GluN2 subunits can alter Ca2+ permeability and voltage dependence, 
causing differences in receptor current dynamics in response to pharmacological 
activation (Kew and Kemp, 2005; Monyer et al., 1992, 1994). For example, 
NMDARs that contain GluN2C and GluN2D subunits have decreased sensitivity 
to Mg2+ block, lower single channel conductance, and GluN2D containing 
receptors in particular have slower deactivation kinetics in comparison to GluN2A 
and GluN2B containing NMDARs (Cathala et al., 2000; Erreger et al., 2007; 
Monyer et al., 1992). GluN3 is thought to modulate NMDAR activity by modifying 
the heteromeric receptor structure, leading to reduced Mg2+ sensitivity and 
reduced Ca2+ influx, although further corroborating evidence is needed 
(Pachernegg et al., 2012). GluN1/GluN3 heteromeric NMDARs form excitatory 
glycine-gated channels which are not Ca2+ permeable and are resistant to Mg2+ 
block, and so therefore function in a non-canonical manner in respect to NMDARs 
(Chatterton et al., 2002; Köhr, 2006). 
NMDAR subunit expression undergoes spatiotemporal regulation. In 
development, GluN2B and GluN2D are abundant, with the progressive addition 
of GluN2A and GluN2C (Monyer et al., 1994; Standaert et al., 1996). In the adult 
brain, GluN2A expression is ubiquitous whilst GluN2B expression is restricted to 
the forebrain (Monyer et al., 1994; Standaert et al., 1996). GluN2C is highly 
expressed in the cerebellum and GluN2D expression is enriched in interneurons 
(Monyer et al., 1994; Standaert et al., 1996). Functional NMDARs are also 




NMDARs suggested to be more mobile and are more frequently detected in the 
extrasynaptic domain (Tovar and Westbrook, 1999, 2002). NMDARs are 
expressed both pre- and post- synaptically, with pre-synaptic NMDARs playing a 
functional role in LTD in layer IV to layer II/III synapses in the barrel cortex 
(Rodríguez-Moreno et al., 2011).  
NMDARs have diverse roles in normal neurophysiology. NMDAR activity 
facilitates non-linear integration of synaptic inputs, which plays a crucial role in 
regulating sensory perception including the control and refinement of response 
tuning curves (Lavzin et al., 2012; Lee et al., 2005; Palmer et al., 2014; Smith et 
al., 2013; Takahashi et al., 2016). This can include the regulation of stimulation 
detection thresholds (Takahashi et al., 2016), preferred directionality of angular 
tuning fields (Lavzin et al., 2012) and the selectivity of neuronal orientation tuning 
(Smith et al., 2013). NMDARs are also implicated in multiple learning and memory 
processes such as LTP, due to its’ function as a coincidence detector and 
activation of downstream Ca2+ dependent signalling pathways (Lau et al., 2009; 
MacDonald et al., 2006; Müller et al., 2009). In pathophysiological conditions, 
glutamate excitotoxicity is suspected to be due to NMDAR overactivation, leading 
to excessive Ca2+ entry which is thought to be neurotoxic (Choi, 1988; Rothman 
and Olney, 1986).  
1.4.2.4 Synaptic plasticity and stabilisation 
The favouring of one pathway within a circuit, whilst weakening others, now 
known as plasticity, is an idea that was proposed in the 1940s (Hebb, 1949; 
Konorski, 1948). Plasticity has been hypothesised as the way that networks, 
neurons, and synapses can dynamically modulate the network in an efficient 
manner, and this is thought to be how we learn and adapt to different behaviours. 
There is increasing recognition that synapses are critical in functional plasticity, 
compared to other nodes of modulation (Busse and Smith, 2013; Citri and 
Malenka, 2008). Synapses can undergo high turnover and can change shape, 
size, or number leading to corresponding changes in synaptic transmission to an 
experience (Trachtenberg et al., 2002). This can be on rapid or longer timescales 
and can occur at both excitatory and inhibitory synapses.  
Short-term plasticity (STP) is a rapid mechanism, thought to be important in 
transient short-term adaptation to behaviours, or short-term forms of memory 




of efficiently converting synaptic information with different temporal scales by 
transformation with either a low- or high-pass filter. STP works by modulating the 
probability of neurotransmitter release at the synapse, and therefore does not 
induce changes in the structure or composition of the synapse.  
Glutamatergic receptor function and regulation is critical for forming and 
maintaining longer term plasticity changes within the brain. Long-term plasticity 
(LTP) occurs on a time scale of hours to days and is thought to be the neural 
foundation of learning and memory (Bliss and Collingridge, 1993; Bliss and Lømo, 
1973). LTP leads to the strengthening of existing spines by increasing the size, 
and also induces the formation of new spines (Barnes and Finnerty, 2010; Engert 
and Bonhoeffer, 1999). The most widely studied mechanisms of LTP relate to 
NMDAR activation, and AMPAR trafficking and regulation at synapse. Other 
forms of synaptic plasticity include homeostatic plasticity, such as synaptic 
scaling, and metaplasticity (Abraham and Bear, 1996; Turrigiano, 2008). These 
forms of plasticity are also regulated in part by glutamatergic receptor expression 
and trafficking at the synapse. For example, a prevailing mechanism for synaptic 
scaling is the availability of AMPARs within the whole cell and within different 
subcellular compartments (Barnes et al., 2017; Gainey et al., 2009; Turrigiano, 
2008).  
The converse of synaptic potentiation, the process of downscaling of responses, 
is short- and long-term depression. The mechanisms for these processes 
typically share common pathways, such as the regulation of excitatory receptor 
expression. For example, one mechanism of long-term depression (LTD) is 
endocytosis of AMPARs at the synapse (Beattie et al., 2000; Granger and Nicoll, 
2014). 
1.4.3 Synaptic dysfunction and degeneration in tauopathy 
In the past decade, the synapse has increasingly been viewed as a vulnerable 
target to tau-mediated disruption (Crimins et al., 2013; Jackson et al., 2019; 
Jadhav et al., 2015; Pooler et al., 2014; Tracy and Gan, 2018). Whilst tau may 
have a physiological role at synapses in stabilisation and plasticity for example, 
hyperphosphorylated tau is abnormally and preferentially located at synapses in 
post-mortem AD brain tissue (Fein et al., 2008; Perez-Nievas et al., 2013; Tai et 
al., 2014). In fact, there is evidence that differential post-translational 




with specific pro-aggregating isoforms promoting synapse loss in models of 
tauopathy (Eckermann et al., 2007; Sahara et al., 2014; Schaler et al., 2020; Xia 
et al., 2015). Infusion of tau oligomers into the brains of C57Bl/6 mice also led to 
a decreased density of synapses (Lasagna-Reeves et al., 2011). In chronic 
tauopathy models, synaptic markers are lost prior to NFT formation, and large-
scale synaptic degeneration is observable (Crimins et al., 2011; Kopeikina et al., 
2013a; Yoshiyama et al., 2007).  
Tau pathology is also suggested to mediate changes to synaptic function prior to 
synaptic degeneration. Some suggested mechanisms include pre-synaptic 
dysfunction by tau association with synaptic vesicles, demonstrated by injection 
of tau into the pre-synapse (Zhou et al., 2017). However, the overall functional 
impact of tau pathology on synaptic function is conflicting, with increased, 
decreased and unchanged excitatory neurotransmission seen in different models 
of tauopathy (Crimins et al., 2013). In addition, studies investigating how 
tauopathy can impact synaptic function typically focuses at either very early pre-
clinical states, or late degenerative stages. Therefore, despite mounting evident 
that tauopathy can promote synaptic disruption and degeneration, information on 
the pathological drivers of this transitionary phase and how this can impact 
function is lacking. 
1.4.3.1 Alterations in the glutamatergic system in tauopathy 
The suggestion that glutamate is key in the pathogenesis of AD has been a 
hypothesis for the past 30 years, with this also being suggested more recently for 
other tauopathies (Benussi et al., 2019). A prevalent hypothesis is that excitatory 
circuitry exhibits a greater degree of vulnerability when compared to their 
inhibitory counterparts in tauopathy post-mortem brain tissue (Dickson et al., 
2011; Fu et al., 2018, 2019). This could be accounted for by alterations in 
inhibitory control of excitability, or loss of glutamatergic or GABAergic neurons or 
other mechanisms of dysregulation of glutamatergic signalling (Frere and 
Slutsky, 2018; Palop et al., 2007; Shimojo et al., 2020). Intracortical facilitation, a 
magnetic transcranial stimulation protocol that relies on intact glutamatergic 
circuitry, is reduced in patients with presymptomatic familial FTD (Benussi et al., 
2016; Gazzina et al., 2018). Within the pR5 mouse model of tauopathy, altered 
glutamate, glutamine, and GABA metabolism has been observed (Nilsen et al., 




AMPARs and NMDARs, a considerable amount of research has aimed to 
deconstruct how tauopathy can influence receptor activity and localisation. 
However, there is a significant lack of information regarding how glutamatergic 
receptor dysfunction specifically relates to synaptic and neuro- degeneration in 
tauopathy. This disease phase is suggested to be when symptomatic impairment 
occurs, and thus characterising dysfunction at this phase provides an ideal 
window for symptomatic rescue (Scheff et al., 2006, 2007). 
NMDARs are an attractive target for glutamatergic dysfunction and thus 
therapeutic intervention in tauopathies (Avila et al., 2017; Lao et al., 2019; Liu et 
al., 2019; Mota et al., 2013; Wang and Reddy, 2017). In chronic models of 
tauopathy, there have been significant reductions in NMDAR expression, 
synaptic localisation, and function (Hoover et al., 2010; Kopeikina et al., 2013a; 
Warmus et al., 2014). In the hT-337M mouse model of tauopathy, enhancing 
NMDAR activity with an agonist lead to behavioural rescue, suggesting targeting 
NMDARs could be an effective tauopathy treatment (Warmus et al., 2014). 
Conversely, Memantine (an NMDAR antagonist) is currently one of the only 
approved symptomatic treatments for moderate to severe AD (Danysz and 
Parsons, 2003; Wang and Reddy, 2017). Memantine treatment lacked efficacy in 
FTD in two small trials, although meta-analysis of these trials suggests possible 
modest benefits of treatment (Boxer et al., 2013; Kishi et al., 2015; Vercelletto et 
al., 2011). Therefore, whilst it seems likely that NMDAR dysfunction occurs in 
tauopathy, it is not clear how and when this dysfunction precipitates at different 
phases of tauopathy, and these therapeutic strategies outlined likely target 
different mechanisms. 
Glutamate excitotoxicity is thought to be mediated by NMDAR overactivation, 
which is a hypothesised mechanism of neurodegeneration (Liu et al., 2019; Mota 
et al., 2013; Wang and Reddy, 2017). Increased extrasynaptic localisation of 
NMDARs regulated by GluN2B subunit expression is thought to underpin 
excitotoxicity (Liu et al., 2007). Interestingly, it has been suggested that tau 
interacts directly with NMDARs at the synapse via fyn kinase, which regulates 
GluN2B phosphorylation, regulating synaptic localisation (Ittner et al., 2010; 
Miyamoto et al., 2017; Mondragón-Rodríguez et al., 2012). In fact, in a tau KO 
mouse model, there was decreased extrasynaptic NMDAR receptor expression 




Bazarra et al., 2019). This mechanism seems to have some validity in human 
tauopathies as the genetic A152T mutation on the MAPT gene, which increases 
the risk for tauopathies, has also been identified as increasing the risk of NMDAR-
mediated excitotoxicity (via the GluN2B subunit) (Decker et al., 2016; Maeda et 
al., 2016). 
Whilst understudied compared to NMDARs, AMPARs are also implicated in 
tauopathy. In FTD patients, autoantibodies for the AMPAR subunit GluA3 were 
present in the CSF and serum (Borroni et al., 2017). Application of the 
autoantibodies to neuronal cultures saw a reduction in spine density, suggesting 
AMPAR dysfunction mediated by reduced GluA3 expression. Conversely, 
increased GluA1 expression was observed in the hippocampus in AD post-
mortem brain tissue suggesting increased AMPAR expression in the brain 
(Marcello et al., 2012). In the CHMP2B mouse model of FTD and in FTD patients, 
there were significantly reduced levels of miRNA for AMPAR subunits GluA2-4 
(Gascon et al., 2014). 
Work in tau KO cultured neurons revealed mislocalised GluA2 puncta and 
abnormal GluA2-containing AMPARs being trafficked out of the synapse under 
normal physiological stimulation, implying a role of tau in regulating AMPAR 
localisation (Suzuki and Kimura, 2017). Phosphorylation of tau at different sites 
can differentially reduce AMPAR activity in cultured neurons, suggesting that tau 
can also mediate reduced AMPAR expression or hypoactivity (Teravskis et al., 
2019). In line with this, downregulation of genes that express AMPAR subunits 
(Alldred et al., 2012) and reductions in AMPAR subunit expression (Hoover et al., 
2010; Kopeikina et al., 2013a) have been observed in the rTg4510 model of 
tauopathy and in cultured rTg4510 neurons. Conversely, AMPAR-mediated 
activity was increased in the rTg4510 model in the hippocampus and frontal 
cortex following neurodegeneration onset (Crimins et al., 2011, 2012; Dalby et 
al., 2014). Overall, it seems that there is reduced expression or hypofunction of 
AMPARs with mislocalisation from the synapse, induced by tauopathy. One 
mechanism of tauopathy-induced AMPAR dysfunction could also be a subunit 
switch from Ca2+ impermeable to Ca2+ permeable GluA2 containing AMPARs, 
which could lead to excessive Ca2+ influx and synaptic dysfunction contributing 




facilitates the release and spread of tau between neurons, promoting the trans-
synaptic spread of pathological tau (Pooler et al., 2013). 
1.4.3.2 Altered synaptic stability and plasticity in tauopathy 
Excitatory networks of connected neurons are highly flexible, with input 
deprivation leading to restructuring of local networks by recruiting neighbouring 
silent neurons and by changing the strength, shape, timing, and number of 
synaptic connections (Albieri et al., 2015; Barnes et al., 2015b, 2015a, 2017; 
Cheetham et al., 2014). In neurodegenerative diseases such as tauopathies, it is 
likely that there are similar changes occurring within networks to help preserve 
established behaviours. In fact, it has been suggested that there is homeostatic 
compensation in response to loss of synaptic connections by surviving neurons 
to maintain the network activity, by changing excitability, dendritic restructuring, 
and the formation of novel synaptic connections (Crimins et al., 2011, 2012, 
2013). This could explain why some behaviours are preserved in the rTg4510 
model of chronic tauopathy following progressed neurodegeneration 
(Kuchibhotla et al., 2014).  
Within these networks, it has been evidenced that spine and bouton turnover is 
increased in prodromal tauopathy in the rTg4510 model, suggesting a lack of 
synaptic stability (Jackson et al., 2017, 2020). In addition, there are an increased 
proportion of filopodia compared to more mature stable synaptic structures in the 
same model (Crimins et al., 2011). This would imply a lack of access to functional 
molecular machinery, such as AMPARs and PSD proteins, required to stabilise 
and strengthen synapses (Ehrlich et al., 2007). Functional assessment of 
plasticity in mouse models of tauopathy suggests alterations in both short- and 
longer-term plasticity mechanisms (Booth et al., 2014, 2016a; Gelman et al., 
2018; Hill et al., 2019; Sydow et al., 2011). 
1.5 NEURAL NETWORK ACTIVITY 
Higher-order mental processes such as cognition require local coordinated 
activity within microcircuits, and more distal coordinated activity across regional 
hubs. Synchronisation of such assemblies is thought to be fulfilled by rhythmic 
oscillations in the brain (Buzsaki, 2006). Oscillations are assumed to be 
generated via the balance of local excitatory and inhibitory neuronal interactions 
or by intrinsic cellular mechanisms (Fell and Axmacher, 2011; Schnitzler and 




neuronal activity, whereas transregional synchronous oscillations are 
hypothesised to help with the transfer of information by facilitating long-range 
neuronal communication (Gupta et al., 2016; Schnitzler and Gross, 2005; Singer 
and Gray, 1995). Oscillations are hypothesised to play a critical role in complex 
behaviours, temporal coding, information processing and transfer, and neuronal 
computation and storage (Buzsaki, 2006; Fell and Axmacher, 2011). Non-
invasive electrophysiological techniques, such as electroencephalogram (EEG) 
recordings, can be used to measure this activity at the level of coordinated 
neuronal ensembles within the human brain.  
1.5.1 Up and down states 
Anaesthetics such as urethane induce a slow wave oscillation termed up and 
down states, comparable to those generated in slow wave sleep and quiescent 
wake, and is used as a model of synchronous cortical network activity (Neske, 
2016). This bistable oscillation fluctuates neuronal membrane potentials between 
hyperpolarised and depolarised membrane voltages at a low frequency (<1 Hz), 
referred to as down and up states respectively (Steriade et al., 1993a; Wilson and 
Groves, 1981). It is thought that these two states are generated and maintained 
due to a balance of excitation and inhibition within neuronal networks, in addition 
to intrinsic cellular properties (Egorov et al., 2002; Haider et al., 2006; Neske, 
2016; Wilson and Cowan, 1972). Studies within the thalamocortical network 
suggest that up and down states can be self-sustained with a cortical column, but 
also receive periodic input from the thalamus to help synchronize neuronal 
populations (Sheroziya and Timofeev, 2014; Steriade et al., 1993b; Timofeev et 
al., 2000). Therefore, measuring different properties of this oscillation can provide 
insight into the local excitatory and inhibitory network activity, making it a 
reasonable model to study cortical network dynamics. 
By studying evoked responses under anaesthesia, the contribution of synaptic 
activity can be more easily isolated in conditions of reduced local and global 
activity associated with awake states. Evoked responses induced by whisker 
stimulation in the somatosensory cortex are multicomponent post-synaptic 
potentials, comprised of glutamatergic and GABAergic components, providing a 
system to experimentally drive synaptic activity in vivo (Gambino et al., 2014; 
Lavzin et al., 2012; Lebedeva et al., 2019). Evoked responses are modulated by 




states compared to down states (Ferrarese et al., 2018; Gambino and Holtmaat, 
2012; Petersen et al., 2003; Sachdev et al., 2004). Therefore, this system can 
also be used to measure local network influence on controlling synaptically-driven 
activity. 
1.5.2 Neural network dysfunction in tauopathy 
Work within models of tauopathy has tried to ascertain more generalised 
tauopathy-induced network disruption. Infusion of tau fibrils into a pathology free 
region within the P301S model of tauopathy, saw a reduction in spontaneous 
neuronal activity (measured via cellular Ca2+ imaging) independent of NFT 
presence (Marinković et al., 2019). Functional connectivity, as detected using 
functional magnetic resonance imaging, was also significantly reduced in mouse 
models which overexpress anti- or pro-aggregant tau isoforms (Green et al., 
2019). Network silencing has been observed in the chronic rTg4510 model of 
tauopathy, as measured by Ca2+ imaging of spontaneous neuronal activity 
(Busche et al., 2019; Jackson et al., 2017). Within the same model, whole-cell 
recordings revealed a reduction in the principal frequency of up and down states, 
a reduction in the number of up states, and increased false up state transitions 
(Menkes-Caspi et al., 2015). These data suggest that there is typically a reduction 
in network activity in tauopathy. There is also evidence for network compensation 
in the face of the pathological accumulation of tau (Crimins et al., 2013). Other 
studies within the rTg4510 model revealed preserved visually evoked responses 
and head direction cell functionality, when other functionalities that also depend 
on the network were disrupted (Kuchibhotla et al., 2014; Ridler et al., 2019). 
These observed differences in neuronal dysfunction between different cortical 
regions may reflect the level of pathological burden within each region, or the 





The pathogenic accumulation of tau is implicated in cognitive impairment, with 
tauopathies displaying progressive, age-associated neurodegeneration 
associated with dementia. It is known that tauopathy can alter synaptic function 
(Jackson et al., 2017), neuronal excitability (Crimins et al., 2012), and network 
activity (Menkes-Caspi et al., 2015). However, the sequence of 
pathophysiological changes occurring early in the neurodegenerative process in 
tauopathy is unclear. Deconstructing the sequence of events triggered by 
tauopathy and how this is compensated for functionally, would provide an 
opportunity to identify mechanisms that can delay cognitive decline. Also, 
interventions targeting earlier stages of the disease would provide an opportunity 
for full symptomatic rescue prior to overt cell loss. Therefore, this thesis aims to 
delineate the relationship between tau pathology, and changes in neuronal 
morphology and function in the earlier neurodegenerative stages of tauopathy, in 
addition to characterising how alterations manifest in more advanced stages of 
tauopathy. This work was performed in the somatosensory cortex of the rTg4510 
mouse model of tauopathy with the following aims: 
1. To examine the effects of prodromal tauopathy on synaptic and neuronal 
physiology, neuronal morphology, and receptor expression in vitro to identify 
biomarkers of dysfunction. Whilst it is known that tau can affect both synaptic and 
neuronal physiology, little is known about what alterations occur early in the 
neurodegenerative process and how these interact within the brain. 
2. To explore how tauopathy-driven dysfunction in vitro manifests in neuronal 
circuits in vivo, and the impact this has on network physiology. The local network 
imposes some regulatory control over intrinsic and synaptic properties, 
noticeable under up and down state oscillations. Within a functional network, 
there is likely to be some masking of synaptic and neuronal dysfunction that may 
be seen in vitro providing compensatory control.  
By characterising the effects of prodromal tauopathy using multiple in vitro and in 
vivo techniques, this work aims to increase our understanding of the functional 





2 NEUROPHYSIOLOGICAL CHARACTERISATION OF THE 
SOMATOSENSORY CORTEX SHOWS SUBTLE 
SYNAPTIC AND NEURONAL DYSFUNCTION IN RTG4510 
MICE IN PRODROMAL TAUOPATHY 
2.1 INTRODUCTION  
Abnormal tau pathology has been shown to affect neurophysiological function, ranging 
from synapses to networks (Ahnaou et al., 2017; Marinković et al., 2019; Stancu et al., 
2015; Zhou et al., 2017). Different functional phenotypes can be seen within the same 
mouse model, which would likely be related to the onset and progression of pathology 
within that cellular population. For example, dysfunctional characteristics identified in 
the rTg4510 mouse model at a young age (2 months (2M)) in the frontal cortex and 
hippocampus, either persisted or were absent at older ages (9M) with the emergence 
of other novel functional changes (Crimins et al., 2011, 2012; Hatch et al., 2017). 
Recent work characterising pre-neurodegeneration physiology (~5M) in the rTg4510 
model revealed specific alterations in synapse dynamics and neuronal activity. This 
included increased spine turnover and an increase in silent neurons (i.e. non active 
neurons), eluding to altered synaptic function and reduced neuronal excitability 
(Busche et al., 2019; Jackson et al., 2017; Menkes-Caspi et al., 2015). However, these 
studies measured action potential (AP) related Ca2+ transients as a proxy of neuronal 
activity, and therefore synaptic and neuronal electrophysiology were not explicitly 
measured within these studies. Therefore, this chapter aimed to characterise synaptic 
and neuronal function in the rTg4510 model of tauopathy at an early 
neurodegenerative phase (~5.5M) using in vitro whole-cell patch clamp 
electrophysiology in the somatosensory cortex. Characterising changes in synaptic 
and neuronal function at this age would highlight potential mechanisms that may be 
underpinning dysfunction. Synaptic function was also examined at more progressed 
neurodegenerative phases (~7.5M) to assess whether any changes seen in synaptic 
function persisted following neurodegeneration onset, or whether the changes were a 




2.1.1 Synaptic function in rTg4510 mice  
Synaptic degeneration is currently the best correlate of cognitive decline in AD (Scheff 
et al., 2006, 2007), and therefore it is paramount to understand synaptic alterations 
that likely correspond to degeneration that occurs over the disease (Jackson et al., 
2019).  
In the rTg4510 mouse model, measures of total synapse density were maintained at 
5.5M of age in the somatosensory cortex, with a reduction in synapse density 
occurring by 8.5M with a corresponding loss of neuropil volume (Jackson et al., 2017; 
Kopeikina et al., 2013a). Excitatory neurons in the model exhibit reduced dendritic 
spine density by 8.5M (with inhibitory synapse density still unexplored) (Kopeikina et 
al., 2013a; Rocher et al., 2010). Prior to reductions in spine density, there is an 
observable shift from larger, more “mature” mushroom type dendritic spines in favour 
of thin filopodia spines (less mature, more likely transient), with a significant increase 
in spine turnover to presumably help compensate for the loss of mushroom type spines 
(Crimins et al., 2011, 2012; Jackson et al., 2017). A change in the distribution of 
synapse shape and size from larger more stable mushroom type spines to filopodia 
and other smaller subtypes would likely correlate with alterations in the composition of 
glutamatergic receptors in synapses (Araya et al., 2014; Bourne and Harris, 2007). 
For example, larger mushroom spines typically have increased expression of AMPA 
receptors (AMPARs) at the synapse leading to increased synaptic strength (Araya et 
al., 2014; Fischer et al., 2000). Therefore, this shift in the distribution of spine shape 
is likely to alter glutamatergic signalling in the model, such as AMPAR or NMDA 
receptor (NMDAR) -mediated activity. 
Synaptic activity in the frontal cortex, characterised using whole-cell electrophysiology, 
revealed an increased frequency of spontaneous excitatory post-synaptic currents 
(sEPSC) at ~9M in the rTg4510 mouse model (Crimins et al., 2011). However, this 
increase was specifically in a subpopulation of neurons with a non-atrophic structure 
compared to atrophic neurons (Crimins et al., 2012). In addition, the distribution of 
event amplitudes were different between these two subpopulations of neurons, 
suggesting a homeostatic change in glutamatergic transmission in neurons with 
differing levels of pathology (Crimins et al., 2012). Cultured neurons from the rTg4510 
mouse model have shown reduced sEPSC amplitude and frequency which is related 




changes in short-term synaptic plasticity, such as a reductions in the paired-pulse 
ratio, has been seen in the hippocampus at age points prior to the onset of 
neurodegeneration in the rTg4510 model (Gelman et al., 2018; Hoover et al., 2010). 
Further characterisation of glutamatergic synaptic activity and short-term plasticity in 
the somatosensory cortex is therefore needed to define and clarify the changes that 
are specifically occurring in this model in relation to neurodegeneration.  
2.1.2 Neuronal function in rTg4510 mice 
Studies performed in aged rTg4510 mice (7+ months old) have revealed a 
hyperexcitability phenotype in neurons in the hippocampus and cortex (Booth et al., 
2016a; Crimins et al., 2011, 2012). Neurons in the hippocampus and medial entorhinal 
cortex have altered firing rate synchrony to local oscillations and a change in phase 
encoding to oscillations (Booth et al., 2014, 2016b; Witton et al., 2016). Reductions in 
AP related Ca2+ transients, measured by fluorescence imaging techniques, suggests 
a reduction in AP firing earlier in the model (4/5M) (Busche et al., 2019; Jackson et al., 
2017). Changes in excitation would alter signal encoding and shape the dynamics of 
network activity (Booth et al., 2016a; Johnston and Wu, 1994). This could have 
consequences for complex cognitive behaviours that require coordinated neural 
activity between multiple brain regions.  
Whole-cell recordings in the hippocampus revealed a hyperexcitable phenotype 
(increased rheobase) pre- but not following neurodegeneration onset (Hatch et al., 
2017). However, a hypoexcitable phenotype was observed (decreased input 
resistance and rheobase) in the frontal cortex pre-neurodegeneration (Crimins et al., 
2012). Interestingly, one paper saw a decrease in AP amplitude only at the more 
advanced age points (9-13M), suggesting that different neurophysiological alterations 
can appear in a progressive manner in the rTg4510 mouse model (Crimins et al., 
2012). A depolarised resting membrane potential, alterations in hyperpolarisation-
activated currents (sag) and changes in the AP waveform have been shown across 
ages within the rTg4510 model in the hippocampus and frontal cortex, with some of 
these changes unrelated to mature tau pathology (Crimins et al., 2012; Hatch et al., 
2017; Kuchibhotla et al., 2014; Rocher et al., 2010). Defining any changes in intrinsic 
neuronal properties in the early neurodegenerative phase of tauopathy in the rTg4510 
mice in the somatosensory cortex may identify changes that precipitate into 





From work by Jackson et al., 2017, it is likely that synaptic function is altered at ~5.5M 
of age in rTg4510 mice in relation to the observed changes in dendritic turnover and 
degeneration. Therefore, this work aimed to characterise excitatory synaptic function 
early (~5.5M) and at more progressed neurodegenerative age points (~7.5M) using in 
vitro whole-cell patch clamp electrophysiology in littermate rTg4510 and wildtype 
control mice. This would provide a more definitive picture of the changes occurring in 
single cells by directly measuring synaptic function using whole-cell patch clamp 
electrophysiology. In addition, this work characterised neuronal function (passive and 
active intrinsic neuronal properties) at an early neurodegenerative phase (~5.5M) of 
tauopathy using in vitro whole-cell patch clamp electrophysiology in littermate rTg4510 
and wildtype control mice. Neuronal excitability, for example, may be altered and thus 
link to changes in the frequency of synaptic currents. Therefore, quantifying changes 
in synaptic function and neuronal function should provide insight into the 
electrophysiological changes that are occurring at a single cell level at a phase where 
dendritic spine stability is decreased. 
2.3 METHODS 
2.3.1 Ethical approval 
This study was approved by the University of Exeter Animal Welfare Ethical Review 
Board. All procedures, including Schedule 1 procedures, were performed in 
accordance with the UK Animal (Scientific Procedures) Act 1986 and its subsequent 
amendment in 2012 to align with European Directive 2010/63/EU on the protection of 
animals used for scientific purposes.  
2.3.2 Animals 
2.3.2.1 rTg4510 mice 
Male rTg4510 (TG) mice and wildtype (WT) littermate controls were bred at ENVIGO 
(Oxon, UK) and provided by Eli Lilly & Company. These mice were kept on a 12:12 
light/dark cycle, with ad libitum access to food and water. TG mice were carriers for 
both the tetracycline transactivator and P301L mutant tau, whereas WT mice were null 
for both transgenes. Animals were transferred to a vivarium at the University of Exeter 
and were habituated to the new environment for at least two weeks prior to 




light/dark cycle, and granted ad libitum access to food and water. Experiments and 
analysis were performed blind with respect to genotype. 
The TG mouse has specific synaptic deficits at 5-6 months which occurs just prior to 
neurodegeneration onset at 6-7 months (Jackson et al., 2017; Kopeikina et al., 2013a; 
Ramsden et al., 2005; SantaCruz et al., 2005). Therefore, the mice used in this chapter 
were at ~5.5 months of age (pre-neurodegeneration onset) and ~7.5 months of age 
(following neurodegeneration onset). Experiments were done in batches of littermate 
animals with details shown below (Table 2.1):  
 
Table 2.1 Experimental batches of animals. Experiments were performed on three 
batches of animals. Each batch were composed of WT and TG littermates. The second 
and third column details the n numbers, and details about the age of the animals used 
in weeks. 
Animal batch WT group details TG group details 
Batch 1 (synaptic 
properties at ~5.5M) 
N: 10 animals 
Range: 19.6 – 24.4 weeks 
Mean: 22.4 weeks 
N: 10 animals 
Range: 19.9 – 25.1 weeks 
Mean: 22.5 weeks 
Batch 2 (intrinsic neuronal 
properties at ~5.5M) 
N: 5 animals 
Range: 21.7 – 26.4 weeks 
Mean: 24 weeks 
N: 5 animals 
Range: 22.2 – 24.7 weeks 
Mean: 23.9 weeks 
Batch 3 (synaptic 
properties at ~7.5M) 
N: 5 animals 
Range: 31.4 – 33.9 weeks 
Mean: 33 weeks 
N: 5 animals 
Range: 32.4 – 34 weeks 
Mean: 33.2 weeks 
 
2.3.3 In vitro whole-cell patch clamp recordings 
2.3.3.1 Slice preparation 
All experiments began approximately between 10:00 and 12:00 (3-5 hours post lights 
on) to reduce experimental variation due to circadian effects (Bridi et al., 2020). Mice 
were sacrificed using cervical dislocation. The brain was then quickly removed with 
care and placed into an ice cold sucrose solution containing (in mM): 189 Sucrose, 10 
D-Glucose, 26 NaHCO3, 3 KCl, 5 MgSO4.7H2O, 0.1 CaCl2 and 1.25 NaH2PO4 bubbled 




The brain was dissected to produce thalamocortical slices as described by Agmon & 
Connors, 1991 (Figure 2.1 A) with slices prepared on a Leica VT1200 vibratome. To 
produce slices, the brain was removed from sucrose solution and placed on a custom 
block (Figure 2.1 B) with a 10° slope, with the rostral end pointing down the slope 
(Figure 2.1 A). The midline of the brain was aligned to be parallel with the edges of 
the slope. A cut was made at an angle of 55° from the midline as close to the olfactory 
bulbs as possible and the rostral tissue was discarded. The cerebellum was cut off 
and discarded and the brain was superglued with the rostral side face down onto the 
specimen holder (Figure 2.1 A). Slices of ~800 µm were cut and discarded until one 
hippocampal hemisphere was visible at ~-2.7 mm anterior-posterior from bregma. 
Cutting speed was then reduced to 0.09 mm/s and cutting thickness was reduced to 
300 µm. Approximately 5 thalamocortical slices were cut to a thickness of 300 µm with 
~4 of these slices containing the region of interest (visible barrel fields in layer IV of 
somatosensory cortex; Figure 2.1 C). Slices were removed from the chamber and 
placed into room temperature (~20°C) artificial cerebrospinal fluid (aCSF) composed 
of (in mM): 124 NaCl, 3 KCl, 24 NaHCO3, 2 CaCl2, 1.25 NaH2PO4, 1 MgSO4, 10 D-
Glucose bubbled in carbogen (95% O2, 5% CO2). Slices were left to recover in room 






Figure 2.1 Thalamocortical slice preparation based on Agmon & Connors, 
(1991). An overview schematic of the preparation of thalamocortical slices (A), 
adapted from Agmon & Connors, (1991). A photograph of the cutting block used to 
make thalamocortical slices with annotations (used with permission from Michael T. 
Craig; B). An example image of a slice with barrel fields (highlighted with a yellow 
dotted line) showing the typical positioning of the recording and stimulating electrode 






2.3.3.2 Electrophysiological recordings 
2.3.3.2.1 Recording solutions 
A slice was placed in the recording chamber, held using a small metal harp, and was 
continuously perfused with oxygenated aCSF (flow rate ~2 ml/min) maintained at a 
temperature of ~33 °C. Drugs applied during in vitro recordings were bath applied with 
details shown in Table 2.2. All slice recordings were performed with bath applied 
Gabazine, a GABAA receptor antagonist, in the aCSF to allow isolation of excitatory 
responses by blocking feed-forward inhibition following electrical stimulation. 
Recording electrodes were fabricated on a P-97 Flaming Brown micropipette puller 
(Sutter Instrument Co.) to a resistance of 3-7 MΩ. Electrodes were then filled with an 
intracellular solution (made as specified in Table 2.3). 
 
Table 2.2 Drugs applied to the aCSF during neurophysiological recordings. A 
table showing details of the drugs applied to the extracellular solution (aCSF) for 
recordings. Drugs were added into the aCSF to produce the concentrations listed from 
stock solutions. 



















Table 2.3 Intracellular solution compositions. A table showing the composition of 
the intracellular solutions used with concentrations in mM. All intracellular solutions 
were adjusted to pH 7.3 using CsOH for solution 1 and KOH for solution 2. The 
osmolarity of all solutions were ~295 mOsm. 




CsMeSO4 120 - 
K-Gluconate - 135 
NaCl 6 5 
QX314-Cl 5 - 
HEPES free acid 10 10 
EGTA - 0.2 
BAPTA 10 - 
GTP-2Na salt 0.3 - 
GTP-Na salt - 0.3 
ATP-Mg Salt 4 4 
Biocytin 13.4 13.4 
 
 
Recording voltages were corrected for a liquid junction potential error (JPE) of -15 mV 
for solution 1 and -10 mV for solution 2, based on a theoretical value calculated from 
the solution compositions, which arose due to the different concentrations of 
electrolytes between the aCSF and the intracellular electrode solution.  
2.3.3.2.2 Barrel visualisation – region of interest identification 
The somatosensory cortex contains discrete regions in layer IV known as barrel fields. 
These are darker elliptical fields which can be seen in Figure 2.1 C, with visual 
changes in darkness between the layers used to identify layer IV for stimulation 
electrode placement. Layer IV axons primarily innervate layer II/III neurons within the 
same cortical column, as part of the lemniscal whisker-sensing pathway, and so 
stimulation in layer IV should evoke synaptically-driven responses in layer II/III (Lefort 
et al., 2009).  
Slices were visualised using a monochrome camera (Thorlabs, USA, Cat# 




(Scientifica, UK) connected to a constant-current isolated stimulator box (Digitimer, 
UK) was placed as close as possible to the centre of the barrel under 4x magnification. 
The stimulating electrode was then found under 40x magnification, and whole-cell 
patch clamp recordings were made from neurons located between the stimulating 
electrode and the edge of the brain slice (pia). This ensured that neurons were 
recorded in the same cortical column as the barrel, targeting putative pyramidal 
neurons in layer II/III specifically. Following recordings, coordinates of the cell in 
relation to the slice orientation and distance from the hippocampus were noted to allow 
for subsequent histological identification of recorded neurons. 
2.3.3.2.3 Recording protocols: Characterisation of in vitro synaptic function 
All recording protocols were optimised in pilot experiments using C57Bl/6J mice aged 
between 3-8 months (data not shown).  
These recording protocols were performed using animals in Batch 1 (~5.5M) and 3 
(~7.5M; Table 2.1). Recordings of in vitro synaptic function were performed in voltage 
clamp (VC) using intracellular recording solution 1 (CsMeSO4 based; Table 2.3). Raw 
signals were lowpass filtered at 5 or 10 kHz, with 10x output gain and sampled at a 
rate of 20 kHz. 
Signals were amplified using either an Axopatch 200B (Molecular Devices, USA) or a 
Multiclamp 700A (Molecular Devices). All were digitised using an Axon Digidata 1550 
analogue-to-digital converter (Molecular Devices) and recorded on a PC using pClamp 
v10.4 (Molecular Devices).  
Following recordings, brain slices were transferred into 4% PFA in 0.1 M PBS and 
fixed overnight. Slices were then stored in 0.1 M PB until needed. 
2.3.3.2.3.1 Characterisation of in vitro synaptic function: Spontaneous excitatory 
postsynaptic currents (sEPSC) 
sEPSCs were measured during the second minute post break-in, with the cell being 
held at fixed voltage of -70 mV. An example recording trace is shown in Figure 2.7 A. 
2.3.3.2.3.2 Characterisation of in vitro synaptic function: NMDA:AMPA receptor 
response ratios 
For recording NMDA:AMPA receptor response ratios, an electrical stimulus was 




ms and the intensity was changed to evoke a consistent EPSC response 
approximately between 50-150 pA in amplitude (range 10 pA-180 pA, with a mean 
response of 58 pA and a mean electrical stimulation intensity of 129 mA (range 10-
900 mA)), based on the protocol described in (Booth et al., 2014). This stimulus 
intensity was kept constant throughout the rest of the recording protocols.  
NMDA:AMPA receptor response ratios were measured by recording the response of 
the cell to a single stimulus at -70 mV, then at +40 mV, to get the AMPAR and NMDAR 
response values respectively. The response at +40 mV was composed of both 
AMPAR and NMDAR activity, and so 50 ms was chosen as a time point post stimulus 
to quantify the NMDAR-mediated component of the response. This time point was 
deemed to be past the end of the fast AMPAR-mediated activity, whilst still including 
NMDAR activity (assessed in pilot studies – data not included). The NMDAR 
antagonist, L689560 (5µm, Abcam; Table 2.2), was added to the extracellular aCSF 
in a subset of experiments to confirm that the recorded NMDA value was composed 
of NMDAR activity (Figure 2.2). The drug was washed on the slice continuously for at 
least 10 minutes prior to recordings (a reduction in the NMDAR evoked response 
leading to a corresponding reduction in the NMDA:AMPA ratio was seen after 5 








Figure 2.2 Measures of synaptic function: NMDA:AMPA receptor response 
ratios.   Traces showing an example NMDAR and AMPAR response profile. The 
AMPAR component was taken as the peak amplitude at -70 mV, labelled and shown 
in black. The NMDAR component (blue line) was taken at +40 mV, as the recorded 
response value at exactly 50 ms post stimulus, with this time point highlighted on the 
trace in a blue box. This box also highlights the AMPAR-mediated response trace, 
showing that there is little contribution of AMPARs to the +40 mV response at this time 
point. This is emphasised by the response recorded following the application of the 
NMDAR antagonist, L689560 (5 µM; grey line). In this, and in all subsequent figures, 
stimulus artifacts were removed from the trace for clarity. The black downward arrow 
denotes stimulus onset. 
 
2.3.3.2.3.3 Characterisation of in vitro synaptic function: evoked excitatory 
postsynaptic currents 
To record evoked EPSCs (eEPSCs), the cell was held at -70 mV and electrical 
stimulation was applied to layer IV with the same settings mentioned above for 
recording NMDA:AMPA ratios. Six stimuli were delivered at 5 Hz every 18 seconds 
(15 second recording sweep, 3 seconds between sweeps) for 10 sweeps and 
responses were recorded. This was then repeated at 10 Hz and 30 Hz frequencies. 






Figure 2.3 Example traces of eEPSCs. Representative traces showing eEPSC 
responses stimulated at 5 Hz (A), 10 Hz (B) and 30 Hz (C) in VC. Arrows denote 
stimulus onset. 
 
2.3.3.2.4 Recording protocols: Characterisation of in vitro intrinsic neuronal properties 
Recordings of intrinsic neuronal properties were performed in current clamp (CC) 
using intracellular recording solution 2 (KGluconate; Table 2.3). These recordings 
were performed using animals from Batch 2 (~5.5M; Table 2.1). Recordings were 
lowpass filtered at 10 kHz, with an output gain of 50x and sampled at a rate of 100 
kHz. The bridge circuit of the amplifier was balanced at the start of each neuronal 
recording to give a more accurate measure of the membrane potential. Recordings 
were performed either at rest or the membrane potential was clamped at -70 mV (JPE 
corrected).  
2.3.3.2.4.1 Characterisation of in vitro intrinsic neuronal properties: Passive and active 
electrical properties 
A series of increasing current steps were injected for 500 ms, starting at -100 pA, 
increasing in 50 pA increments to + 300 pA. This was done at rest and at -70 mV (JPE 
corrected), and was used to determine passive electrical membrane properties from 
sweep 1 and excitability across all sweeps (Figure 2.4 A.).  
Rheobase, the minimum amount of current needed to evoke an AP, was found by 
injecting a square pulse of increasing amplitude in 2 pA increments (200 ms pulse) at 
both rest and -70 mV (JPE corrected; Figure 2.4 B). The current step that evoked the 








Figure 2.4 Passive and active electrical properties determined by square current 
injection. Current injections of increasing amplitude (sweeps) to evoke APs in cells 
with example responses to increasing current injection shown (A). An example 
rheobase protocol, where the minimum amount of current needed to evoke an AP was 
determined by injections of increasing current (B).  
 
2.3.3.3 Analysis 
2.3.3.3.1 Exclusion criteria 
Cells were excluded based on the calculated series resistance at the start of 
recordings. To calculate series resistance, the cell was voltage clamped at -70 mV, 
and briefly depolarised to -65 mV using a square current injection. At the onset of this 
current injection, there was a large and fast capacitive transient, the amplitude of which 
is determined solely by the flow of charge through the recording electrode (the series 
resistance). The transient peak amplitude was quantified and by using Ohm’s law 
(voltage = current x resistance), the series resistance was calculated by dividing the 
voltage step amplitude (5 mV) by the transient peak amplitude (pA). Cells with a series 
resistance greater than 40 MΩ were excluded from all in vitro data sets as this was 
greater than the 95th percentile distribution for the first batch of experiments (Batch 1, 




Epileptiform activity was occasionally seen in recordings (~20% of recording sweeps 
excluded) when stimulating slices, due to the lack of GABAa receptor-mediated 
inhibition from bath application of Gabazine during recordings (Figure 2.5 B). This 
activity was considerably larger than the typical evoked response (typical evoked 
response was typically within the range of 50-150 pA, epileptiform activity was >400 
pA; Figure 2.5 B). Any sweeps that appeared to have this activity were excluded from 




Figure 2.5 Exclusions criteria for in vitro recordings. A distribution plot of the 
recorded series resistance measurements per cell from Batch 1 (A), with the cut off 
criteria (determined as the 95th percentile of all series resistance measurements) 
shown as a dashed black line. An example of a typical evoked response to electrical 
stimulation (shown in black; B) and an epileptiform response to electrical stimulation 
shown in red from the same cell. Arrows denote electrical stimulations in B. 
 
The experiments for the ~5.5M synaptic recordings (Batch 1) and the ~7.5M synaptic 
recordings (Batch 3) were performed 10 months apart, and between these batches 
the skill of the experimenter to record neurons improved significantly. This is reflected 
by a significant decrease in series resistance (generalised linear mixed model: 
genotype effect (p=0.97), batch(age) effect (χ2 (1, 227) = 17.4, p<0.005***), interaction 
(p=0.37); Figure 2.6). An increased series resistance generally reflects poorer quality 
recordings, reducing the accuracy of recorded event kinetics. This would likely reduce 




recordings with lower series resistance. Due to this, these experimental batches were 
compared within age groups but not between age groups. 
 
 
Figure 2.6 Series resistance of recordings from Batch 1 and Batch 3. A box and 
dot plot showing a significant decrease in series resistance in neuronal recordings 
between the ~5.5M and ~7.5M experiments. This and all subsequent box plots will 
show the mean represented by a filled circle within the box plot, the median as a line 
within the box, and the standard error of the mean (SEM) as the edges of the box. 
Individual cells are shown as filled circles to the right of the box plot. 
 
2.3.3.3.2 sEPSCs 
Analysis of sEPSCs was performed using a custom MATLAB code, with a sliding 
template fitting algorithm which scanned traces using a scaled template looking for 
matches (based on Clements & Bekkers, 1997). The framework for this code was 
provided by Michael C Ashby. Raw traces were filtered using a moving average filter 
with a window-size of 0.5 ms. The sum of squared error (SSE) between the filtered 
trace and a scaled EPSC waveform template (based on an idealized synaptic event 
consisting of an exponential rise and decay function) was calculated. A threshold of 
typically <20 SSE was used to detect sEPSCs. An overview of this is shown in Figure 
2.7 C. sEPCS amplitude (peak height of sEPSC) and inter-event interval (time 
between sEPSC events) were calculated based on all extracted events. Rise time (10-




to baseline from a fitted exponential decay) were analysed based on the average 
waveform of the recording. An example of this is shown in Figure 2.7 B. 
 
Figure 2.7 Measures of synaptic function: spontaneous activity.  A representative 
trace showing spontaneous activity (A) with an average event waveform from one 
recording shown in B. Amplitude, rise time (in red) and decay Ƭ (in green) are labelled. 
Template scanning and analysis of spontaneous activity is shown in C. The top axis 
plots the unfiltered (grey) and filtered (blue) trace, with red circles highlighting detected 
events. The bottom axis plots the SSE when scanning the filtered recorded trace with 
a scaled waveform template (shown in inset). The detection threshold is shown as a 
dashed red line with red circles highlighting points past the threshold.   
 
2.3.3.3.3 NMDA:AMPA ratios 
For the NMDA:AMPA receptor ratio, the amplitude from baseline was measured at 
+50 ms post stimulus for the NMDAR-mediated component. This was divided by the 
peak amplitude of the AMPAR-mediated component (absolute peak at -70 mV) to 
produce an NMDA:AMPA ratio (Figure 2.2.). This was measured using custom 





For evoked EPSCs, peak amplitude was calculated using the baseline just prior to the 




Figure 2.8 Quantification of eEPSCs. A representative trace showing evoked 
EPSCs (A) with a red dotted line showing the baseline value and the solid red line 
showing the quantified amplitude. Arrows denote stimulus onset. 
 
The average response for each stimulation was then normalised to the first stimulus 
response amplitude using the following equation:  
Normalised eEPSC = eEPSC amplitude(n) / eEPSC amplitude(1) 
This measure was displayed per stimulus number as eESPC summation (changes in 
normalised response). The sum normalised area under the curve (i.e. the normalised 
change overall), was also measured to determine the overall facilitation or depression 
of the response and was calculated as the sum normalised response divided by 6. 
These analyses were completed using custom MATLAB code or manually using 
Clampfit v10.4. 
2.3.3.3.5 Passive properties 
Custom MATLAB code was used to analyse passive properties, with the framework 
provided by Jon T Brown. The resting membrane potential (RMP) was taken as the 
average membrane voltage prior to any current injection on the first sweep. Passive 
properties were taken from the first current injection step (-100 pA) which evoked a 
negative voltage deflection (Figure 2.9 A.). Input resistance (Ri) was calculated using 




deflection, divided by the amplitude of the negative current injection (100 pA). An 
exponential curve was fitted to the response at the start of the current step, with the 
time constant Ƭ calculated from 10-90% of this curve. Another way of measuring Ri 
(extrapolated) was calculated from the exponential fit, extrapolated to a steady state 
response. This assesses Ri independently of Ih current (sag) activation. Similarly, sag 
was calculated using two methods. One measure of sag (“fit”) was based on the 
exponential fit, calculating the difference between the change in voltage deflection at 
steady state compared to the extrapolated exponential curve at steady state. The other 
(“sub”) was taken as the difference between the peak hyperpolarisation to the current 
step compared to the mean voltage change at steady state. An approximation of 






Figure 2.9 Passive and active electrical properties determined by square current 
injection. Sweep 1 showing a hyperpolarising response of the cell (shown in black) 
and the different properties analysed from this sweep (A). An extrapolated exponential 
fit was fitted to the start of the hyperpolarising response, shown in maroon. The point 
of steady state of the neuronal response is also labelled on in maroon. Ƭ was quantified 
as shown in purple from the exponential fit. RMP was taken as the measure just before 
the current injection, with the difference between RMP and neuronal steady state used 
to calculate one measure of Ri, indicated with black arrows. Ri extrapolated was 
calculated from RMP to the extrapolated fit steady state, also shown in black arrows. 
The sag current measures are labelled in green, with sag sub calculated from the peak 
hyperpolarising response and sag fit from the extrapolated fit. Sweep 9 showing a 
depolarising active neuronal response with spike number quantified (B). An AP 
waveform showing quantification of width at threshold (highlighted in green), AP 
amplitude (shown in blue), AP peak (labelled in black) and AP threshold (shown in 
grey) (C). The afterhyperpolarisation (AHP) is also labelled on in red. A phase-plane 
plot of the AP showing membrane potential (Vm) plotted against the rate of change 
(dV/dt) (D). Highlighted are AP peak, threshold (in grey) and the maximum rate of 





2.3.3.3.6 Active properties 
Custom MATLAB code was used to analyse AP properties, with the framework 
provided by Jon T Brown. Excitability was explored by measuring the number of APs 
evoked in response to increasing amounts of injected current (Figure 2.9 B), with 
sweeps excluded if APs were deemed to be part of epileptiform activity (determined 
by visual inspection) as the recorded properties could be different in this scenario 
(Figure 2.5 B). Excess excitation under sustained input currents of increasing strength 
also led to depolarisation block, where neurons stop eliciting APs (Bianchi et al., 2012; 
Dovzhenok and Kuznetsov, 2012). This was observed in some recordings with higher 
current injections. These traces were manually quantified and excluded if not showing 
accurate AP waveforms, determined by visual inspection. 
Rheobase was calculated as the minimum amount of current needed to elicit an AP. 
AP properties were analysed from this elicited AP (Figure 2.9 C). AP threshold was 
calculated from phase-plane plots, where dV/dt surpassed 30 mV.ms-1 (Naundorf et 
al., 2006; Tamagnini et al., 2017; Figure 2.9 D). The AP peak was taken as the 
maximal voltage (mV) response with AP amplitude calculated as the difference 
between AP peak and AP threshold. AP width was measured as the width of the 
waveform at threshold and at -15 mV. Peak afterhyperpolarisation (AHP) was 
measured as the difference between AP threshold and the peak hyperpolarisation 
following the AP.  
2.3.3.4 Statistics 
Statistical tests were performed using R software (v3.5.1) with the RStudio (v1.1.456) 
integrated development environment.  
The datasets were split into three experimental batches: Batch 1 (synaptic properties 
at ~5.5M), Batch 2 (intrinsic neuronal properties at ~5.5M), Batch 3 (synaptic 
properties at ~7.5M). Whilst Batch 1 and 3 have similar experimental conditions, there 
was a significant difference in the series resistance in these recordings (Figure 2.6 B). 
Therefore, for these results statistics were calculated per batch and not compared 
between batches. 
The experimental unit for this work was individual cells, with the data presented and 
compared as such. Each cell may respond differently, with pathology potentially 




how each individual cell behaved in the brain in pathological conditions. However, by 
the nature of the experimental design, multiple cells were sometimes recorded from 
single animals (nested variable) and cells from within one animal may be more similar 
compared to cells from other animals (pseudo-replication). Therefore, I used 
generalised linear mixed models (GLMM) to help statistically account for this to avoid 
pseudo-replication (Figure 2.10; Lazic, 2010; Moen et al., 2016). GLMMs are an 
extension of linear models such as analysis of variance tests (ANOVAs), that can 
account for sources of random variability from sampling (such as sampling multiple 
cells from the same animal) (McCullagh, 2018; Nelder and Wedderburn, 1972). It can 
also model data that has a non-linear distribution. 
 
 
Figure 2.10 Diagram to show nesting of cells within animals for the two 
genotypes. A figure showing the hierarchy and clustering of cells to animals within 
genotypes. There were two genotypes in the study (WT and TG; fixed factor). Multiple 
cells could be recorded from a single animal (nested variable), and there could be an 
infinite number of animals and cells, which made animal number a random factor. 
 
For this work, genotype was considered as a fixed factor and animal number was 
included as a random factor (Figure 2.10). Whilst slice number from animals could also 
be considered as a random effect, adding extra random variables with a low sample 
size would increase the dimensionality of the model whilst decreasing the modelling 
power (overly complex modelling for a low n number). In addition, slices from the same 
animal were handled in the same way, likely minimising variance between slices. 
Therefore, slice was not considered as a random factor in the statistical modelling. 
Before modelling the data, the distribution was visualised using a histogram and 
quartile-quartile-plot and factored into the model when necessary (i.e. normal 




For results with single data points (i.e. where there was one measure from the cell 
such as mean Vm), the GLMM had the following structure: 
 
The main effect tested was the effect of genotype on the variable of interest. Random 
factors were included as 1\random factor using the R syntax for GLMM testing. 
 
For results with repeated measures (i.e. multiple responses to a stimulus or paired 
measures within the same cell), the GLMM used had the following structure: 
 
Similar to the first GLMM, the main effect of genotype on the variable of interest was 
statistically modelled. However, when repeated measures were taken, these were 
accounted for by factoring in the repeated measure (i.e. stimulus number) as a fixed 
interacting factor (interaction denoted by the asterisk). The repeated measure was 
modelled as a fixed effect, and cell number was factored in as a random effect as 
multiple measures were taken from the same cell. 
The best model for the data was chosen based on the lowest Akaike information 
criterion (AIC) value along with other measures of fit from the model such as 
assessment of the residuals for normality and heteroscedasticity. The intraclass 
coefficient (ICC) was measured to determine whether animal number had a significant 
effect on the data variability (values greater than 0.1 were included, quantified on a 
scale of 0 to 1). If so, then a GLMM was used to examine the data. For ICC values of 
<0.1, t-tests were used to help reduce the dimensionality of the model and avoid an 
overly complex model with lower statistical power as t-tests are specifically 




For GLMMs, goodness of fit chi squared (χ2) tests were used to evaluate the fit of each 
factor included within the model to determine the statistical significance within the 
model. Significant results were described as (χ2 (df, n) = a, p=b*). This lists the degrees 
of freedom within the χ2 test (df) and the number of observations within this linear 
model (n). The χ2 value was then listed (a) along with the corresponding p value (b) 
with asterisks denoting significance when alpha <0.05. Non-significant results were 
listed with a p value only. Results were sometimes also stated as the estimate of 
change with standard error in brackets as part of the reported output from the GLMM 
to help signify the amount and direction of the effect. A Tukey-Kramer multiple 
comparison adjustment was used for post hoc testing whilst controlling for multiple 
comparisons. 
If animal number was shown to have no effect on the variance (i.e. an ICC value of 
<0.1), then the data was tested for normality using a Shapiro-Wilk test. If the data was 
not normally distributed (i.e. non-parametric), then a Mann-Whitney U non-parametric 
t-test was run. If the data was normally distributed with equal variances, then a 
Student’s t-test was run. If the variances were unequal, then a Welch t-test was run. 
Significant results were described as (t(df, n) = a, p=b*), where a was the t-test statistic 
(t), df was the degrees of freedom, n was the total n number, and the p value was b. 
Significance was denoted with asterisks: p<0.05*, p<0.01**, p<0.005***. Non-
significant results were listed as a p value only. 
Two-sample Kolmogorov-Smirnov tests were used on cumulative distribution plots to 
determine if the samples came from different populations. Significant results were 
described as (D(df) = a, p =b*). A was the Kolmogorov-Smirnov test statistic (D), df was 
the degrees of freedom, and the p value was b. Significance was denoted with 
asterisks: p<0.05*, p<0.01**, p<0.005***. Non-significant results were listed as a p 
value only. 
Unless stated otherwise, data was presented as mean ± standard error of the mean 
(SEM). Box plots show mean (square), median (line) ± SEM (box). Significance was 





2.4.1 Spontaneous synaptic activity was reduced in frequency 
following neurodegeneration onset in the rTg4510 mice 
A total of 46 cells across 20 animals (10 animals per genotype, n = 23 cells per 
genotype, ~5.5M of age, Batch 1) were recorded and analysed for spontaneous 
synaptic activity. There was no significant difference in series resistance between 
genotypes (WT 21.89 ± 0.72 MΩ, TG 21.91 ± 0.78 MΩ, GLMM, p=0.98).  
Amplitude (WT 12.19 ± 0.89 pA; TG 13.86 ± 0.89 pA, GLMM, p=0.24) and inter-event 
interval (WT 807 ± 171 ms; TG 653 ± 122 ms, GLMM, p=0.91) of sEPSCs were not 
statistically different between genotypes (Figure 2.11 A & B). Whilst the average 
responses were similar, the distribution of events may have been different (i.e. 
proportion of different event amplitudes). However, the cumulative frequency 
distribution of amplitude (KS test, p=0.65) and inter-event interval (KS test, p=0.99) 
were also not statistically different between genotypes (Figure 2.11 C & D). 
 
Figure 2.11 sEPSC properties in ~5.5 M old TG and WT mice were not statistically 
different between genotypes.  Mean inter-event interval (A) and amplitude (B) are 
shown as box and dot plots. Cumulative frequency plots of inter-event interval (C) and 
amplitude (D) are shown below. For C & D, the line plots the average, and the shading 





In addition, the kinetics of the average sEPSC waveform were analysed and rise time 
(WT 0.8 ± 0.05 ms; TG 0.8 ± 0.06 ms, GLMM, p=0.63) and decay Ƭ (WT 3.11 ± 0.22 
ms; TG 2.70 ± 0.22 ms, GLMM, p=0.34), were not statistically different between 
genotypes (Figure 2.12).  
 
 
Figure 2.12 sEPSC waveform kinetics in ~5.5M old TG and WT mice were not 
statistically different between genotypes. The average waveform (line) of all 
recorded neurons, based on the average waveform per neuron per genotype, scaled 
to values between 0 and 1 with SEM (shaded) (A). Box plots of average rise time (B) 
and decay Ƭ (C) are also shown. 
 
A total of 43 cells were analysed across 10 animals to assess differences following 
neurodegeneration onset (5 animals per genotype, n=20 WT & 23 TG cells, ~ 7.5M of 
age, Batch 3). There was no differences in series resistance between genotypes within 
the batch (WT 15.56 ± 0.73 MΩ, TG 15.57 ± 1.24 MΩ, GLMM, p=0.2, Figure 2.6). As 
mentioned in the methods, there was a significant reduction in series resistance 
between Batch 1 and 3 (Figure 2.6). This change would alter the ability to faithfully 
record the kinetics of the synaptic currents recorded, producing artificial differences 
between the two batches. Therefore, statistical comparisons were restricted to within-
age group comparisons, and not used to compare across age groups. 
sEPSC inter-event interval was significantly increased in the TGs following 
neurodegeneration onset (WT 1273 ± 389 ms; TG 1740 ± 289, U(1,43)=145, p=0.04*, 
Mann-Whitney U t-test; Figure 2.13 A). Amplitude was not statistically different 
between genotypes (WT 18.71 ± 1.23 pA; TG 16.85 ± 0.83, p=0.22, students t-test) 
(Figure 2.13 B). Cumulative frequency plots of inter-event intervals revealed a right-
ward shift in the distribution of all interval sizes (KS test, D(31)=0.42, p=0.03*, Figure 




frequency plot of amplitude was not statistically different between genotypes (KS test, 
p=0.52, Figure 2.13 D). Rise time (WT 0.6 ± 0.04 ms; TG 0.6 ± 0.03 ms, GLMM, 
p=0.38) and decay Ƭ (WT 3.12 ± 0.29 ms; TG 2.52 ± 0.16 ms, GLMM, p=0.28) were 
also not statistically different between genotypes (Figure 2.14). 
 
 
Figure 2.13 A significant increase in inter-event interval was observed in ~7.5M 
old TG mice compared to WT mice when assessing sEPSC properties. Mean 
inter-event interval (A) and amplitude (B) were shown as box and dot plots with 
cumulative frequency plots of inter-event interval (C) and amplitude (D). Significance 
denoted with asterisks: p<0.05*. 
 
Figure 2.14 sEPSC waveform kinetics were not statistically different in ~7.5M old 
TG and WT mice. The traces plot the average sEPSC waveform (A) from each 
genotype normalised between 0 to 1 with SEM (shaded) of all recorded neurons based 





2.4.2 Observed reductions in the NMDA:AMPA receptor ratio in TG 
mice at early but not progressed neurodegenerative phases of 
tauopathy 
At the ~5.5M age point (Batch 1), a total of 39 and 33 cells in 10 WT and 10 TG animals 
respectively, were recorded for synaptically-evoked NMDA:AMPA receptor ratios. The 
stimulation electrode was positioned within layer IV, in the same cortical column as 
the recorded cell. This ratio was significantly lower (WT 0.79 ± 0.1; TG 0.53 ± 0.1, 
Mann-Whitney U t-test, U(1,72)=755, p=0.05*), in the TGs compared to WTs (Figure 
2.15 A & B). This ratio was reduced to near 0 (mean=0.1, range=0.01 – 0.43) with 
application of L689560 (an NMDAR antagonist) in both genotypes, reflecting a block 
of recorded NMDAR responses which confirms the specificity of the recorded NMDAR 
current.  
At the ~7.5M age point (Batch 3), a total of 42 WT and 30 TG cells were measured in 
10 animals (5 animals per genotype). There were no significant differences in the 
NMDA:AMPA receptor ratio between genotypes (WT 0.71 ± 0.13; TG 0.65 ± 0.16, 







Figure 2.15 NMDA:AMPA receptor ratio responses in TG mice were reduced at 
~5.5M. The average normalised waveforms (normalised to AMPAR peak, plotted as 
thick lines) from all recorded cells at ~5.5M (A) and ~7.5M (C). The vertical arrow 
indicates stimulus onset and shading represents SEM. Box and dot plots of the 
NMDA:AMPA receptor response ratio in dark blue and red which were reduced with 
the application of L689560 (shown in lighter blue and pink) at ~5.5M (B) and ~7.5M 





2.4.3 Evoked synaptic transmission was not altered in the TG mice 
at either early or progressed phases of tauopathy-mediated 
neurodegeneration 
Six stimuli were applied at 5, 10 and 30 Hz frequencies, to investigate the short-term 
plasticity of evoked synaptic transmission in 29 WT and 27 TG cells (8 and 9 animals 
respectively) at ~5.5M (Batch 1). The number of sweeps excluded for epileptiform 
activity did not change between genotypes across all frequencies (WT 1.18 ± 0.16 
sweeps ,11% of total sweeps; TG 1.51 ± 0.2 sweeps, 15% of total sweeps). For all 
stimulation frequencies, a large proportion of the variance was accounted for by the 
animal and cell number (as seen by high ICC values). This suggested that although 
different cells exhibited different short-term synaptic plasticity profiles, any single cell 
likely responded in the same manner across all stimuli (i.e. facilitating cells will 
facilitate for the whole of the response). 
For all three stimulation frequencies (5 Hz, 10 Hz, 30 Hz), there was a significant effect 
of stimulation number in altering the response when normalised to the first eEPSC (5 
Hz: χ2 (5, 336) = 33.8, p<0.005***; Figure 2.16 A), (10 Hz: χ2 (5, 312) = 36.23, p<0.005***; 
Figure 2.16 C), (30 Hz: χ2 (5, 276) = 16.56, p<0.005***; Figure 2.16 E). There was no 
significant effect of genotype (5 Hz p=0.78, 10 Hz p=0.67, 30 Hz p=0.67) or interaction 
(5 Hz p=0.94, 10 Hz p=0.88, 30 Hz p=0.56) between repeated stimulation and 
genotype (i.e. the cells responded in a similar manner per evoked response) at any of 
the stimulation frequencies.  
At the lower stimulation frequencies (5 Hz and 10 Hz), the mean cellular response was 
reduced in response to subsequent stimuli (depressing) (paired pulse ratio of 0.85 ± 
0.05 WT cells and 0.9 ± 0.09 TG cells at 5 Hz, Figure 2.16 B; 0.94 ± 0.08 WT cells 
and 0.92 ± 0.09 TG cells at 10 Hz, Figure 2.16 D). At 30 Hz, the mean response 
showed an increasing (facilitating) response to subsequent stimuli (paired pulse ratio 
of 1.26 ± 0.17 WT cells and 1.28 ± 0.26 TG cells, Figure 2.16 F). Overall, there was 






Figure 2.16 Serial evoked responses at ~5.5M of age in WT and TG mice were 
not statistically different. Normalised response summation from 6 stimuli given at a 
frequency of 5 Hz (A), 10 Hz (C) and 30 Hz (E) are shown as joined dot plots 
representing normalised responses (area under the curve normalised to the first 
evoked response amplitude) to stimulations, with the mean normalised response 
summation shown in a coloured line (WT shown in blue and TG in red) and shading 
representing SEM. The right-hand panels (B, D, F) show the paired pulse ratio (the 
second response normalised to the first response). Values above 1 suggest an overall 





Post-neurodegeneration onset (Batch 3, ~7.5M), 38 WT and 19 TG cells were 
recorded for eEPSC analysis (from 5 animals per genotype). The number of sweeps 
excluded for epileptiform activity did not change between genotypes across all 
frequencies (WT 2 ± 0.02 sweeps, 20% of total sweeps; TG 1.8 ± 0.03 sweeps, 18% 
of total sweeps).  
At ~7.5M, the results mirror those seen at the earlier age point. For all three stimulation 
frequencies (5 Hz, 10 Hz, 30 Hz), there was a significant effect of stimulation number 
in altering the response when normalised to the first eEPSC (5 Hz: χ2 (5, 342) = 113, 
p<0.005***; Figure 2.17 A), (10 Hz: χ2 (5, 324) = 36.95, p<0.005***; Figure 2.17 C), (30 
Hz: χ2 (5, 294) = 22.75, p<0.005***; Figure 2.17 E). There was no significant effect of 
genotype (5 Hz p=0.77, 10 Hz p=0.8, 30 Hz p=0.92) or interaction (5 Hz p=0.34, 10 
Hz p=0.77, 30 Hz p=0.41) between repeated stimulation and genotype (i.e. the cells 
responded in a similar manner per evoked response) at any of the stimulation 
frequencies.  
At the lower stimulation frequencies (5 Hz and 10 Hz), the majority of cells displayed 
a reduced response to subsequent stimuli (depressing) (mean paired pulse ratio in 
WT of 0.9 ± 0.14 and in TG of 0.63 ± 0.08 at 5 Hz, p=0.21; Figure 2.17 B; mean paired 
pulse ratio in WT of 0.9 ± 0.09 and TG of 1.05 ± 0.17 at 10 Hz, p=0.89 ; Figure 2.17 
D). At 30 Hz, the mean cellular response was facilitating in response to subsequent 
stimuli (mean paired pulse ratio in WT of 1.16 ± 0.16 and TG of 1.26 ± 0.2 at 30 Hz, 
p=0.95; Figure 2.17 F). Similar to the ~5.5M age group, there was no significant effect 






Figure 2.17 Serial evoked responses from ~7.5M old TG and WT mice were not 
statistically different. Normalised response summation from 6 stimuli given at a 
frequency of 5 Hz (A), 10 Hz (C) and 30 Hz (E) are shown as joined dot plots 
representing normalised responses (area under the curve normalised to the first 
evoked response amplitude) to stimulations, with the mean normalised response 
summation shown in a coloured line (WT shown in blue and TG in red) and shading 
representing SEM. The right-hand panels (B, D, F) show the paired pulse ratio (the 
second response normalised to the first response). Values above 1 suggest an overall 







2.4.4 TG neurons from ~5.5M mice were significantly depolarised 
with a decreased capacitance when recorded at RMP 
18 WT and 44 TG cells were recorded from 4 and 5 animals respectively (Batch 2 
~5.5M). A series of current injection protocols were run in CC recording mode to 
determine the passive and active electrical membrane properties at both RMP and a 
held membrane potential of -70 mV. Passive properties such as Ri, Ƭ, capacitance, 
and sag were measured using a -100 pA square-wave current injection at RMP or 
when RMP was held at -70 mV. 
With no current injection, the RMP of TG neurons (measured at the fourth minute 
following break-in) was significantly depolarised compared to WTs (WT -74.57 ± 3.41 
mV; TG -67.47 ± 2.12 mV; Mann-Whitney U t-test, U(1,44)=261, p=0.04*; Figure 2.18 
A). 
At RMP (WT -75 mV, TG -67 mV), membrane capacitance was significantly lower in 
TG cells (63.67 ± 7.84 pF, 50.71 ± 4.82 pF, Mann-Whitney U t-test, U(1,44)=474, 
p=0.05*; Figure 2.18 E). Ri measured by steady-state difference (WT 145.52 ± 17.94 
MΩ; TG 236.31 ± 25.94 MΩ, Mann-Whitney U t-test, p=0.08; Figure 2.18 B) and by 
extrapolation of exponential fit (WT 155.67 ± 22.31 MΩ; TG 262.07 ± 32.36 MΩ, Mann-
Whitney U t-test, p=0.09; Figure 2.18 C) was not significantly different between 
genotypes. The membrane time constant (Ƭ, students t-test, p=0.69; Figure 2.18 D) 
and sag (students t-test, p=0.9; Figure 2.18 F) were also not statistically different 







Figure 2.18 Depolarised RMP and decreased capacitance when measured at 
RMP in ~5.5M old TG mice. Passive electrical membrane properties measured in 
response to a -100 pA current injection. RMP (A), input resistance (B & C), Ƭ (D), 




2.4.5 Decreased capacitance in TG neurons at ~5.5M at a held 
membrane potential of -70 mV 
Under conditions in which the membrane potential was held at -70 mV, capacitance 
was significantly decreased in TG cells compared to WTs (WT 73.18 ± 10.26 pF; TG 
53.80 ± 5.06 pF; Mann-Whitney U t-test, U(1,50)=513, p=0.05*; Figure 2.19 D). Ri 
calculated from steady state (WT 155.69 ± 20.45 MΩ; TG 224.72 ± 23.07 MΩ; Mann-
Whitney U t-test, p=0.07; Figure 2.19 A) and by extrapolation from exponential fit (WT 
169.93 ± 26.57 MΩ; TG 240.19 ± 26.57 MΩ; Mann-Whitney U t-test, p=0.07; Figure 
2.19 B), although not significantly different trended towards an increase, which may 
reflect the change in capacitance. Ƭ (Mann-Whitney U t-test, p=0.96; Figure 2.19 C) 




Figure 2.19 Decreased capacitance at -70 mV in ~5.5M old TG mice.  Passive 
electrical membrane properties in response to a -100 pA hyperpolarising square 
current injection when the RMP was held at -70 mV. Ri (A & B), Ƭ (C), capacitance (D) 




2.4.6 Neuronal excitability: significant interaction effects of 
genotype in response to increasing current injections in ~5.5M 
old WT and TG cells 
 
 
Figure 2.20 AP firing in response to a series of progressively increasing current 
injections in WT and TG cells from ~5.5M old animals. The average number of APs 
in response to increasing amounts of injected current at rest (A) and at -70 mV (D). 
The line plots the average response, and the shaded error bars plot the SEM. 
Individual input output plots shown for WT and TG cells at rest (B & C respectively) 
and at -70 mV (E & F respectively). Significant effects written with significance denoted 
with asterisk: p<0.01**, p<0.005***. 
 
Square current injections were applied starting at -100 pA to 300 pA in increasing 
steps of 50 pA in order to measure cellular excitability. At rest and when RMP was 
held at -70 mV, depolarising current injections of 100 pA or larger led to significantly 
more firing as expected (RMP: χ2 (8, 486) = 1011, p<0.005***; Figure 2.20 A; -70 mV: χ2 
(8, 504) = 1141, p<0.005***; Figure 2.20 B). There was no significant effect of genotype 
at rest (p=0.94) or when the cell was held at -70 mV (p=0.47). There was a significant 
interaction of genotype with stimulus at rest (χ2 (8, 486) = 19.75, p<0.01**) and when the 
cell was held at -70 mV (χ2 (8, 504) = 39.35, p<0.005***). However, post hoc comparisons 




2.4.7 Neuronal excitability: rheobase was not statistically different 
between genotypes in ~5.5M TG and WT cells 
The rheobase was determined as the minimum current injection needed to elicit an 
AP from incremental 2 pA current injections. At both -70 mV and at RMP, rheobase 
was not statistically different between genotypes (Mann-Whitney U t-test, RMP: 
p=0.18, -70 mV: p=0.3; Figure 2.21 A & B). For both genotypes, there was a significant 
negative correlation between RMP and rheobase with more depolarised cells needing 
less current to elicit an AP (Pearson’s rank test; WT F1,15 4.5, r=-0.49, p=0.05*; TG 
F1,30 64.3, r=-0.83, p<0.005***; Figure 2.21 C).  
 
Figure 2.21 Rheobase at rest and at -70 mV. Rheobase value (pA) at RMP (A; rest) 
and when the RMP was held at -70 mV (B; -70 mV). Resting membrane potential 






2.4.8 AP-related properties revealed an increased peak AHP at RMP 
and increased AP width at -70 mV in ~5.5M rTg4510 mice 
AP properties were calculated from the rheobase evoked AP. At RMP, AP peak 
(students t-test, p=0.89), AP maximum dV/dt (students t-test, p=0.17), AP width at -15 
mV (students t-test, p=0.11), AP width at AP threshold (Mann-Whitney U t-test, 
p=0.08), and AP amplitude (Mann-Whitney U t-test, p=0.22) were not statistically 
different between genotypes. Peak AHP was significantly increased (WT 12.40 ± 0.79 
mV; TG 15.11 ± 1.08 mV; Welch t-test, t(1,42)=-2.02, p=0.05*), and AP threshold 
trended towards an increase, although this was not significantly different (WT -50.49 
± 1.55 mV; TG -47.25 ± 0.95 mV; Student’s t-test, p=0.07). This data is summarised 
in Figure 2.22. 
At -70 mV, AP peak (students t-test, p=0.63), maximum dV/dt (students t-test, p=0.17), 
AP amplitude (students t-test, p=0.53), and peak AHP (students t-test, p=0.89) were 
not significantly different between genotypes. AP threshold showed a trend towards a 
more depolarised threshold in the TG cells, although this was not significantly different 
(WT -52.29 ± 1.55 mV; TG -48.71 ± 1.09 mV; Students t-test, p=0.06). AP width at -
15 mV (WT 0.40 ± 0.05 ms; TG 0.57 ± 0.04 ms; Mann-Whitney U t-test, U(1,42)=142, 
p=0.03*) and at threshold (WT 1.35 ± 0.24 ms; TG 1.47 ± 0.09 ms; Mann-Whitney U 







Figure 2.22 Increased AHP at RMP in ~5.5M old TG mice. AP-related properties 
calculated on APs evoked from rheobase at RMP, with average AP waveforms (A) 
and average phase plots (B) shown with WT in blue and TG in red (shading & outline 
denotes SEM). Box plots showing AP peak value (C), maximal dV/dt (D), peak AHP 
(E), AP width at -15 mV (F), AP threshold (G) and AP width at threshold (H). 








Figure 2.23 Increased AP width at a held membrane potential of -70 mV in ~5.5M 
old TG mice. AP average waveforms (A) and average phase plots (B) are shown with 
WT in blue and TG in red (shading and outlines denote SEM). Box plots showing AP 
peak value (C), maximal dV/dt (D), peak AHP (E), AP width at -15 mV (F), AP threshold 







This chapter presents a functional assessment of the somatosensory cortex in the 
rTg4510 model at early neurodegenerative phases of tauopathy (~5.5M). These data 
showed a significant decrease in the NMDA:AMPA receptor ratio, suggesting a subtle 
alteration in the synaptic function of layer II/III somatosensory neurons at this age 
point. Following neurodegeneration onset, the sEPSC inter-event interval was 
decreased whilst the NMDA:AMPA receptor ratio was balanced in contrast with the 
younger age point, with other measures of synaptic function similar between 
genotypes. Alterations in some intrinsic neuronal properties were observed at ~5.5M 
of age in the rTg4510 cells (change in capacitance, AP width, peak AHP), with some 
of these changes being voltage dependent.  
2.5.1 Subtle synaptic dysfunction was observed in the rTg4510 
model that differed at early and progressed neurodegenerative 
phases of tauopathy 
In early neurodegenerative phases of tauopathy (~5.5M age point), there was no 
observed difference in the inter-event interval of spontaneous synaptic activity (Figure 
2.11). Previous studies suggest that synapse density was unchanged (Kopeikina et 
al., 2013a) and spine turnover was increased at this age point (Jackson et al., 2017), 
which could help to maintain function in the face of synaptic degeneration by 
increasing the formation of new synapses to replace degenerating ones. However, 
increases in sEPSC inter-event interval were measured post-neurodegeneration onset 
(~7.5M; Figure 2.13). Large reductions in synapse density and spontaneous AP-
related Ca2+ transients have been observed in the rTg4510 model post-
neurodegeneration onset (Crimins et al., 2011, 2012; Jackson et al., 2017; Kopeikina 
et al., 2013a), which would likely have an impact on spontaneous synaptic currents. 
This result was in contrast with Crimins et al., 2012 who detected an increased sEPSC 
frequency post neurodegeneration onset (9M). There may be further compensatory 
mechanisms and dynamic reshaping of synaptic activity such as synaptic scaling or 
local homeostatic plasticity that come into play at more aged points such as 9M that 
could explain the discrepancy between this study and Crimins et al., 2012. There may 
also be differences in the overall excitability of neurons in the slices, with sEPSCs but 




neuronal excitability into the measured events (Johnston and Wu, 1994). These 
recordings were also performed in different brain regions which have different 
timelines of pathological tau accumulation and neurodegeneration (Harrison et al., 
2020). There were no changes in sEPSC waveform properties and kinetics such as 
amplitude, rise time or decay Ƭ at either age point (Figure 2.12 & Figure 2.14). Overall, 
a reduction in sEPSCs following neurodegeneration onset could be mediated by 
decreased spontaneous pre-synaptic activity, supported by lowered neuronal activity 
seen at this age (Jackson et al., 2017). It could also be due to a reduction in AMPAR 
receptor containing synapses, with no change in existing AMPAR function related to 
subunit composition, following neurodegeneration onset (Grosskreutz et al., 2003; 
Lomeli et al., 1994; Mosbacher et al., 1994; Vicini et al., 1998). These recordings could 
be further complimented by recordings of miniature EPSCs to confirm whether 
changes in sEPSC frequency were related to changes in excitability.  
The ratio between NMDAR to AMPAR responses is thought to be important in 
governing synapse plasticity and excitatory synaptic integration (Rao and Finkbeiner, 
2007; Watt et al., 2000). The reduction in the NMDA:AMPA receptor ratio observed in 
this study at ~5.5M within the rTg4510 mice (Figure 2.15) potentially highlights 
dysfunctional synapses or neurons prior to synaptic or neuronal degeneration. 
Following neurodegeneration onset, this difference appears to be rebalanced (Figure 
2.15), which could relate to a loss of these imbalanced synapses. Alterations in 
NMDA:AMPA receptor ratios can affect the ability of the neuron to entrain with 
oscillations (Wolf et al., 2005) and a reduced NMDA:AMPA receptor ratio has been 
associated with reduced LTP in a model of AD (Tozzi et al., 2015). This altered ratio 
may therefore impact LTP and oscillatory entrainment, and so work to investigate 
these two measures in this neuronal population could reveal further deficits.  
It is not possible to tell from the NMDA:AMPA receptor ratio specifically which receptor 
function is altered. However, in consideration with the other measures examining 
putative AMPAR function (sEPSCs and eEPSCs at -70 mV; Figure 2.11 & Figure 
2.16), it is more likely to be NMDAR dysfunction or a reduction in NMDAR expression. 
This could be clarified by recording and quantifying spontaneous NMDAR-mediated 
currents at +40 mV. It is likely that there is a shift in NMDAR expression towards silent 
synapses (Moldavski et al., 2019), when considered together with the observed shift 




preserved total spine density at ~5.5M in the rTg4510 mice (Crimins et al., 2011; 
Jackson et al., 2017; Kopeikina et al., 2013a). The NMDA:AMPA receptor ratio would 
also be affected by a change in receptor expression. Expression of glutamatergic 
receptor subunits (NR1 & GluR1) were decreased in the rTg4510 model at 12M 
(Kopeikina et al., 2013a), but whether these changes in expression occur 
simultaneously with the changes in function observed here is unknown.  
Short term plasticity measures in the barrel cortex showed depression at lower 
frequency simulation patterns and facilitation at higher ones (Lefort and Petersen, 
2017). This was replicated in the present study, albeit with some subtle discrepancies 
in the facilitation pattern between the two age points in this study (Figure 2.16 & Figure 
2.17). Changes in short term plasticity likely reflect a change in the pre-synapse, either 
in release probability, vesicle depletion or calcium dependent mechanisms (Fioravante 
and Regehr, 2011). Overall, there was no change in short-term plasticity between 
genotypes at either age (Figure 2.16 & Figure 2.17). In consideration with the other 
measures of synaptic function (sEPSCs and NMDA:AMPA receptor ratio), it is likely 
that there was a change in post-synaptic activity with no observable changes at the 
pre-synapse. Interestingly, abnormal tau pathology can be found at both the pre- and 
post-synapse, and has also been shown to influence pre-synaptic physiology by 
binding to pre synaptic vesicles (McInnes et al., 2018; Zhou et al., 2017). This is 
implied to be another early mechanism of synaptic dysfunction, and so is perhaps 
occurring in other vulnerable synaptic pathways or degeneration may have already 
occurred within these pre-synaptic partners. Altered synaptic plasticity has been 
observed in recordings with acute application of oligomeric tau via the intracellular 
recording solution and in an inducible overexpression model of pro-aggregant tau (Hill 
et al., 2019; Sydow et al., 2011). These changes in synaptic plasticity may therefore 
occur early in the rTg4510 model development in acute exposure to more soluble tau 
isoforms, but perhaps not to chronic tau exposure that would be in a more fibrillar form.  
One limitation of the present study is that there was a change of series resistance 
between different batches of recordings which precluded direct comparison of 
measures of synaptic function between batches (Figure 2.6). An increased series 
resistance reduces the recording accuracy of certain waveform parameters such as 
rise time, decay Ƭ and event amplitude (Johnston and Wu, 1994). As there were no 




not an issue. However, it would be interesting to see if these properties are changed 
across aging within genotype. 
Another limitation of this study relates to the whole-cell patch clamp methodology, 
measuring synaptic currents using the voltage clamp configuration. Voltage clamp 
recordings are inaccurate in recording synaptic currents in neurons with complex 
structures, as the voltage clamp is not uniformly controlled throughout the dendritic 
tree and decays across the length of dendrites (space-clamp issues; Williams and 
Mitchell, 2008). Changes in dendritic structure, which have been previously reported 
in the rTg4510 mice, may also compound this effect skewing the proportion of detected 
synaptic currents (Crimins et al., 2012; Rocher et al., 2010). Compartmentalisation of 
electrical signals in the heads of dendritic spines has also been shown to prevent 
voltage clamping of spines, reducing the accuracy of recording synaptic activity 
(Beaulieu-Laroche and Harnett, 2018; Yuste, 2013). Again, changes in the shape and 
size of dendritic spines have also been reported within the rTg4510 model, which 
would skew recordings of synaptic currents between genotypes (Crimins et al., 2011; 
Jackson et al., 2017). Although this may be considered as a limitation of the study, 
whole-cell patch clamp electrophysiology remains the pre-eminent method for 
recording synaptic physiology. 
2.5.2 Neurophysiological function was altered in early 
neurodegenerative phases of tauopathy in the rTg4510 model 
The intrinsic properties of wildtype neurons in this study were similar to other 
recordings made from layer II/III cells in the barrel cortex (Lefort et al., 2009). A 
depolarised RMP and a decreased capacitance were seen in this study in rTg4510 
mice (Figure 2.18 & Figure 2.19). A depolarised RMP has been seen in the rTg4510 
model (Crimins et al., 2011, 2012; Rocher et al., 2010) and also with the acute 
application of intracellular tau oligomers (Hill et al., 2019). This could be caused by a 
number of different alterations including changes in the maintenance of 
transmembrane ionic currents such as Na+ and K+ currents, tau-mediated blockages 
of ion channels such as K+ channels, or by changes in overall excitatory or inhibitory 
synaptic tone  (Shimojo et al., 2020). Changes in capacitance could reflect a change 
in the structure of these neurons, and therefore a change in ion channel expression. 




8 M, and suggested that a 30% change in capacitance would have an effect on sag, 
Ƭ, AHP and resonance (Booth et al., 2016a). In this study, there was alterations in 
AHP and capacitance, without effects on sag and Ƭ, and so it would be interesting to 
see if resonance was also altered in this population of neurons at this earlier age point 
in comparison to Booth et al., 2016a. Further investigation of neuronal structure and 
ion channel expression is needed to pinpoint the mechanisms related to the observed 
change in capacitance. A decreased capacitance would produce larger and quicker 
responses to a given voltage, and in consideration with the depolarised RMP, would 
suggest neurons would need less depolarisation to reach AP threshold and therefore 
be more excitable. However, rheobase showed no difference between genotypes and 
increasing current injection spiking outputs trended towards lowered spiking outputs 
in the rTg4510 cells. There is research to suggest that the axon initial segment is 
mislocated further down the axon within the rTg4510 model, which could also reduce 
excitability by depolarising the threshold for AP initiation (Hatch et al., 2017; Kaphzan 
et al., 2011; Sohn et al., 2016). Other models of tauopathy have shown changes in 
excitability and other AP properties (Tamagnini et al., 2017) and so it is surprising to 
not observe altered excitability in this study. 
This study showed that layer II/III somatosensory cortex neurons exhibited a wider AP 
waveform and increased AHP in ~5.5M rTg4510 mice (Figure 2.22 & Figure 2.23). In 
the hippocampus, decreased AP amplitude, depolarised AP threshold and reduced 
firing to increasing current was seen prior to neurodegeneration (Hatch et al., 2017). 
Oligomeric, but not monomeric, tau application has also been shown to affect the AP 
waveform (Hill et al., 2019). It is therefore likely that at least some of the changes 
observed are due to localised increases in soluble tau expression from transsynaptic 
spread within the rTg4510 mice, and not to the more progressed tau pathology 
accumulation and neurodegeneration. Doing a time course characterisation in the 
somatosensory cortex would confirm this, as the deposition of tau pathology has been 
suggested to be heterogeneous across the cortex in this model (Harrison et al., 2020). 
There are observable alterations in the firing pattern and network dynamics in the 
rTg4510 model, and this could be related to changes in the AP waveform by altering 
ion flow dynamics across the neuronal membrane (Booth et al., 2016b; Busche et al., 




Some of these properties (increased AHP at rest and increased AP width at -70 mV) 
appear to be altered in a voltage dependent manner (Figure 2.22 & Figure 2.23). 
Alterations in properties based on the voltage of the neuron would suggest there was 
an involvement of voltage gated ion channels. Inhibition of voltage sensitive potassium 
channels such as Kv2 and BK, have been shown to increase AP width and alter AHP 
currents without affecting excitability (Kimm et al., 2015; Palacio et al., 2017). 
Blockage of Kv2 channels also showed an increased propensity to enter 
depolarization block (Palacio et al., 2017), which was also seen in this study (data not 
shown). Other voltage sensitive channels, such as HCN channels, could also be 
implicated. However, HCN channels are unlikely to be playing a role as sag was similar 
between genotypes. Functional characterisation or quantification of expression of 
these voltage sensitive potassium channels in this model may reveal a mechanism 
behind the changes in AP properties observed. 
As this analysis was blinded, exclusion criteria were based on non-physiological 
properties such as the series resistance of the recordings. The population of neurons 
recorded in the rTg4510s may be dying or changing their intrinsic properties including 
Vm. Therefore, neurons with non-typical properties such as a depolarised Vm were 
included as to not bias the results. By not excluding cells in both groups that were 
depolarised, we may have a more complete picture of the physiology of these neurons 
in the rTg4510s. Neuronal recovery would increase the confidence of the recordings, 
both by revealing if neuronal structure looked abnormal or whether the recordings are 
from the correct cell type which could explain these property changes.  
2.6 CONCLUSIONS 
At earlier neurodegenerative phases of tauopathy, there was a subtle synaptic deficit, 
observed as reductions in evoked NMDA:AMPA receptor ratios with other measures 
of synaptic activity unchanged. Glutamatergic receptor function imbalance could be 
an early change that could link to changes in synapse stability as seen in Jackson et 
al., 2017. Following neurodegeneration onset, there was an increase in sEPSC inter-
event interval which could be mediated by a decrease in synapse density, as has been 
observed in the cortex of rTg4510 mice at >7M (Crimins et al., 2011; Kopeikina et al., 
2013b). The presence of a subtle synaptic phenotype implies homeostatic 




in intrinsic function, which have been seen in other tauopathy models, were also seen 
in this study such as a depolarised RMP and changes in the AP waveform. These 
changes would likely lead to aberrant encoding and integration of incoming sensory 
information at earlier neurodegenerative phases of tauopathy, mediated by 




3 NEURONAL RESHAPING AND REDUCTIONS IN THE 
EXPRESSION OF SYNAPTIC PROTEINS IN RTG4510 
MICE IN THE SOMATOSENSORY CORTEX IN 
PRODROMAL AND PROGRESSED TAUOPATHY 
3.1 INTRODUCTION 
In tauopathies, progressive brain atrophy occurs, with degeneration of both neurons 
and synapses occurring in parallel (Braak et al., 1994; Merino-Serrais et al., 2013; 
Scheff et al., 2006, 2007). Changes in dendritic architecture prior to 
neurodegeneration is thought to occur, potentially as a homeostatic mechanism to 
compensate for loss of synaptic connections (Dickstein et al., 2010; Rocher et al., 
2010). The process of synaptic dysfunction and degeneration is also thought to be an 
early change, that may happen separately to neurodegeneration (Crimins et al., 2013; 
Hoover et al., 2010; Jackson et al., 2019). An important mediator of synaptic 
dysfunction in tauopathies is likely to be changes in the expression of synaptic 
proteins, such as alterations in glutamatergic receptor expression (Crimins et al., 
2013). 
Results presented in Chapter 2 demonstrated changes in membrane capacitance in 
layer II/III somatosensory cortex neurons in ~5.5 month (5.5M) old rTg4510 mice. This 
result may correspond to a change in dendritic architecture. To investigate this, 
dendritic morphology was analysed within a subset of neurons from which 
electrophysiological recordings were made. In addition, electrophysiological 
measurements of synaptic function revealed alterations in glutamatergic signalling in 
both ~5.5M and ~7.5M rTg4510 mice, which could reflect changes in glutamate 
receptor expression. This was further investigated by measuring protein expression in 
isolated synaptosomes from the somatosensory cortex (compared to control tissue 
from the cerebellum) at both 5.5M and 7.5M age points in rTg4510 and wildtype 
littermate mice. 
3.1.1 Tau pathology alters neuronal structure 
Alzheimer’s disease (AD) patients with advanced tau pathology (e.g. neurofibrillary 
tangles) have dendritic atrophy and a loss of dendritic spines (Braak et al., 1994; 




tauopathy (Crimins et al., 2011, 2012; Jaworski et al., 2011). Within tauopathy models, 
dendritic structure progressively changes with the development of pathology, with 
neurons displaying either increased complexity in their dendritic arbours in mice that 
overexpress human tau (Dickstein et al., 2010), or atrophy and reduced dendritic 
complexity in mice that overexpress mutant human tau (Crimins et al., 2012; Rocher 
et al., 2010). These conflicting results suggest that these changes may reflect different 
pathological disease stages in response to different tau isoforms. Changes in dendritic 
structure would be sufficient to alter input resistance and capacitance, as these 
measures both relate to total membrane area, and could explain the decreased 
neuronal excitability that has been observed in tauopathy models, including in rTg4510 
mice (Booth et al., 2016a). Changes in dendritic structure could therefore provide a 
mechanistic explanation for some of the changes in the intrinsic membrane properties 
and synaptic function in rTg4510 neurons reported in Chapter 2. 
3.1.2 Tau-mediated dysfunction and degeneration of synapses 
Abnormal tau pathology is thought to mislocate and accumulate in synapses. Tau 
pathology has been detected in synapses in post-mortem AD brain tissue (Fein et al., 
2008; Perez-Nievas et al., 2013; Tai et al., 2014) and in tauopathy mouse models 
(Hoover et al., 2010; Xia et al., 2015). This process is suggested to then lead to tau-
mediated synaptic dysfunction and degeneration (Eckermann et al., 2007; Kopeikina 
et al., 2013b; Rocher et al., 2010). Within the rTg4510 model of tauopathy, there has 
also been observed reductions in the expression of synaptic genes and proteins 
(Castanho et al., 2019; Kopeikina et al., 2013a). Synaptic structure and structural 
plasticity were also altered in other models of tauopathy, with changes in spine shape, 
volume and turnover observed (Hoffmann et al., 2014; Jackson et al., 2017).  
Overall, tauopathy has been implicated in the physiological alteration of synapses, but 
few studies have investigated how these changes relate to the progression of 
neurodegeneration. Investigating changes in synaptic protein expression at early and 
progressed neurodegenerative phases of tauopathy in the rTg4510 model will 
generate a pathological timeline of synaptic protein expression, that can be cross-




3.1.3 The role of tau pathology in excitatory receptor dysfunction 
Glutamate receptor dysfunction has been a long-standing hypothesis for symptomatic 
changes observed in tauopathies (Benussi et al., 2019). NMDA receptors (NMDARs) 
are a likely candidate to play a role in the dysfunction and degeneration observed in 
tauopathies (Liu et al., 2019). NMDAR activity can modulate excitotoxicity of neurons, 
by the overactivation of extrasynaptic NMDARs (Hardingham and Bading, 2010; 
Léveillé et al., 2008; Wang and Reddy, 2017). NMDAR subunit expression (GluN1, 
GluN2A and GluN2B) was also reduced in models of tauopathy (Kopeikina et al., 
2013a). Recently, it has been suggested that tau interacts with NMDARs and fyn 
kinase to regulate NMDAR excitotoxicity via GluN2B phosphorylation (Ittner et al., 
2010; Miyamoto et al., 2017; Mondragón-Rodríguez et al., 2012). In support of this, 
the A152T variant of tau, which increases the risk for tauopathies, has also been 
identified as increasing the risk of NMDAR-mediated excitotoxicity (via the GluN2B 
subunit) (Decker et al., 2016; Maeda et al., 2016).  
The importance of other ionotropic glutamate receptors, such as AMPA receptors 
(AMPARs), in tauopathies has been less extensively studied. In AD post-mortem brain 
tissue, AMPAR binding sites were decreased in the hippocampus (Dewar et al., 1991) 
and AMPAR subunit expression was decreased in the hippocampus (Yasuda et al., 
1995). Downregulation of genes that express AMPAR subunits (Alldred et al., 2012) 
and reductions in AMPAR subunit expression (Hoover et al., 2010; Kopeikina et al., 
2013a) have been observed in chronic tau overexpression models. Also, 
phosphorylation of tau at different sites can differentially reduce AMPAR activity in 
cultured neurons (Teravskis et al., 2019), suggesting that tauopathies are associated 
with reduced AMPAR expression and hypoactivity. Conversely, AMPAR-mediated 
activity was increased in the rTg4510 model in the hippocampus and frontal cortex 
following neurodegeneration onset (Crimins et al., 2011, 2012; Dalby et al., 2014). 
Interestingly, AMPAR activity, but not NMDAR activity, also facilitates the release of 
tau from neurons, which would suggest a mechanism for trans-synaptic spread of 
pathological tau that may involve AMPAR activity (Pooler et al., 2013).  
Results presented in Chapter 2 showed alterations in glutamate receptor function in 
early (~5.5M) and progressed (~7.5M) neurodegenerative phases of tauopathy in 




to changes in the expression of NMDARs and AMPARs, whether that be overall 
receptor expression or subunit expression. 
3.2 AIMS 
This work aimed to address whether there were changes in dendritic morphology 
which may account for some of the changes observed in neuronal properties, such as 
a reduced capacitance, at 5.5M of age in rTg4510 mice in Chapter 2. To do this, 
changes in morphology was assessed by reconstructing dendritic morphology from 
previous recorded neurons in Chapter 2. 
In addition, at 5.5M of age in the rTg4510 mice, there was an observed reduction of 
the NMDA:AMPA receptor ratio which could be linked to altered expression of AMPA 
and NMDA receptors. Therefore, synaptosomes were isolated from the 
somatosensory cortex of 5.5M and 7.5M rTg4510 and wildtype littermate mice to 




Whole-cell patch clamp recordings were made from neurons in layer II/III of the 
somatosensory cortex in thalamocortical brain slices. Protocol details and 
electrophysiological data from this population of cells was presented in Chapter 2. 
These recordings were performed in three experimental batches (Batch 1, 2, 3): Batch 
1 and 2 from ~5.5M old rTg4510 (TG) mice and wildtype (WT) littermate controls, 
Batch 3 from ~7.5M old TG mice and WT littermate controls. During these recordings, 
neurons were simultaneously filled with biocytin that was dissolved in the intracellular 
solution. This labelling procedure allowed recorded neurons to be detected and 
morphological reconstructed post hoc.  
Following whole-cell patch clamp recordings, brain slices were fixed overnight in 4% 
paraformaldehyde (in 0.1M phosphate buffered saline (PBS)) at 4°C. Slices were then 
transferred to 0.1M phosphate buffer (PB) at 4°C until immunofluorescence staining. 
3.3.1.2 Immunofluorescence staining 
Two different immunofluorescence protocols were used. The first protocol used no 




protocol was used on brain slices from Batch 1, which measured synaptic physiology. 
In this first protocol, no recorded neurons colocalised with tau pathology. It was 
thought that this may be due to antigen masking during the fixation process. Following 
this, heating was used to help increase the recovery of the tau signal. In addition, this 
second protocol also included an extra blocking step in glycine to help reduce non-
specific background signal seen in the first protocol (Figure 3.1). This protocol was 
used on the brain slices from Batch 2 (Protocol 2), which assessed intrinsic neuronal 
properties.   
 
 
Figure 3.1 Non-specific background signal observed in brain slices following 
neuronal recovery. The left-hand image (A) is from Protocol 1, with large amounts of 
non-specific background signal. The right-hand image (B) shows a large reduction in 
non-specific background signal using Protocol 2. Dendrites from a filled cell are clearly 
visible in the top right-hand corner of this image. Scale bars: 100 µm. 
 
3.3.1.2.1 Immunofluorescence protocols: Protocol 1 used on Batch 1 
Brain slices were rinsed 3 times for 5 minutes in 0.1M PB, followed by 3 lots of 5 minute 
washes in 0.1M PBS. Slices were blocked for 1 hour at room temperature using 
Normal Goat Serum (Vector Labs, UK, Cat#S-1000) diluted 1:200 in 0.1M PBS with 
0.3% Triton-X and 0.05% Sodium Azide. Slices were then incubated in the primary 
antibody (MC-1 IgG1, 1:1000, specific for conformationally changed tau epitopes 
(kindly provided by Peter Davies)) diluted in 0.1M PBS with 0.3% Triton-X and 0.05% 
Sodium Azide at 4°C for 3 days. Following this, slices were rinsed 3 times for 5 minutes 




mouse AlexaFluor 594 IgG (Cat#A11005, ThermoFisher, USA) & anti-avidin 
Alexafluor 488 conjugate (Cat#A21370, ThermoFisher)) in 0.1M PBS with 0.3% Triton-
X and 0.05% Sodium Azide at 4°C overnight. Following this, slices were rinsed in dH2O 
for at least 5 minutes and then were mounted using VectaShield Mounting Medium for 
Fluorescence (Cat#H-1000, Vector Labs) and coverslipped. 
3.3.1.2.2 Immunofluorescence protocols: Protocol 2 used on Batch 2 
The additional steps from Protocol 2 are shown in italics and underlined. 
Brain slices in PB storage solution were placed in wells in dH2O and incubated within 
a waterbath until at 78°C for 25 minutes (for increased antigen retrieval). The brain 
slices were then left to cool in wells for 35 minutes. Brain slices were rinsed 3 times 
for 5 minutes in 0.1M PB, followed by 3 times 5 minutes washes in 0.1M PBS. Slices 
were then incubated in glycine (100 mM diluted in PBS with 0.3% Triton-X and 0.05% 
Sodium Azide, Sigma-Aldrich Cat#G7126) for 30 minutes. Following this step, slices 
were treated the same as per Protocol 1 from the Normal Goat Serum blocking step.  
3.3.1.3 Imaging 
Slices were imaged using a two-photon microscope (Scientifica, UK) equipped with a 
tuneable Ti:Sapphire pulsed laser (Coherent, Chameleon Discovery NX, USA) or a 
confocal microscope (SP8; Leica, Germany). Slices were imaged using two-photon 
microscopy, with the laser wavelength set to 790 nm to excite both AlexaFluor 488 
and 594, with 0.5 µm optical slices taken with an average of 8 frames per slice at a 
512x512 pixel resolution using a 20x objective. For the confocal microscope, pre-set 
dye bandwidth filter settings for AlexaFluors 488 and 594 were picked with 0.5 µm 
optical slices taken with a line average of 2 at a 512x512 pixel resolution using a 20x 
objective. Images were acquired using ScanImage (Vidrio, USA) and Leica application 
suite X (Leica) acquisition software for the two-photon microscope and the confocal 
microscope, respectively. 
3.3.1.4 Analysis 
Image stacks were analysed using the Fiji distribution of ImageJ software (Schindelin 
et al., 2012). The two imaging channels were split from the acquired image stack and 
the green channel (AlexaFluor 488) was used for cell tracing to ensure blinding to 
genotype. Cells were morphologically traced using the Simple Neurite Tracer plugin 




(soma and dendrites visible). Traced neurons were than analysed by Sholl analysis 
(Ferreira et al., 2014) with radii binning occurring every five µm (Figure 3.2).  
 
 
Figure 3.2 Sholl analysis of a traced neuron. A max projection image of a biocytin 
labelled neuron (soma highlighted with an arrowhead) (A), and a max projection image 
of its’ skeleton following morphological tracing (B). Sholl analysis was used to analyse 
the dendritic structure (C), where intersections are measured at radii of increasing 
size. This generates a Sholl plot (inset), which plots the number of intersections 
against the radial distance. Scale bar: 100 µm. 
 
3.3.1.5 Statistics 
Statistical tests were performed using R software (v3.5.1) with the integrated 
development environment RStudio (v1.1.456).  
Consistent with statistical analyses presented in Chapter 2, the experimental unit 
considered was the ‘cell’. Yet again, by nature of the experimental design, multiple 
cells may have come from a single animal. Cell from the same animal may therefore 
be more similar when compared to cells that came from another animal. Therefore, a 
generalised linear mixed model (GLMM) was used to estimate the contribution of 
animal to the spread of the individual datasets.  
The following GLMM was used to model results with single data points (i.e. when there 
was a single point measure):  
𝑉𝑎𝑟𝑖𝑎𝑏𝑙𝑒 ~ 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒 + (1|𝑎𝑛𝑖𝑚𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 ) 
The variable was the experimental measure being tested, with genotype as the main 




variable, denoted as 1|animal number to conform with standard notation. The 
interclass correlation coefficient (ICC) measured the effect of animal variability on the 
measured outcomes. If the ICC value was >0.1, then a GLMM was used to determine 
significance (Fiero, 2016). The best model for the data was chosen based on lowest 
Akaike information criterion (AIC) value along with other measures of fit from the model 
such as assessment of the residuals for normality and heteroscedasticity. The data 
distribution was visualised using a histogram and quartile-quartile-plot and factored 
into the model when necessary (i.e. normal, tweedie, gamma distribution).   
For GLMMs, goodness of fit chi squared (χ2) tests were used to evaluate the fit for 
each main effect to determine significance of factors in the model. Significant results 
were described as (χ2(df, n) = a, p=b*). The degrees of freedom were listed for the χ2 
test (df) with the number of observations within this linear model (n). The χ2 value was 
then listed (a) along with the corresponding p value (b) with asterisks denoting 
significance when alpha <0.05. Non-significant results were listed with a p value only. 
Results were sometimes also stated as an estimate of change with standard error in 
brackets to help signify the amount and direction of the effect. A Tukey-Kramer 
multiple comparison adjustment was used for post hoc testing whilst controlling for 
multiple comparisons. 
If the ICC value <0.1, then t-tests were used for statistical comparisons between 
genotypes (Fiero, 2016). If the data was not normally distributed (i.e. non-parametric), 
then a Mann-Whitney U non-parametric t-test was run. If the data was normally 
distributed with equal variances, then a Student’s t-test was run. If the variances were 
unequal, then a Welch’s t-test was run. Significant results were described as (t(df, n) = 
a, p=b*), where a was the t-test statistic (t), df was the degrees of freedom, n was the 
total n number, and the p value was b. Significance was denoted with asterisks: 
p<0.05*, p<0.01**, p<0.005***. Non-significant results were listed as a p value only. 
The sholl plot analysis was a repeated measure, quantifying number of intersections 
over increasing radii. Therefore, the GLMM used was changed to account for repeated 
measurements within the same cell.  
Therefore, for the Sholl plot analysis, the following GLMM used was: 




Within this model, the number of intersections was the tested variable of interest, to 
test whether there was a difference in intersections at different radii between 
genotypes. Radius, genotype and the interaction between these two effects (denoted 
as an asterisk) were modelled in as the main effects for statistical testing. Because 
these repeated measures came from a single cell, this was included in the random 
variable to account for nesting of measures. This was denoted as (1|animal 
number/cell number), which means cell number was a nested variable that came from 
an animal number.  
Unless stated otherwise, data is stated as mean ± standard error of the mean (SEM). 
Box plots show the mean (square shape), median (line), and SEM (box). Significance 
was denoted with asterisks: p<0.05 *, p<0.01 **, p<0.005 ***. For line plots, the line 
represents the mean and the shaded area is the SEM. 
3.3.2 Synaptosome preparations 
3.3.2.1 Animals: P301S mice 
Aged P301S mice (over 5 months of age) and WT littermate controls were used to 
optimise the synaptosome protocol and to determine suitable antibody concentrations 
for protein detection. The P301S model is a mouse model of tauopathy which 
overexpresses human tau with the P301S mutation. Mature tau pathology is 
detectable at around 5-6 months of age (Allen et al., 2002). 
3.3.2.2 Samples 
Whole brains were used to optimise and compare different protocols for synaptosome 
isolation. This was done using whole brains from aged P301S mice and WT littermates 
(>5M).  
The TG brain tissue dissections for synaptosome preparations were kindly performed 
by Tracey K Murray and Lukasz Jankowski (Eli Lilly, Surrey, UK). For these samples, 
mouse body weight was recorded and mice were then culled using a Schedule 1 
procedure. The whole brain was removed, and brain weight was recorded. The brains 
were placed in a mouse brain matrix to create 2.3mm thick coronal slices between 
Bregma 0.38 - -1.94 (Figure 3.3). The somatosensory cortex was dissected, weighed 
and snap frozen on dry ice. The cerebellum was dissected, weighed and snap frozen 
on dry ice (Figure 3.3). Samples were collected in RNAase free vials. Cerebellar 








Figure 3.3 Isolation of the somatosensory cortex and cerebellum. The cerebellum 
(shown in red) was dissected, and somatosensory cortex (shown in green) was 
isolated between stereotaxic coordinates (from Bregma): 0.38 - 1.94 mm. 
 
3.3.2.3 Synaptosome preparations: overview 
To study synaptic proteins, synaptosomes were isolated from TG and WT controls. 
Synaptosomes are sealed nerve terminal ends which encompass and preserve the 
synaptic environment including vesicles and synaptic bound receptors (Evans, 2015; 
Whittaker, 1993). Three methods were compared in this chapter (pellet 2 (P2), lysed 
pellet (LP), and a discontinuous sucrose gradient) to measure the total output protein 
concentration (i.e. synaptosome concentration) and to confirm the enrichment of 




1962; Huttner et al., 1983; Nagy and Delgado‐Escueta, 1984; Tenreiro et al., 2017). 
An overview of the three protocols is shown in Figure 3.4, with buffer composition for 
the protocols listed in Table 3.1. Protocols were based specifically on methods 
described by Mazzo et al., 2016 & Sahara et al., 2014. 
 
 
Figure 3.4 Synaptosome preparation overview. A schematic overview of the three 
methods used for synaptosome preparations (1. P2, 2. LP1 and 3. Discontinuous 
sucrose gradient purified synaptosomes (highlighted in red)). Acronyms: H = 
homogenate, S = supernatant, P = pellet, LP = lysed pellet, LPS = lysed pellet 






Table 3.1 Formulation of buffers used for isolated synaptosome preparations. 
Buffer formulations used for the three protocols (P2, LP1 and discontinuous sucrose 













1 tablet 1 tablet 1 tablet 1 tablet 1 tablet 
Phosphatase 
inhibitor cocktail 
#2 (Sigma, USA, 
Cat# P5726) 
1:100 dilution 1:100 dilution 1:100 dilution 1:100 dilution 1:100 dilution 
Phosphatase 
inhibitor cocktail 
#3 (Sigma, Cat# 
P0044) 
1:100 dilution 1:100 dilution 1:100 dilution 1:100 dilution 1:100 dilution 
Tris-HCl, pH 7.4 50 mM / 50 mM 50 mM 50 mM 
Tris-HCl, pH 8.0 / 5 mM / / / 
Sucrose 0.3 M / 1.2 M 0.85 M / 
EDTA, pH 7.4 50 mM / / / / 
EGTA, pH 8 50 mM 0.5 mM 0.5 mM 0.5 mM / 
 
3.3.2.3.1 Sample preparation (H1) 
All samples were sonicated in an ice cold sonicating buffer (see Table 3.1) using a 
QSonica sonicator (CL-18) set to 40% amplitude pulses on 1 second, off 1 second for 
~10 seconds. A subset of experiments also used a homogeniser (Ultra-Turrex T10 
with S10N-8G metal tip – 12 strokes) to homogenise, rather than sonicate the 
samples.  
3.3.2.3.2 Crude synaptosome (P2) preparation 
TG and WT littermate samples underwent synaptosome preparation up to P2. P301S 
WT littermate control samples were further purified to explore synaptosome 




Sonicated tissue samples (H1) were centrifuged in a Sigma 4-16KS centrifuge (rotor: 
12130) for 20 minutes at 800 x g at 4°C to separate the nuclei (P1) from the 
homogenate (H1). The supernatant (S1) was transferred to a new centrifuge vial and 
centrifuged for 30 minutes at 16,000 x g at 4°C to separate microsomes and other 
soluble enzymes (S2) from the crude synaptosomal preparation (P2). If crude 
synaptosomes (P2) were required, then this 2nd pellet was resuspended in 100 µl of 
50 mM Tris (Table 3.1) and the protein concentration was calculated using a 
Bicinchoninic acid (BCA) assay. The P2 fraction was then diluted to 1 mg/ml in 50mM 
Tris (Table 3.1) and stored at -80°C until needed. 
If further purifying the P2 fraction, P2 was then resuspended in a solution specific for 
the LP1 or discontinuous sucrose gradient protocol. 
3.3.2.3.3 Purified synaptosomes (LP1) 
The P2 pellet underwent further purification (LP1 protocol) as highlighted on Figure 
3.4 (protocol 2).  
The P2 pellet was resuspended in Buffer A in falcon tubes. Samples were left on ice 
for 30 mins to lyse out internal organelles such as mitochondria from synaptosomes, 
known as hypo-osmotic shock. The samples were then centrifuged for 25 minutes at 
25,000 x g to get LP1 (“Synaptosome membranes”). The supernatant was discarded 
(LPS) and the pellet (LP1) was resuspended in 50 mM Tris (Table 3.1). The protein 
concentration was calculated using a BCA assay. 
3.3.2.3.4 Purified synaptosomes (Syn) 
The P2 pellet underwent further purification using a discontinuous sucrose gradient as 
highlighted in red on Figure 3.4 (protocol 3).  
The P2 pellet was resuspended in 2.04 mL of buffer B (Table 3.1) in 15 ml falcon 
tubes. The tube was left on ice for 45 mins to lyse out internal organelles such as 
mitochondria from synaptosomes, known as hypo-osmotic shock. Following hypo-
osmotic shock, the sample was mixed well by pipetting. 0.96 ml of 1 M sucrose solution 
was added to the lysed solution to take the total volume up to ~ 3 ml and the sucrose 
concentration to ~0.3 M. The solution was then mixed well with a pipette. A 
discontinuous sucrose gradient with equal volumes of liquid was made in a 13.4 mL 
Beckman Coulter Ultra Clear tube (Cat#344059). From the bottom to the top of the 




solution (buffer B, Table 3.1), 0.85M sucrose-based solution (buffer C, Table 3.1), 
prepared sample (~0.3M sucrose-based solution; Figure 3.4). This tube was added to 
the Sorvall TH-641 swing bucket rotor (rotor: SW41Ti) with appropriate 
counterbalances as necessary. Samples were spun at 60,000 x g for 2 hours at 4°C 
on a Beckman Coulter Optima XPN-80 Ultracentrifuge. During centrifugation, 
separation of three different layers occurred. From top to bottom of gradient, there was 
the top band (TB) (myelin) fraction, the synaptosome fraction in middle (S3), and the 
bottom band (BB) fraction (mitochondrial). Each fraction was removed carefully with a 
pipette and put into individual eppendorf’s. The S3 fraction was diluted with 50 mM 
Tris (Table 3.1) to 10% sucrose (assuming the band collected contained ~30% 
sucrose concentration, so 2 volumes of 50 mM Tris was added to one volume of band 
sample collected (~1ml recovered: 2ml added)). The S3 fraction was spun at 48,000 
x g for 30 mins at 4°C (Rotor: 45TI, Centrifuge: Beckman Coulter Optima XPN-80 
Ultracentrifuge). The supernatant S4 was discarded and the pellet (Syn) was 
resuspended in 50 mM Tris (Table 3.1). The protein concentration was calculated 
using a BCA assay. 
3.3.2.3.5 Bicinchoninic acid (BCA) assay: protein concentration  
A BCA protein concentration assay was performed on all samples using a BCA Protein 
Assay Kit (#23227; ThermoFisher). Manufacturer guidance was followed for the 
protocol. In brief, an albumin standard (within the kit) was used as the assay standard. 
Samples and standards were serial diluted using Tris 50 mM (Table 3.1). Samples 
and standards were plated in duplicate on 96-well plates. The BCA working reagent 
was formulated and added to all samples, and was left to incubate for 30 minutes at 
37 °C. Following this, well plates were imaged on a spectrophotometer (Precision 
microplate reader, Molecular devices) and sample values were compared to a 
calculated standard curve from the standard measures. 
For the TG samples, all P2 purified cerebellum samples had a protein concentration 
above 1mg/ml. Therefore, they were normalised to 1 mg/ml stocks using 50 mM Tris 
buffer (Table 3.1). The majority of the P2 purified somatosensory cortex samples were 
above 1mg/ml in concentration. These samples were normalised to 1mg/ml stocks 
using 50 mM Tris (Table 3.1). However, some samples were below 1mg/ml, likely due 
to the low starting sample weight prior to purification (Table 3.2). These samples were 




Table 3.2 Protein concentration of somatosensory cortex P2 samples from TG 
mice. Rows contain data for individual TG mice samples. Columns contain the mouse 
ID number, genotype (wildtype homozygous, W:W; transgenic homozygous, CC), age, 
extracted tissue weight and calculated P2 concentration (plate concentration). 
Highlighted rows were samples that were run at below 1mg/ml concentration. 
ID Genotype Age 




1 W:W 5.5M 10.7 1043 
2 W:W 5.5M 9.1 1226 
3 W:W 5.5M 7.9 1510 
4 W:W 5.5M 13.4 1918 
5 W:W 5.5M 8.5 1088 
6 W:W 5.5M 8.8 1828 
7 W:W 5.5M 9.7 1441 
8 W:W 5.5M 9.4 1313 
9 W:W 5.5M 10.2 1340 
10 W:W 5.5M 7.6 1184 
11 C:C 5.5M 8.3 1041 
12 C:C 5.5M 9.2 992 
13 C:C 5.5M 7.7 980 
14 C:C 5.5M 8.9 1162 
15 C:C 5.5M 8.0 1972 
16 C:C 5.5M 6.5 692 
17 C:C 5.5M 8.4 993 
18 C:C 5.5M 5.6 779 
19 C:C 5.5M 9.6 1194 
20 C:C 5.5M 8.0 1175 
21 C:C 5.5M 8.9 1149 
22 W:W 7.5M 13.1 1938 
23 W:W 7.5M 8.9 1177 
24 W:W 7.5M 8.9 1082 
25 W:W 7.5M 9.5 1937 
26 W:W 7.5M 9.3 1300 
27 W:W 7.5M 12.5 1332 
28 W:W 7.5M 10.1 1383 
29 W:W 7.5M 13.3 1677 
30 W:W 7.5M 11.2 1382 
31 W:W 7.5M 11.1 1556 
32 C:C 7.5M 8.6 1051 
33 C:C 7.5M 8.5 1238 
34 C:C 7.5M 5.8 735 
35 C:C 7.5M 4.4 424 
36 C:C 7.5M 3.0 223 
37 C:C 7.5M 5.8 957 
38 C:C 7.5M 5.8 694 
39 C:C 7.5M 6.2 849 
40 C:C 7.5M 6.4 805 
41 C:C 7.5M 7.1 931 





3.3.2.4 Protein Detection  
3.3.2.4.1 SDS-Page 
Antibody concentrations were optimised for ideal detection of proteins of interest on 
crude P2 synaptosomes prepared from P301S whole brains (data not shown). 
Therefore, P301S P2 synaptosomes was ran as a positive control alongside samples 
from the TG and WT samples.  
Samples were diluted into 2x Laemmli Sample Buffer (BioRad, Cat#161-0737), or 4x 
NuPage LDS Sample Buffer (Novex, NP0008), diluted with Mercaptoethanol (1:20 and 
1:10 respectively, Cat#161-0710, Bio-Rad). Samples were then heated at 95°C for 5 
minutes using a Grant QBD2 heating block. Samples were loaded, 20 µl (~10 µg) per 
lane (Figure 3.5), into an Invitrogen NuPAGE 8% Bis-Tris Midi Gel 
(Cat#WG1002BX10) with 1x MOPS SDS Running Buffer (diluted from 20x to 1x, 
Novex, Cat#NP0001) and ran at 150 V for 75 minutes (or until the protein band 
reached the bottom of the gel) using a PowerEase 300W (Life Technologies). SeeBlue 
Plus 2 Prestained Standard (Invitrogen, Cat#LC5925) was used as the molecular 
weight ladder.  
 
 
Figure 3.5 SDS-Page gel loading map. Three gels were run per antibody per brain 
region (this example shows the somatosensory cortex (SCTX)). Blue samples are WT 
5.5M, orange TG 5.5M, green WT 7.5M and grey TG 7.5M. Samples were randomly 
spread across the three gels to reduce confounding variability due to gels. The first 
row per gel is the sample description, the second row specifies sample ID number and 




3.3.2.4.2 Western Blotting 
Proteins were transferred onto a nitrocellulose membrane (Amersham Protran 
Premium 0.4 µm Nitrocellulose, Cat#10600003) soaked in a transfer buffer (NuPage 
Transfer Buffer, Novex, Cat#NP0006-1, diluted to 1x concentration with 20% 
methanol), using a BioRad PowerPac Universal which was ran at 25 V for 80 minutes. 
Following protein transfer, Ponceau S (Sigma-Aldrich) staining was used to ensure 
protein transfer and to confirm where to cut blots if required. Following this, 
membranes were incubated for an hour in PBS containing 0.05% tween (PBS-T) and 
5% milk (Marvel, Original Dried Semi Skimmed Milk). Next, membranes were 
incubated overnight at 4°C in primary antibodies (targeted at either tau, synaptic 
proteins, AMPARs or NMDARs; Figure 3.6) diluted to the optimised concentrations 
(Table 3.3) in PBS-T with 5% milk. The next day, membranes were washed 3 times 
for 10 minutes with PBS-T. Corresponding secondary antibodies were used at either 
1:20,000 for anti-mouse, 1:10,000 for anti-rabbit (Table 3.3) and incubated for one 
hour at room temperature in PBS-T with 5% milk. Membranes were washed again 3 
times for 10 minutes with PBS-T. Membranes were then incubated using Dura or 
Femto detection substrates depending on signal strength (SuperSignal West Dura 
Extended Substrate, Cat#34075, ThermoScientific; SuperSignal West Femto 
Maximum Sensitivity Substrate Cat#34095, ThermoScientific) for 5 minutes, and 
following this membrane images were taken using an Amersham Imager 600. If 
required, membranes were stripped by incubation in Restore PLUS Western Blot 
Stripping Buffer (ThermoScientific, Cat#46430) for 10 minutes. Membranes were then 
rinsed with PBS-T. Membranes then underwent the blocking step and the protocol 
continued as before (i.e. block, primary antibody incubation, etc). Stripping was only 
done once per membrane as this removes some of the protein on the membrane which 






Figure 3.6 Synapse schematic. An overview of a synapse to highlight antibody 
targets at the pre- and post-synapse. Note: GAPDH is mainly localised to the cytosol 
(as indicated by the lines) but is also found at plasma membranes, nuclear membranes 
and vesicles (Tristan et al., 2011). 
 
Table 3.3 Antibodies used for protein detection on western blots. A table showing 
all primary and secondary antibodies used for protein detection within synaptosomes 
preparations. Secondary antibodies are highlighted in yellow and antibodies that did 
not work (deemed as no visible detection in optimisation samples) in this assay are 
highlighted in green. 
 

















AT-8 Tau Mouse 1:1000 Peter Davies - - 
CP27 Tau Mouse 1:1000 Peter Davies - - 



























































































- 1:10000 GE, USA NA934V Multiple 
Anti-NR1, CT 





















































Images were analysed using ImageQuantTL (v8.2.0 GE). Bands of interest were 
highlighted and the background signal was subtracted using a rolling ball filter. This 
gave a raw value for protein expression. This was then normalised to the raw protein 
expression value for the housekeeper protein (GAPDH), to account for loaded sample 
differences, particularly important for those samples below 1mg/ml. 
3.3.2.6 Statistics 
Samples were excluded if the detected bands were incomplete (e.g. a bubble in the 
middle of the detected band) or if significantly faint compared to the rest of the gel 
(determined by visual inspection). Randomised block allocation of sample groups 
across each of the gels and normalisation of protein expression to GAPDH controlled 
for regional variation in signal intensity within areas of the gel. If the GAPDH band was 
excluded, then any samples that were normalised to that band were also excluded. 
Statistical tests were performed using R (v3.5.1) with RStudio (v1.1.456). GLMMs 
were used on the normalised expression data to assess statistical significance.  
The following formula was used to statistically model the data: 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 ~ 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒 ∗ 𝑎𝑔𝑒 + (1|𝑔𝑒𝑙 𝑛𝑢𝑚𝑏𝑒𝑟) 
Normalised protein expression was the tested variable of interest, genotype and age 
were the main effects with interactions between the two effects tested (indicated by 




block design, gel was built into the model as a random variable (as there were an 
infinite number of gels that could have been run). This was written into the formula as 
1|gel number to conform with R syntax. An overview of the different tested effects and 
the subgroupings that were part of the experimental design are shown in Figure 3.7. 
 
 
Figure 3.7 Overview of effect subgroups in the synaptosome assay. Each sample 
(animal; A1-A6), was run on a gel (gel; G1-G2). Different gels had different detection 
levels unrelated to age or genotype and so were a random grouping factor. Each 
animal belonged to a genotype (TG & WT) and an age group (5.5M & 7.5M) which 
were the main effects of interest. These factors may also have an interaction effect, 
which was also explored in the model.  
 
Consistent with other statistical modelling described in this chapter, the best model 
was chosen based on AIC along with other measures of fit. The ICC value was listed, 
which describes the effect the different gel numbers had on the total variance on a 
scale of 0-1. Values close to 0 were deemed non-influential on the variance of the 
data, whereas values closer to 1 suggested that different gels had an influential value 
on the clustering of the data. This may be due to labelling variability per gel for 
example. Significant results were described as (χ2 (df, n) = a, p=b*). Non-significant 
results were listed with a p value only. Least squares means with Tukey-adjusted 
comparisons were used to analyse main effects between groups by performing post 
hoc comparisons. Asterisks were used to denote significance with p<0.05 *, p<0.01 ** 







3.4.1 Tau pathology was only detectable in TG brain tissue 
Tau pathology was detected using the MC-1 antibody, specific for pathogenic 
conformationally changed tau epitopes. MC-1 antibody staining was present in all 
tissue samples from TG mice and absent from WT controls (Figure 3.8). Colocalisation 
between MC-1 staining and recovered neurons was not observed in any of the 
samples with either staining protocol. 
 
 
Figure 3.8 WT and TG neurons from ~5.5M old mice with and without MC-1 
positive staining. Two example filled neurons labelled in green (AlexaFluor-488, 
highlighted with white arrowheads), with MC-1 staining in magenta. The neuron in A 
was from a WT animal, and the tissue section does not contain any MC-1 positive 
inclusions. There was some cellular staining surrounding the neuron in green, which 
was detected non-specific biocytin recovery from electrophysiological recordings. The 
neuron in B was from a TG animal. Note the large amount of MC-1 positive pathology, 
including neuronal inclusions (magenta). The pia is denoted with a dashed white line. 
Scale bars: 100 µm. 
 
3.4.2 Increased dendritic complexity proximal to the soma at ~5.5M 
in TG mice compared to WT mice 
Biocytin labelled neurons from the two recorded batches were grouped together 
(similarly aged animals) and morphologically traced. 21 WT neurons (10 animals) and 




quality for analysis for changes in dendritic structure. Sholl analysis quantified how 
many times the traced neuron intersected radii of increasing size until there were no 
more intersections. From this analysis, the complexity of the dendritic structure can be 
quantified. There was a significant main effect of radius (χ2 (119,5520) = 5715, 
p<0.005***), but not genotype (p=0.89) on the sholl analysis. However, there was a 
significant interaction effect between genotype and radius (χ2 (119,5520) = 310.4, 
p<0.005***). This analysis revealed a significant increase in the number of 
intersections between 35-95 and 105-110 µm from the soma (GLMM; p<0.05; See 
Figure 3.9 for individual p values) in the TG neurons compared to WT neurons.  
 
 
Figure 3.9 Sholl plots of morphologically traced TG and WT neurons. A Sholl plot 
of the average distribution of dendritic intersections per radial distance from the soma 
for WT neurons (blue) and TG neurons (red) (A). The black line denotes a significant 
difference of p<0.05, with the p values for the Sholl plot between the highlighted range 
listed in a table (B). Sholl plots for each individual neuron are shown in grey for WT 
(C) and TG (D), with the average distribution plotted in blue and red respectively. Lines 





The maximum intersections value and maximum intersecting radius determines the 
maximum intersections that occurred at one radius. A change in the maximum 
intersections and which radius this occurred in would suggest a change in the shape 
of the neuron, but perhaps not a change in the complexity. The maximum intersecting 
radius was not significantly different between genotypes (p=0.32, Figure 3.10 A). 
However, the maximum number of intersections was significantly increased for TG 
neurons (WT 30.52 ± 3.32 intersections, TG 40 ± 3.56 intersections; Mann-Whitney U 
t-test, U(1,47) = 175, p<0.04*; Figure 3.10 B). 
The enclosing radius is the largest radius that encloses the whole structure (i.e. the 
last radius to have at least one dendritic intersection). This value can be used as a 
proxy for the size or area covered by the neuron. The enclosing radii was not 
statistically different between genotypes (WT 374 ± 25 µm, TG 353 ± 22 µm; p=0.55; 
Figure 3.10 D). 
The sum intersections value was the total number of intersections detected across all 
measured radii. The mean intersections value was this value divided by the total 
number of measured radii. Any of these variables changing would represent a change 
in the complexity of the dendritic arbour. Higher mean intersections for example would 
suggest a more complex arbour across the whole dendritic structure. However, neither 
the sum (WT 982 ± 141 intersections, TG 1146 ± 144 intersections; p=0.4, Figure 3.10 
E), median (WT 12.14 ± 1.35 intersections, TG 12.33 ± 0.93 intersections, p=0.41; 
Figure 3.10 C) or the mean number of intersections (WT 12.70 ± 1.30 intersections, 
TG 15.19 ± 1.22 intersections; p=0.13; Figure 3.10 F) were statistically different 






Figure 3.10 Measures of dendritic structure and complexity from Sholl analysis. 
Box and dot plots of the maximum intersections radius (A), maximum intersections 
(B), median intersections (C), enclosing radius (D), sum intersections (E) and mean 
intersections (F) with WT in blue and TG in red. Statistical significance is denoted as 
p<0.05 *. 
The traced skeleton was also analysed using Simple Neurite Tracer to extract total 
branch length, mean branch length, number of junctions, number of branches and 
number of end points. The total branch length was the total length of all traced 
branches. Mean branch length was the mean length of each dendrite branch. Number 
of branches was the total number of skeleton branches, with the number of junctions 
being a proxy measure of neuronal branching. The number of end points was the 
number of ending points of the skeleton (i.e. no more branches following that point). 
Looking at the overall dendritic skeleton in the traced cells, total dendritic length was 
significantly increased for TG neurons (WT 5750.33 ± 802.70 µm, TG 9258.53 ± 
1063.74 µm; GLMM, χ2 (1,47) = 5715, p=0.02*, ICC 0.19; Figure 3.11 A), with an 
increase in the number of dendritic branches (WT 86.52 ± 15.73 branches, TG 151.58 
± 24.83 branches; Mann-Whitney U t-test, U(1,47) = 158, p=0.01**; Figure 3.11 E), 
junctions (WT 39.24 ± 7.40 junctions, TG 72.54 ± 12.91 junctions; Mann-Whitney U t-
test, U(1,47) = 161, p=0.02*; Figure 3.11 D) and end points (WT 49.48 ± 8.07 end points, 
TG 70.85 ± 7.67 end points; Mann-Whitney U t-test, U(1,47) = 154, p=0.01**; Figure 
3.11 F). Together with the results of the Sholl analysis, this suggests that there was 
an increase in the complexity of lower order dendrites within close proximity (<110 µm) 






Figure 3.11 Properties measured from the dendritic skeleton. Measures of total 
length (A), mean branch length (B), length of the longest branch (C), number of 
junctions (D), number of branches (E) and the number of end points (F) with WT in 
blue and TG in red. Statistical significance is denoted as p<0.05 *; p<0.01 **. 
 
3.4.3 Synaptosomes: purification methods 
Methods of synaptosome purification were compared to find the optimum method to 
be used for TG and WT samples. 
Shear force is required to tear nerve terminals from axons and dendrites, which then 
reseal to form synaptosomes. Homogenisation is the typical method of cellular 
disruption used for synaptosome preparations to produce the H1 fraction (Dunkley and 
Robinson, 2018). Homogenisation was compared to sonication, which is another 
common method of cellular disruption which uses ultrasonic soundwaves rather than 
physical force. Sonication provides a gentler disruption of cell membranes compared 
to homogenisation (Burden, 2012). Sonication was therefore tested to determine 
whether it yielded increased recovery of synaptosomes.  
Protein concentration was examined at a number of points throughout the P2 protocol 
to determine whether there was a difference in protein concentration (i.e. recovery of 
synaptosomes) between the two methods of cellular disruption. Two brains per 




concentration. The average concentration of protein in the H1 fraction using 
homogenisation was 2139 mg/ml (range: 2130 - 2148 mg/ml) and using sonication 
was 2829 mg/ml (range: 2375 - 3282 mg/ml). The average P2 concentration using 
homogenisation was 7339 mg/ml (range: 3971 – 10706 mg/ml) and sonication was 
10215 mg/ml (range: 7995 – 12434 mg/ml). From this, sonication was deemed to be 
the optimal method for cellular disruption as it produced a higher protein concentration 
output and therefore a higher putative synaptosome output. 
The P2 protocol was then compared to the LP and sucrose gradient protocols to 
measure protein concentration and synaptosome enrichment (by quantification of 
synaptosome markers), with sonication used as the method of cellular disruption. The 
synaptosome fractions were P2 for the P2 protocol, LP1 for the LP protocol and Syn 
for the sucrose gradient protocol. The average protein concentration at the end of the 
P2 protocol was 10215 mg/ml (range: 7995 – 12434 mg/ml), compared to 9344 mg/ml 
for the LP1 protocol (range: 8059 – 10628 mg/ml) and 2246 mg/ml (range: 1150 – 
3341 mg/ml) for the sucrose gradient protocol. The P2 protocol was therefore deemed 
to yield the highest “synaptosome output”. 
Each of the methods were also compared for protein expression to ensure that 
synaptosomes were present and being enriched per fraction. P2, Syn and LP1 all 
showed synaptosome enrichment when compared to H1 (as measured by 
synaptophysin and PSD95 detection) (Figure 3.12). Syn and LP1 showed larger 
enrichment compared to H1 than the P2 fraction.  
The P2 protocol was therefore selected to isolate synaptosomes from the TG samples, 
due to its higher protein concentration per volume yield compared to the sucrose 







Figure 3.12 Synaptosome enrichment of synaptophysin and PSD95 using the 
three synaptosome protocols. A western blot with the corresponding fraction listed 
above each lane (A). P2 was the synaptosome fraction compared from the crude 
synaptosome protocol, Syn was the synaptosome fraction from the sucrose gradient 
protocol, and LP1 was the synaptosome faction from the LP protocol. Synaptophysin 
detection, PSD95 detection and the corresponding GAPDH detected band is shown 
with the corresponding molecular weight on the right-hand side. The intensity of 
antibody labelling was normalised to the GAPDH expression band. The normalised 
intensity of synaptophysin (B) is shown with light grey filled circles and PSD95 (C) with 
dark grey filled circles. Each synaptosome fraction is listed underneath on the x axis, 






3.4.4 Synaptosomes in TG and WT mice 
Synaptosomes were isolated using the P2 fraction method (with sonication) which 
produced crude synaptosomes. The somatosensory cortex and cerebellum 
synaptosome preparations from 42 animals across two different age points, 5.5M (10 
WT; 11 TG) and 7.5M (10 WT; 11 TG) were probed for synaptic proteins.  
3.4.5 Synaptic markers were lower in 5.5M old TG mice  
In the somatosensory cortex, there was a significant effect of genotype on 
synaptophysin expression (GLMM, χ2 (1,42) = 4.73, p=0.02*, ICC 0.53; Figure 2.1 B). 
There was no age effect (p=0.64) or interaction (p=0.58) between the two factors. 
There was also a significant effect of genotype on PSD95 expression in the 
somatosensory cortex (GLMM, χ2 (1,40) = 14.13, p<0.005***, ICC 0.39; Figure 2.1 C). 
In addition, there was a significant age effect (GLMM, χ2 (1,40) = 3.75, p=0.05*, ICC 
0.39), with no interaction between the two factors (p=0.31). Overall, synaptic marker 
expression was altered with genotype in the somatosensory cortex. 
Unlike the somatosensory cortex, there was no effect of genotype (p=0.08) on 
synaptophysin expression in the cerebellum (Figure 2.1 E). However, there was a 
significant age effect (GLMM, χ2 (1,42) = 4.84, p=0.03*, ICC 0.45). There was also a 
significant interaction between age and genotype (GLMM, χ2 (1,42) = 5.7, p=0.02*, ICC 
0.45). In contrast to the somatosensory cortex, there was no effect of genotype 
(p=0.22), age (p=0.73) or interaction (p=0.25) between the two factors on expression 






Figure 3.13 Synaptic marker expression was significantly reduced in the 
somatosensory cortex in TG mice throughout tauopathy. Representative western 
blots of synaptophysin and PSD95 protein expression in the somatosensory cortex (A) 
and cerebellum (D) from WT and TG animals at 5.5 and 7.5M (labelled along the top). 
Along the left-hand side are the detect proteins of interest with the corresponding 
GAPDH band below. Along the right-hand side is the molecular weight of the detected 
protein. Each detected protein band was normalised to the corresponding GAPDH 
band as a control. Quantification of normalised synaptophysin (B & E) and PSD95 (C 
& F) protein expression. Statistics: GLMM, main significant effects written on the 





3.4.6 AMPAR expression was lower in TG mice in the somatosensory 
cortex  
There was no effect of genotype (p=0.26), age (p=0.11) or interaction (p=0.44) on 
GluA1 expression in the somatosensory cortex (Figure 3.14 B). Interestingly, there 
was a significant effect of genotype on GluA2 (GLMM, χ2 (1,42) = 29.1, p<0.005***, ICC 
0.06; Figure 3.14 C) and GluA3 (GLMM, χ2 (1,41) = 9, p<0.005***, ICC 0.25; Figure 3.14 
D) expression in the somatosensory cortex. There was also a significant age effect on 
GluA2 expression (GLMM, χ2 (1,42) = 4.33, p=0.04*, ICC 0.06), but not for GluA3 
(p=0.15). There was no interaction (p=0.43) between the two factors for either GluA2 






Figure 3.14 AMPAR subunit expression in the somatosensory cortex was 
significantly decreased in TG mice throughout tauopathy. Representative 
western blots of AMPAR subunit expression (GluA1-3) from the somatosensory cortex 
of WT and TG animals at 5.5 and 7.5M (groups labelled along the top) shown in panel 
A. Along the left-hand side of the western blots is the detect protein expression, with 
the corresponding quantified housekeeping protein GAPDH band below. The 
expression of each protein of interest was normalised to the corresponding GAPDH 
expression. Along the right-hand side of the western blots is the molecular weight of 
each protein band. Quantification of normalised GluA1 (B), GluA2 (C), and GluA3 (D) 
expression. Statistics: GLMM, main significant effects written on the graph, post hoc 






For cerebellar expression of AMPAR subunits, there was no significant effect of any 
factor on expression. Specifically, there was no effect of genotype (p=0.86), age 
(p=0.27) or interaction (p=0.29) between the two factors on expression of GluA1 in the 
cerebellum (Figure 3.15 B). There was no effect of genotype (p=0.3), age (p=0.78) or 
interaction (p=0.35) between the two factors on expression of GluA2 in the cerebellum 
(Figure 3.15 C). There was also no effect of genotype (p=0.76), age (p=0.53) or 
interaction (p=0.26) between the two factors on expression of GluA3 in the cerebellum 
(Figure 3.15 D).  
 
 
Figure 3.15 AMPAR expression in the cerebellum was not significantly different 
between genotypes at either age point. Representative western blots of AMPAR 
subunit expression (GluA1-3) in the cerebellum from WT and TG animals at 5.5 and 
7.5M (labelled along the top) shown in panel A. Along the left-hand side of the western 
blots are the detected proteins, with corresponding molecular weight listed on the right. 
Protein expression was normalised to the corresponding GAPDH band shown below. 
Quantification of normalised GluA1 (B), GluA2 (C), and GluA3 (D) expression in the 





3.4.7 NMDA receptor expression was lower in TG mice in the 
somatosensory cortex 
There was a significant effect of genotype on GluN1 expression in the somatosensory 
cortex (GLMM, χ2 (1,42) = 6.27, p=0.01**, ICC 0.27; Figure 3.16 B). There was also a 
significant effect of age (GLMM, χ2 (1,42) = 5.72, p=0.02*, ICC 0.27), which suggests 
GluN1 expression was decreased with genotype and with age. There was no 
interaction (p=0.62) between the two factors. For GluN2A expression, there was no 
effect of genotype (p=0.27), age (p=0.38) or interaction (p=0.34) between the two 
factors (Figure 3.16 C). There was also no effect of genotype (p=0.1), age (p=0.16) or 
interaction (p=0.89) between the two factors on sum GluN2B expression (Figure 3.16 
D). GluN2C was not detectable in the somatosensory cortex, as expected based on 
NMDAR subunit expression data (Monyer et al., 1992). Surprisingly, there was a 
significant effect of genotype on GluN2D expression in the somatosensory cortex 
(GLMM, χ2 (1,41) = 8, p<0.005***, ICC 0.14; Figure 3.16 E). There was no effect of age 





Figure 3.16 NMDAR expression was decreased in progressed tauopathy in the 
somatosensory cortex. Representative western blots of NMDAR subunit expression 
(GluN1, GluN2A, GluN2B, GluN2D) in the somatosensory cortex from WT and TG 
animals at 5.5 and 7.5M (labelled along the top) shown in panel A. Along the left-hand 
side of the western blots are the detected protein, with corresponding molecular weight 
listed on the right. Where there were multiple detected bands, all detected band 
expression was summed and the total value was normalised to GAPDH expression. 
Protein expression was normalised to the corresponding GAPDH band shown below. 
Quantification of normalised GluN1 (B), GluN2A (C), and sum GluNB (D) and sum 
GluN2D (E) expression in the somatosensory cortex. Statistics: GLMM, main effects 
were stated on the graphs, with post hoc significance denoted by asterisks between 






Within the cerebellar samples, there was no effect of genotype (p=0.43), age (p=0.24) 
or interaction (p=0.7) between the two factors on expression of GluN1 (Figure 3.17 B). 
There was no effect of genotype (p=0.46), age (p=0.5) or interaction (p=0.59) between 
the two factors on expression of GluN2A in the cerebellum (Figure 3.17 C). GluN2B 
was not detectable in the cerebellum, as expected based on NMDAR subunit 
expression data (Monyer et al., 1994). Surprisingly, there was a significant effect of 
genotype on GluN2C expression (GLMM, χ2 (1,28) = 3.86, p=0.05*, ICC 0.36; Figure 
3.17 D). There was no effect of age (p=0.95) or interaction (p=0.49) between the two 
factors on expression of GluN2C in the cerebellum. There was no effect of genotype 
(p=0.13), age (p=0.61) or interaction (p=0.95) between the two factors on expression 






Figure 3.17 NMDAR expression in the cerebellum. Representative western blots of 
NMDAR subunit expression (GluN1, GluN2A, GluN2B, GluN2D) in the cerebellum 
from WT and TG animals at 5.5 and 7.5M (labelled along the top) shown in panel A. 
Along the left-hand side of the western blots are the detected protein, with 
corresponding molecular weight listed on the right. Where there were multiple detected 
bands, all detected band expression was summed and the total value was normalised 
to GAPDH expression. Protein expression was normalised to the corresponding 
GAPDH band shown below. Quantification of normalised GluN1 (B), GluN2A (C), 
GluN2C (D), and sum GluN2D (E) expression in the cerebellum. Statistics: GLMM, 






The HUman synapse proteome integrity ratio (HUSPIR) (Bayés et al., 2014) was also 
calculated based on the GluN2B detected degradation product from the 
somatosensory cortex synaptosome preparations (Figure 3.18 A).  
The ratio was calculated by: 
𝐻𝑈𝑆𝑃𝐼𝑅 = 𝐻𝑖𝑔ℎ 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝐺𝑙𝑢𝑁2𝐵 𝑏𝑎𝑛𝑑
𝑑𝑒𝑔𝑟𝑒𝑑𝑎𝑡𝑖𝑜𝑛 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠 𝑜𝑓 𝐺𝑙𝑢𝑁2𝐵 
(𝑙𝑜𝑤𝑒𝑟 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑏𝑎𝑛𝑑𝑠)
⁄  
This ratio gives a measure of synaptosome quality: ratios higher than 1 are thought to 
be of good quality, typically indicating a low post-mortem delay. This is mostly used 
for human synaptosome preparations where there can be long delays between death 
and tissue isolation, but there may be faster degradation in the TG samples for 
example due to being structurally compromised and vulnerable to damage. Therefore, 
this was checked within all the samples. There was no effect of genotype (p=0.9), age 
(p=0.24) or interaction (p=0.3) between the two factors on HUSPIR (Figure 3.18 B). 
There were two samples in the WT 7.5M group that had a HUSPIR lower than 1. These 
samples were in a region of weaker detection on one of the gels and so all bands 
detected in this area were lower compared to other gels. Therefore, it is likely that the 
ratio is low in these two samples due to a technical issue and not because these 
samples are outliers. GluN2B was not detectable in the cerebellum, and so this was 






Figure 3.18 HUSPIR measurement in synaptosomes. GluN2B detection by western 
blot in the somatosensory cortex (A). The HUSPIR is calculated as the 180 kDa band 
divided by the sum of the other lower molecular weight bands, which represents the 
degradation products of the GluN2B protein. Quantified HUSPIR values across all 
somatosensory cortex samples shown as a box and dot plot for WT and TG samples 






3.4.8 Total tau and hyperphosphorylated tau were increased in the 
TG mice 
CP27 is a marker for total human tau, and AT8 is a marker for hyperphosphorylated 
tau (Goedert et al., 1995; Jicha et al., 1999). Tau expression (using these two makers) 
was not detectable in any WT sample from any brain region or age (Figure 3.19 A & 
D). AT8 positive tau was not detectable in the cerebellum. Multiple bands between 50-
60 kDA were detected using CP27 in TG mice at both 5.5M and 7.5M of age (Figure 
3.19 A & D). Higher molecular weight bands (i.e. 60 kDa band) are thought to be 
representative of tau which has large amounts of post-translation modifications such 
as hyperphosphorylation, with these species only detectable in tauopathies (Zhou et 
al., 2018). In the somatosensory cortex, this higher molecular weight band was also 
detected using AT8 confirming that this was indeed hyperphosphorylated tau (Goedert 
et al., 1995). This higher molecular weight band was not present in the cerebellum, 
and AT8 labelling was also undetectable. This confirms the absence of  tau aggregate 
pathology in the cerebellum, consistent with previous reports in the TG model 
(Ramsden et al., 2005; Spires et al., 2006). 
There was a significant effect of genotype on CP27 expression in the somatosensory 
cortex (GLMM, χ2 (1,42) = 421.88, p<0.005***, ICC=0.15; Figure 3.19 B). There was 
also a significant age effect (GLMM, χ2 (1,42) = 15.54, p=0.005***, ICC=0.15) with 
expression decreased with age, and a significant interaction (GLMM, χ2 (1,42) = 7.57, 
p<0.005***, ICC=0.15) between the two factors. There was a significant effect of 
genotype on sum AT8 expression in the somatosensory cortex (GLMM, χ2 (1,42) = 
47.03, p<0.005 ***, ICC=0; Figure 3.19 C). There was no age effect (p=0.55) or 
interaction (p=0.16) between the two factors. 
There was a significant effect of genotype (GLMM, χ2 (1,38) = 91.74, p<0.005***) and 
age (GLMM, χ2 (1,38) = 19.66, p=0.007**) on CP27 detected expression in the 
cerebellum (Figure 3.19 E). There was no interaction (p=0.95) between the two factors 






Figure 3.19 Tau expression in the somatosensory cortex and cerebellum. 
Representative western blots of human (CP27) and hyperphosphorylated (AT8) tau 
expression in the somatosensory cortex (A) and cerebellum (D) from WT and TG 
animals at 5.5 and 7.5M (labelled along the top). Along the left-hand side of the 
western blots are the detected protein, with corresponding molecular weight listed on 
the right. For CP27, all detected bands that were expressed were summed and the 
total value was normalised to GAPDH expression. Protein expression was normalised 
to the corresponding GAPDH band shown below. Quantification of normalised sum 
CP27 (B) and AT8 (C) expression in the somatosensory cortex is shown as dot and 
box plots. Quantified normalised CP27 expression for the cerebellum is shown in (E) 
Statistics: GLMM, main effects were stated on the graphs, with post hoc significance 






The results in this chapter demonstrate a role of tauopathy in the early 
neurodegenerative phase of tauopathy in altering dendritic structure and synaptic 
protein expression. There was increased dendritic complexity closer to the soma of 
neurons and a reduction in synaptic markers and glutamatergic receptor expression. 
Following neurodegeneration onset, further decreases were observed in glutamatergic 
receptor expression. 
3.5.1 Dendritic structure was changed with tauopathy 
rTg4510 neurons had an increased overall branch length with increased branching 
proximal to the soma, without changes in total area covered by the dendrites in this 
study (Figure 3.9, Figure 3.10 & Figure 3.11). Dendritic proliferation in apical dendritic 
branches was observed in a subset of pyramidal neurons in aged rTg4510 mice 
(~10M) (Crimins et al., 2012). Similar changes in dendritic complexity was also 
observed in 12M hTau mice, which was suggested to be a compensatory mechanism 
of neurons in response to loss of dendritic spines (Dickstein et al., 2010). This is in 
contrast to other work suggesting significant atrophy of neurons in tauopathy (Jaworski 
et al., 2011; Rocher et al., 2010). Increased dendritic branching could be in response 
to deprivation or loss in inhibitory tone, alterations in synaptic connectivity, or aberrant 
neuroplasticity which is known to occur in tauopathy (Jackson et al., 2017, 2020; 
Shimojo et al., 2020). This could also reflect subsampling of a specific neuronal 
phenotype, whilst other neurons are showing significant atrophy (Crimins et al., 2012).  
Early in neurodegeneration, there could be a change in synaptic inputs from 
neighbouring neurons, suggested by the increased structural synaptic plasticity 
observed in the rTg4510 mice (5-6M) (Jackson et al., 2017). A decrease in the 
frequency and/or efficacy of synaptic inputs that target the proximal dendrite may lead 
to increased dendritic growth to compensate for these changes. It is likely that these 
same connections may also increase in strength leading to an amplification of the 
signal to compensate for reduced efficacy of other synaptic inputs. In either case, this 
would likely skew signal processing towards proximal inputs. Within layer II/III, neurons 
receive differential inputs to different parts of the dendrite. For example, the distal 
apical tuft of layer II/III pyramidal neurons extends into layer I and typically receives 




whereas proximal dendrites receive local excitatory inputs from layer IV and 
neighbouring layer lI/III neurons (Cauller, 1995; Cauller and Connors, 1994; 
Feldmeyer et al., 2002, 2006; Lübke et al., 2000; Waters et al., 2003; Zhang and 
Bruno, 2019). Increased dendritic branching proximal to the soma in the rTg4510 
model may therefore skew signal processing to local bottom-up signals. Overall, an 
increase in dendritic complexity is likely to alter dendritic filtering and signal integration, 
leading to altered processing of incoming synaptic information by the neuron.  
Capacitance was lower in rTg4510 mice compared to wildtypes at this time point 
(Chapter 2). Capacitance is a measure of how well the membrane can separate 
electrical charge and impacts how much charge is needed to cause a change in 
voltage. Capacitance is related to total membrane area, with larger cells typically 
having a higher capacitance as there is more membrane to separate and store the 
charge (Henderson and Miller, 2002). Whilst the increased structural complexity 
observed in this chapter may contradict the decreased capacitance observed in 
Chapter 2, voltage clamp recordings from the soma are limited in their ability to 
uniformly control and record voltages across the dendritic tree (space-clamp issues; 
Williams and Mitchell, 2008). Therefore, capacitance is only a crude measure of cell 
surface area and by extension dendritic complexity. 
One limitation to note is that none of these cells colocalised with tau pathology markers 
(Figure 3.8). This may be due to wash out of the detectable tau isoform during 
recordings, or potentially a preferential skew towards healthy cells during recordings. 
I would think that it is more likely the former, as it is highly unlikely that all of the cells 
recorded from were negative for tau pathology, especially when some cells were in 
regions with a high tau pathology burden. However, if these recordings are from 
healthier cells, this may suggest that this phenotype is only seen in cells that have a 
lower pathological burden. 
3.5.2 Synaptic marker expression was reduced in the 
somatosensory cortex in rTg4510 mice 
In the somatosensory cortex, there was a significant effect of genotype on both 
synaptophysin and PSD95 expression (Figure 2.1). Bouton (pre-synapse) and 
dendritic spine (post-synapse) density and structural plasticity in the rTg4510 model 




turnover rates and increased stability, compared to spines which showed increased 
turnover with decreased stability (Jackson et al., 2017). There was a subtle but 
significant genotype effect on synaptophysin expression which does not change 
following neurodegeneration, which would link to a lower but stabilised bouton 
presence. There was a dramatic reduction in PSD95 expression in the somatosensory 
cortex in 5.5M rTg4510 mice compared to controls, which progressively decreased 
with age. This could be a consequence of a generalised loss of dendritic spines from 
rTg4510 neurons, but may also reflect the increased turnover of dendritic spines 
observed by Jackson et al., 2017, with an observed increase in the proportion of 
smaller immature dendritic spines expressed by rTg4510 neurons (Crimins et al., 
2011). PSD95 help anchor AMPARs and NMDARs to the synaptic membrane and 
stabilises synapses (Cane et al., 2014; Chen et al., 2015b). Therefore, lower PSD95 
expression would likely lead to reductions in glutamatergic receptor expression and 
decreased spine size, which have been observed in the rTg4510 model (Crimins et 
al., 2011, 2012; Kopeikina et al., 2013a). 
3.5.3 Glutamatergic receptor expression was reduced in the 
somatosensory cortex of rTg4510 mice 
Expression of the AMPAR subunit GluA1 was similar to wildtype levels at both ages 
(Figure 3.14). However, GluA2 and GluA3 expression in rTg4510 mice was 
significantly lower compared to wildtypes (Figure 3.14). This would suggest a 
reduction in AMPAR expression at the synapse. AMPARs are highly mobile, with 
AMPAR localisation and stabilisation to the synapse regulated in part by PSD95 
(Anggono and Huganir, 2012; Henley and Wilkinson, 2013). As there was a significant 
decrease in PSD95 expression in rTg4510 neurons, GluA2/3 containing AMPARs may 
not be able to stabilise at the synapse leading to a detected reduction in 
synaptosomes. In fact, PSD95 knockdown leads to redistribution of AMPARs to the 
extrasynaptic space (Elias et al., 2006). However, PSD95 knockout mice do not show 
this redistribution, with other membrane-associated guanylate kinases performing a 
compensatory role (Elias et al., 2006). Therefore, measuring the expression of other 
membrane-associated guanylate kinases in the rTg4510 model may provide further 





Whilst there were large reductions in subunit expression, there was no change in 
AMPAR-mediated function at ~5.5M in the rTg4510 mice (Chapter 2). GluA1 
containing AMPARs may be functionally compensating for the lack of GluA2/GluA3 
containing AMPARs at synapses. GluA2 containing receptors can compensate for 
GluA1 knockdown by redistributing to the synapse  (Terashima et al., 2019), and so it 
is possible that the inverse could also be true. GluA3 containing AMPARs have low 
conductance in basal states and therefore contribute little to synaptic currents such as 
sEPSCs (Renner et al., 2017). This may also explain why no difference in function 
was observed at ~5.5M. 
Following neurodegeneration onset, there was a reduction in AMPAR-mediated 
function (Chapter 2) and a progressive age effect on GluA2 expression (Figure 3.14). 
The most common subunit compositions of AMPARs are GluA1/2 and GluA2/3 
(Wenthold et al., 1996), with GluA1/2 heteromers accounting for the majority of 
AMPARs at synapses (Lu et al., 2009). Therefore, this decrease in AMPAR-mediated 
activity following neurodegeneration may be underpinned by a reduction in GluA2 
expression reducing GluA1/2 containing AMPARs at the synapse. In addition, GluA2/3 
containing AMPARs are thought to replace GluA1 containing AMPARs in long-term 
potentiation and other forms of plasticity. The reduction in GluA2/3 expression would 
suggest alterations in the long-term stability of synaptic plasticity at early 
neurodegenerative phases of tauopathy. This would also align with the increased 
turnover of dendritic spines observed at this age point (Jackson et al., 2017).  
The constitutive NMDAR subunit, GluN1 was significantly lower in the rTg4510 model 
(Figure 3.16). This would suggest a reduction in overall NMDAR expression. Results 
presented in Chapter 2 demonstrated a reduction in the NMDA:AMPA receptor ratio 
in rTg4510 neurons at 5.5M of age. A reduction in NMDARs would lead to a lowering 
of NMDAR -mediated synaptic transmission, which would reduce the NMDA:AMPA 
ratio. GluN1 expression was also reduced with age. The NMDA:AMPA ratio following 
neurodegeneration onset was similar between genotypes, suggesting that there was 
a large reduction in AMPA function or expression by this age to balance out the ratio. 
Interestingly, the changes in AMPAR expression do not suggest that this is the case.  
Subunits of the NMDAR change with development and control many aspects of 




Hansen et al., 2018; Traynelis et al., 2010). GluN2A and GluN2B subunits are involved 
in plasticity processes such as long-term potentiation and long-term depression, and 
GluN2B is thought to mediate NMDAR excitotoxicity, one of the hypothesised 
mechanisms of neurodegeneration in neurodegenerative diseases (Hardingham and 
Bading, 2010; Léveillé et al., 2008; Liu et al., 2007; Wang and Reddy, 2017). 
Interestingly, the expression of these two subunits were similar between genotypes. 
However, as overall NMDAR expression was reduced (GluN1 expression decreased), 
it was unusual that the GluN2 subunits were not reduced in a similar pattern. It is 
possible that there was subunit switching or upregulation of certain NMDAR subtypes 
compared to other subtypes. GluN2D expression was lower in the rTg4510 model at 
5.5M, so perhaps NMDARs containing GluN2D subunits are preferentially lost first in 
the neurodegeneration process. GluN2D containing NMDARs have low voltage and 
agonist sensitivity with a slow deactivation curve and are thought to be involved in 
tonic NMDAR activity (Hansen et al., 2018; Traynelis et al., 2010). This reduction of 
GluN2D expression would therefore not be measured in the NMDA:AMPA receptor 
ratio, so measuring tonic NMDAR activity may show differences in the rTg4510 model.  
Different glutamatergic receptor subunits are also expressed in different populations 
of cells in different brain regions. Results presented in Chapter 2, characterised the 
synaptic function of putative excitatory neurons. However, glutamatergic receptors are 
also expressed by glia and interneurons (Akgül and Mcbain, 2016; Lee et al., 2010; 
Verkhratsky and Kirchhoff, 2007). For example, GluN2D containing receptors are 
mostly expressed in interneurons (Küppenbender et al., 2000; Standaert et al., 1996), 
and glial cells also express both NMDARs and AMPARs (although GluA2 expression 
is low in glial cells) (Burnashev et al., 1992). Directly comparing the results of receptor 
subunit expression analyses presented here with electrophysiology analyses 
presented in Chapter 2 may therefore be confounded by the fact that receptor 
expression was determined from a crude synaptosome preparation, and not from an 
isolated subpopulation of neurons. 
3.5.4 Tau overexpression did not alter protein expression in the 
cerebellum at 5.5M 
The cerebellum in the rTg4510 model does not develop aggregate pathology, nor does 




(SantaCruz et al., 2005; Spires et al., 2006). The cerebellum in this study showed very 
few changes in receptor expression or synaptic marker expression. Human tau was 
significantly higher in this region than in wildtype mice, as detected by increased CP27 
labelling in western blot analysis of isolated synaptic proteins (Figure 3.19). AT8 was 
undetectable, and there was also a lack of the higher molecular weight species in the 
CP27 labelling that were seen in the somatosensory cortex, which suggests a lack of 
aggregate pathology. 
Interestingly, synaptophysin was increased in the cerebellar synaptosome fraction in 
7.5M old rTg4510 mice (Figure 2.1). There was also a genotype effect observed in 
GluN2C expression, with expression being higher in the rTg4510 mice. GluN2C 
expression is largely restricted to cerebellum granule cells (Thompson et al., 2000) 
and GluN2C expression is increased in granule cells following dendritic growth (Iijima 
et al., 2008). This could also lead to increases in synaptophysin expression via 
increased synapses. Therefore, perhaps there is some form of dendritic growth that 
occurs with longitudinal soluble tau incubation, with support for this seen in a model of 
human tau overexpression which developed increased dendritic complexity in neurons 
(Dickstein et al., 2010). Alternatively, GluN2C expression is also detected within glia 
cells (Karavanova et al., 2007), which play a role in synapse function. Therefore, 
perhaps there is increased glial proliferation and/or recruitment following 
neurodegeneration onset, leading to an upregulation in synapses. Nevertheless, this 
result was surprising and therefore more work would need to be done to determine 
what changes were occurring in the cerebellum following neurodegeneration onset. 
Overall, whilst there were two changes in markers at 7.5M in the rTg4510 mice within 
the cerebellum, there were no changes at 5.5M. Therefore, if the changes observed 
in the somatosensory cortex were solely due to soluble tau overexpression, we would 
expect to see similar changes in the cerebellum. As this was not the case, there is 
added confidence that the changes observed in the somatosensory cortex are related 
to expression of progressed tauopathy in the rTg4510 mice. 
3.6 CONCLUSIONS 
Synaptic and structural dysregulation occur within the early neurodegenerative phase 
of tauopathy in the rTg4510 model. Dendritic complexity was altered, and synaptic and 




compensation to changes in synaptic inputs in the local environment. Following 
neurodegeneration onset, synaptic and glutamatergic protein expression decreased, 
suggesting these processes occurred in parallel to the progression of 
neurodegeneration. The cerebellum showed no changes in protein expression at 5.5M 
as expected. This suggests that the disruption in the somatosensory cortex was 
related to expression of progressed tau pathology. Overall, this provides evidence of 
subunit selective synaptic vulnerability and structural alterations in response to 
increasing tau pathology concentrations and changes in synaptic connections in the 
local neuronal environment. It is likely that there may be a degree of homeostatic 
compensation within the network, which when past a threshold leads to widescale 
network alterations and symptomatic changes. Deconstructing this mechanism in the 





4 IMPLEMENTATION AND OPTIMISATION OF IN VIVO 
TWO-PHOTON TARGETED WHOLE-CELL PATCH 
CLAMP ELECTROPHYSIOLOGY IN THE 
SOMATOSENSORY CORTEX OF ADULT MICE   
5.1 INTRODUCTION 
This chapter will summarise a series of experiments to set-up and validate the use of 
in vivo two-photon targeted whole-cell patch clamp electrophysiology in the mouse 
somatosensory cortex. This was done as a necessary precursor to using this method 
to examine the physiological function of somatosensory neurons in the rTg4510 model 
at ~5.5 months (5.5M; see Chapter 5). Recordings were performed under urethane 
anaesthesia to help isolate spontaneous and synaptically-evoked activity without the 
contamination of other local and global activity seen in awake states. The majority of 
in vivo recordings in the literature are performed in juvenile mice (<1M), and so adult 
mice of >3M were used for recordings to ensure comparability with the age of the mice 
that will be used for the rTg4510 experiment as electrophysiological properties can 
change with age (Cheng and Lin, 2013; Luebke et al., 2015; Randall et al., 2012). 
Whole-cell properties were recorded in vivo from layer II/III of the somatosensory 
cortex to establish typical electrophysiological properties under urethane anaesthesia. 
In addition, in light of the glutamatergic deficits identified in Chapter 2 and 3 in the 
rTg4510 model (i.e. reduced NMDA:AMPA ratio and reduced AMPA receptor 
(AMPAR) and NMDA receptor (NMDAR) expression in the rTg4510 mice at 5.5M), 
part of the work discussed in this chapter aimed to develop a protocol to quantify how 
this alteration manifested in vivo.  
4.1.1 The value of in vivo whole-cell patch clamp recordings 
Whole-cell recordings are highly versatile and can provide information on subthreshold 
membrane potential dynamics, intrinsic properties, and can be combined with post hoc 
recovery of recorded neurons allowing for cellular identification. The ability to record 
in the intact brain as a physiological system provides invaluable information about how 
a single cell behaves within the network. Some properties such as input resistance, 
action potential (AP) threshold and neuronal spike output can also differ significantly 




Rosa, 2006; Fernandez et al., 2018; Tsuno et al., 2015). Therefore, the ability to 
perform this technique can fully characterise how a neuron behaves in a 
physiologically relevant environment. 
4.1.2 In vivo whole-cell recordings in the somatosensory cortex 
under urethane anaesthesia 
Recordings made under urethane anaesthesia induce a slow wave oscillation (<1 Hz), 
known as up and down states, which are also observed during other physiological 
states such as slow wave sleep (Steriade et al., 1993c; Wilson and Groves, 1981). Up 
and down states are thought to be representative of the local network activity, with 
down states representing periods of reduced synaptic input, and up states periods of 
increased synaptic input, arising from a balanced excitatory and inhibitory dynamic 
system (Arieli et al., 1995; Haider et al., 2006; Lampl et al., 1999; Okun et al., 2010; 
Renart et al., 2010). Measuring up and down state activity seems to be a reasonable 
model of cortical network dynamics, and can also inform on how that neuron behaves 
within the network. 
Up state initiation within the cortical column is thought to be driven from layer V 
pyramidal neurons, likely when a critical amount of synchronised synaptic drive is 
provided onto these cells (Beltramo et al., 2013; Chauvette et al., 2010; Lőrincz et al., 
2015; Sanchez-Vives and McCormick, 2000; Timofeev et al., 2000). Up states then 
persist for periods of up to a few seconds, maintained by a combination of recurrent 
excitatory synaptic activity with contribution of intrinsic mechanisms that maintain 
bistable cellular states (Egorov et al., 2002; Palmer et al., 2014; Sanchez-Vives and 
McCormick, 2000). In vitro and early in vivo characterisation of up states suggests a 
paramount role of ionotropic glutamate receptors in up state maintenance (Sanchez-
Vives and McCormick, 2000; Steriade et al., 1993a). However, in vivo characterisation 
with bath or intracellular application of NMDAR antagonists shows conflicting results 
in comparison, suggesting no effect of NMDARs on up state frequency or maintenance 
(Chen et al., 2013; Palmer et al., 2014; Smith et al., 2013). Synaptic inhibition also 
helps sustain up states, as a consequence of balanced synaptic excitation and 
inhibition at these more depolarised potentials (Haider et al., 2006; Waters and 
Helmchen, 2006). Up state termination occurs from a likely combination of increased 




Sanchez-Vives and McCormick, 2000; Steriade et al., 1993a). Down states are said 
to be stable periods of synaptic quiescence, facilitated by the network refractory period 
(Neske, 2016; Wilson, 2008). Overall, this activity reflects local synchronous synaptic 
activity with balanced inhibition and excitation during state maintenance.  
The somatosensory cortex in the rodent has been used extensively as a classical 
model system, due to its stereotypical and somatotopic architecture, experimental 
accessibility, and the ease of evoking a defined response using a behavioural stimulus 
(whisker stimulation) (Adibi, 2019; Petersen, 2007). Unsurprisingly, some of the 
earliest two-photon targeted whole-cell recordings in vivo were made in the 
somatosensory cortex, with almost all recordings performed in juvenile animals 
(Kitamura et al., 2008; Margrie et al., 2003). Intracellular recordings have confirmed 
neurons in the somatosensory cortex respond to whisker stimulation with an evoked 
post-synaptic potential (PSP) and that this response is modulated by up and down 
states (Ferrarese et al., 2018; Gambino and Holtmaat, 2012; Petersen et al., 2003; 
Sachdev et al., 2004). This response is thought to be glutamatergic with a short latency 
non-NMDAR component and a slower component which is NMDAR-mediated 
(Armstrong-James et al., 1993; Gambino and Holtmaat, 2012; Gambino et al., 2014). 
Therefore, evoked responses could be used to determine glutamatergic function, and 
help isolate NMDAR-mediated responses in vivo. 
4.2 AIMS 
This chapter aimed to identify typical neuronal properties in vivo in ~5M old mice in 
the somatosensory cortex under urethane anaesthesia, as age can alter 
neurophysiological properties and typical in vivo whole cell recordings are performed 
in adolescent mice (<1M). Following on from the results in Chapter 2 and 3, there was 
altered glutamatergic receptor expression and function, which may manifest in 
different ways in vivo, and so a protocol to explore this in vivo was also established. 
In addition, the local field potential (LFP) was recorded to characterise how neuronal 
properties link to the LFP and whether this would be altered with MK801 application 
(an NMDAR antagonist). 
Therefore, this work characterised typical neuronal properties in ~5M old mice in the 
somatosensory cortex under urethane anaesthesia in vivo. In addition, different 




to establish a protocol that could explore glutamatergic receptor function, particularly 
NMDAR-mediated activity. Extracellular recordings of the LFP were made to gain an 
understanding of wider scale dynamics and were compared to whole-cell recordings 
which helped determine and confirm how responses of the single cell related to the 
network.  
4.3 METHODOLOGY 
4.3.1 Ethical approval 
All procedures including sacrifice by schedule 1 methods were performed in 
accordance with the UK Animal (Scientific Procedures) Act 1986 and its subsequent 
amendment in 2012 to align with European Directive 2010/63/EU on the protection of 
animals used for scientific purposes. Mice were kept on a 12:12 light/dark cycle and 
granted ad libitum access to food and water.  
4.3.2 Animals 
Mouse lines used to establish in vivo whole-cell patch clamp electrophysiology were 
from a mixture of genotypes including C57BL/6J, Ai95, vGluT2-IRES-cre & TdTomato. 
C57BL/6J mice were supplied by Charles River, with the rest bred in house. These 
mice were aged between 3-12 months. All animals were held in a vivarium at the 
University of Bristol and if supplied externally, animals were habituated to their new 
environment for at least two weeks prior to experiments.  
4.3.3 Surgery Preparation 
All surgical procedures were done using sterile and aseptic conditions where possible. 
Animals were weighed before surgery began to ensure the correct urethane 
anaesthetic doses were given. Experiments were acute, non-recovery procedures. At 
the end of experiments, the animal was sacrificed using cervical dislocation. 
4.3.4 Surgical Procedure 
Animals were anaesthetised under isoflurane (3-4% in O2) in an induction chamber. 
Once anaesthetised, the fur was shaved from the scalp above the skull using hair 
trimmers (Wella). Animals were then transferred and placed into an anaesthetic mask 
on a customised stereotaxic frame (Figure 4.1). Isoflurane flowed through the mask at 
a rate of ~0.4L/min, with isoflurane concentration adjusted to give sufficient 




This was also adjusted throughout the procedure to maintain appropriate anaesthetic 
depth based on breathing rate and signs of wakefulness such as twitching. Internal 
body temperature was monitored using a rectal temperature probe and controlled 
thermostatically via a heat pad underneath the animal set to 37°C. Lacri-lube 
(Allergan, Ireland) was applied to the animals’ eyes to prevent drying. The mouse was 
fixed within the frame using ear bars and a bite bar.  
 
 
Figure 4.1 Overview of customised stereotaxic frame. Face-on (A) and side-on (B) 
views of the stereotaxic frame which was customised to have a Thorlabs metal 
breadboard (4) fixed to it. A removable smaller breadboard (3) was placed on top and 
held down with a thumbscrew and clamp. This allowed for easy transfer between 
surgery and experimental recordings. Attached to this was removable head bar clamps 
(2) and a custom-made heat pad (1). 
 
The scalp was washed with iodine (Videne, Ecolab), and lidocaine (Aspen, South 
Africa) was applied. An incision was made in the scalp and stretched to expose the 
top of the skull, which was then cleaned with cortical buffer soaked cotton buds (aCSF, 
buffer composed of (in mM) 135 NaCl, 5 KCl, 5 HEPES (Free Acid), 1.8 CaCl2 and 1 




(anterior-posterior +1.3 mm, medial-lateral -3.4 mm from bregma; Paxinos & Franklin, 
2001) were marked on the skull with a permanent marker. The skull was then scored 
with a microlance needle (BD, USA) to provide extra surface area for the super glue 
to affix to, to increase grip. A thin layer of super glue was then applied over the whole 
skull avoiding the area marked for the craniotomy. A custom-made linear head bar 
was then attached to the posterior of the skull (on the interparietal bone) using 
superglue and left to set (ensuring it was flat and level; Figure 4.2). The head bar was 
further covered with super glue to ensure that it was firmly secured and to increase 
the water tightness of the well. As the head bar was metal, this needed to be 
completely covered in areas which would contain extracellular solution which could 
break the electrical circuit during whole-cell recordings. The whole area that was 
covered with super glue was then covered with a thin layer of dental cement (Kemdent, 
UK; Figure 4.2). Once this was dried, a well was built up out of dental cement around 
the edge of the skull. The well needed to hold in the aCSF and so had high walls, but 
was also wide enough for the objective to image the craniotomy unimpeded (~1.5 cm 
x 1.5 cm). 
A ~1mm craniotomy was made at the coordinates marked out (anterior-posterior +1.3 
mm, medial-lateral -3.4 mm from Bregma), corresponding to the somatosensory 
cortex. This was done by drilling slowly in a circle until the skull became thin. At this 
point, the well was filled with aCSF and the thin bone was pricked with a microlance 
needle (BD) to reduce damage to the cortical surface. Once the drilled skull fragment 
was loose and unattached from the surrounding skull, the fragment was removed 
using a hooked needle (BD Microlance Needle, bent to make a hook). Once the skull 
fragment was removed, the buffer was refreshed and maintained at a high level in the 
well for the rest of the procedure including experimental recordings. 
The dura was then carefully removed in this area using a hooked syringe needle (BD 
Micro-Fine U-100 Insulin Needle, bent to a 45° angle) which was carefully dragged 
over the brain surface to make a hole in the dura. The dura was then removed from 
the surface of the brain. A schematic showing an overview of the finished surgical 






Figure 4.2 Surgical overview schematic. A schematic showing an overview of a 
finished surgical preparation with the dental cement well labelled in pink, the 
craniotomy with dura removed, a head bar attached and labelled at the back, with the 
glue and cement layer shown as a shaded area. 
 
For a subset of experiments, an LFP electrode was fixed into place following the 
duratomy. A PlasticsOne (USA) wire electrode was bent to sit within the brain, 
perpendicular to the surface. This wire was inserted into the brain and fixed to the wall 
of the well with superglue (Figure 4.3).  
 
 
Figure 4.3 Overview of the surgical procedure with the addition of an LFP 
electrode. A photo following LFP electrode placement (A) with a cartoon schematic 






Following the procedure, mice were injected with urethane prior to transfer to the two-
photon recording set up. Electrophysiology recordings were made solely under 
urethane anaesthesia. The dose varied between 1.5 - 2 mg/kg based on responsive 
depth from the mouse, with top up doses given throughout the recording periodically 
as required.  
After confirming the anaesthetic depth of the mouse by checking toe pinch and corneal 
reflexes, the head bar fixation clamps were attached to the removable plate and the 
mouse was removed from the stereotaxic frame (i.e. ear bars and bite bar). The mouse 
was then fixed using the head bar to the removable plate (Figure 4.1). This plate was 
then transferred and fixed within the in vivo two-photon recording set up. The aCSF in 
the well was topped up if required, a rectal probe was placed and the heat mat was 
plugged into the recording set up, set to 37°C. A ground electrode was placed into the 
well (Figure 4.4). Whiskers were clumped together using Vaseline and the tips trimmed 
if required to form the bundle. Then two different whisker stimulation methods were 
used. A piezo wafer was placed near the whiskers with an attached metal tube to place 
the whiskers in, or an open-ended cone was placed next to the whiskers to allow air 
puff stimulation using a Pneumatic PicoPump (World precision instruments, UK, 
PV820). 
 
Figure 4.4 Overview of the mouse in the recording set up. A photo following the 
end of the surgical procedure, with the mouse in the recording set up. The mouse is 
head fixed via the attached head bar, with a dental cement well which encompassed 
the craniotomy (A). A ground electrode has been placed in the well away from the 
craniotomy. A side angle photo shows further components of the recording set up (B) 
including the position of the recording electrode, the surgical removable plate, the 




4.3.5 Recording equipment 
The surgical plate was attached to a customised Scientifica (UK) microscope on a 
motorised stage. A camera was attached to the microscope allowing visualisation 
using Micromanager software (version 1.4.22; Edelstein et al., 2014) on the PC. A 
flexible gooseneck lamp was used to help illuminate the recording area. Brightfield 
imaging was used to visualise the craniotomy to determine the target region of interest 
and electrode placement. 
For two-photon imaging, a MaiTai Ti-Sapphire tuneable laser (Spectra Physics, USA) 
was used at an 800 nm excitation wavelength. The power used was kept to the 
minimum necessary for accurate visualisation of cellular shadows when recording in 
the brain. Image acquisition was controlled using SciScan software (Ward et al., 2017). 
For electrophysiology recordings, signals were amplified using a Multiclamp 700A 
(Molecular Devices, UK) and digitised using a CED Power 1401 data acquisition 
system (CED, UK). Recordings were made and stored on a PC using Signal v5.07 
software (CED). Whole-cell recordings were low pass filtered at 10 kHz, with an output 
gain of 10x. LFP recordings were low pass filtered at 1 kHz and had an output gain of 
100x. Both recordings were sampled at 50 kHz. 
4.3.5.1 Intracellular recordings combined with local field potentials (LFP) 
Recording simultaneous local field potentials (LFP) with whole-cell recordings 
provides insight into the local network activity and how that relates to the subthreshold 
dynamics of the single cell. Two different LFP methods were tried. One was a fixed 
wire electrode implanted during surgery (Figure 4.3). The second was a glass 
electrode attached to a separate headstage to the recording electrode, on a second 
micromanipulator (Scientfica PatchStar) that was in place on the electrophysiology 
recording set up. 
The glass electrode had limited placement options as it was a rigid electrode and the 
curvature of the objective needed to be considered when placing it within the brain. 
However, as it was on a micromanipulator, it could be moved easily and replaced as 
needed. 
The wire electrode provided a flexible solution that was flat to the skull which meant 




recordings. This also reduced the time needed to place the LFP electrode during 
recordings. However, the electrode was difficult to place within the craniotomy without 
damaging the brain or spilling adhesive onto the exposed brain. Therefore, LFP 
recordings were done using the glass electrode as this led to the least amount of 
overall brain damage.  
4.3.5.2 Recording electrode fabrication and recording solutions 
Whole-cell and LFP electrodes were fabricated on a Narishige (UK) PC-10 puller with 
a resistance of 5-10 MΩs. The LFP electrode was filled with aCSF. The whole-cell 
recording electrode was filled with one of two intracellular solutions (Table 4.1). 
Initial optimisation of the technique was performed using solution 1, before switching 
to solution 2 to maintain consistency with the rest of the work in this thesis. Both 
intracellular solutions were made up with the addition of 25 µM of AlexaFluor 
Hydrazide 594 (Invitrogen, UK). The inclusion of AlexaFluor dye allowed for neuronal 
visualisation in the brain when imaged using two-photon microscopy. MK801 (1 mM; 
HelloBio, UK) was also added to the intracellular solution for a subset of recordings, 
as is stated in the description of relevant results. The whole-cell recording electrode 
was connected to a pneumometer (AP-C30W; Keyence, UK) to measure the pressure 





Table 4.1 Composition of intracellular solutions. Table of intracellular solution 







K-Gluconate - 135 
KMeSO4 115 - 
NaCl 8.5 5 
QX314-Cl - - 
HEPES free acid 5 10 
EGTA 0.5 0.2 
BAPTA - - 
GTP- 2Na salt - - 
GTP- Na salt 0.3 0.3 
ATP- Mg Salt 4 4 
Sucrose 31 - 
Biocytin - 6.7 
 
 
4.3.6 Visualisation and targeting of neurons for recordings 
Under a 4x objective (Olympus UPlanFl, 4x/0.13), an area within the craniotomy was 
identified for whole-cell recordings. This area was away from any surgical damage and 
had low amounts of blood vasculature as this could obscure imaging and could also 
get damaged during electrode placement.  
Once an area was identified, the objective was changed to a 40x objective (Olympus 
LUMPlanFL N, 40x/0.80 W, UIS-2). For LFP recordings, the glass electrode was 
located under the 40x objective and then inserted into an area nearby to the region 
selected for recordings. This was done prior to the insertion of the whole-cell recording 
electrode. This was inserted to an estimated depth of 150 µm from the surface of the 
brain based on measurements from the PatchStar controller and micromanager 
software. 
For whole-cell recordings, a glass electrode filled with an intracellular solution was 




lowered to focus on the surface of the brain and ~300 mBar pressure was applied to 
the electrode. The electrode was inserted into the brain on the approach angle to a 
depth of ~50 µm from the pia. The objective was focussed approximately near the 
electrode tip and all lights were turned off, to switch to visualisation using two-photon 
imaging. Frames were scanned at 32 Hz using a resonant galvanometer. 
The methodology used to visualise the electrode and cells within the brain is referred 
to as ‘Shadow Patching’, and was first described by Kitamura et al., 2008  (Figure 4.5). 
Perfusion of the AlexaFluor containing intracellular solution within the brain allowed 
for visualisation of the extracellular space. This solution was not taken up by the cells 
or blood vessels within the brain, leading to dark “shadows” of these structures (Figure 
4.5 B). This technique can therefore be used to navigate the electrode through the 
brain with minimal damage and visualise cells to target for recordings. If shadows were 
not visible using two-photon imaging upon insertion of the electrode, the electrode was 
likely clogged and was removed from the brain and changed. If shadows of cells were 
visible, the pressure at the electrode was reduced to ~85 mBar. The electrode was 
progressed deeper into the brain to around 80-150 µm from the surface, avoiding 
blood vessels. Whilst progressing the electrode into the brain the electrode resistance 
was also observed, as deflections or a change in resistance would suggest a blockage 
of the tip. Layer II/III was targeted based on depth of the electrode and also by 
visualisation of the cell density. At layer II, there was a very noticeable increase in the 
number of cells in the visible area. Once at layer II, the pressure was reduced to ~45 
mBar. Pyramidal neurons were targeted based on their shape (triangular). Once 
selected, whole-cell recordings were made based on the methodology in Margrie et 
al., 2002 (Figure 4.5 C). Pulsatile deflections were looked for alongside visualisation 
of the electrode approaching the cell. Once confirmed to be on the cell, suction 
(negative pressure) was applied to the electrode and the current was held at -70 mV 
to seal onto the cell (“cell-attached mode”), to then allow break in. Small suction pulses 
were applied to attempt to break into the cell. If successful, deflections were seen on 





Figure 4.5 In vivo whole-cell “Shadow Patching” recording methodology. 
Shadow patching involves observation of the resistance changes of the electrode 
alongside visual neuronal identification. A shows a schematic of shadows of neurons 
being visualised via dye spreading into the extracellular space. Once the neuron is 
recorded, this dye clears from the extracellular space whilst the neuron simultaneously 
fills with the dye, leading to neuronal visualisation. B shows shadows of the electrode 
(in dashed red lines), an outline of some cellular shadows (in dashed red circles) and 
blood vessels (labelled in white). C shows the typical changes in electrode resistance 
throughout the process. When close to the surface of a cell, pulsations are observed 
(“strike”) in the electrode resistance, shown in the second line of the schematic. A max 
projection of a z-stack of a filled neuron following recordings with the recording 
electrode still attached (D). The image is depth colour coded (hotter colours 
correspond to an increase in depth (86 µm depth range); pia - blue to bottom of neuron 





During recordings, junction potential error (JPE) was not corrected for as the makeup 
of the external solution (i.e. the brain cerebrospinal fluid (CSF)) was not known. Bridge 
balance correction was also not applied as series resistance is thought to change more 
throughout in vivo recordings and therefore would be inappropriate (Kodandaramaiah 
et al., 2018; Schramm et al., 2014; Wang et al., 2016). 
During recordings, cells filled with the AlexaFluor dye that was used for visualisation 
(Figure 4.5 A). This allowed for cell visualisation following recordings, imaged using 
two-photon microscopy (Figure 4.5 D). A z-stack from the pia to the depth of filled 
neuron visibility (32 frames per plane, 1 µm steps) was taken using a 40x objective, 
visualised using an excitation wavelength of 800 nm. This helped to confirm neuronal 
identity (putative pyramidal neurons) post recording by imaging the structure looking 
for a large dendritic arbour with the presence of dendritic spines.  
Afterwards, mice were sacrificed using a schedule 1 method. Following this, the whole 
brain was extracted and drop fixed into 4% PFA in 0.1M PBS and fixed overnight. 
Brains were then stored in PBS (0.1M). 
4.3.7 Technical considerations of note 
A funded placement (an award from the MRC flexible funding supplement that I 
gratefully acknowledge in allowing this placement to occur) in Berlin in the laboratory 
of James Poulet with Jean-Seb Jouhanneau provided insight into what details are 
important for successful two-photon targeted in vivo patch clamp electrophysiology 
recordings. Therefore, some technical details are highlighted here as they were 
deemed important to experimental success.  
4.3.7.1 Equipment 
4.3.7.1.1 Removable surgical plate 
An image of the surgical set up is shown in Figure 4.1. One crucial component of acute 
in vivo whole-cell patch clamp recordings is speed (as shorter surgery times typically 
equals longer recording time). Therefore, the surgical set up was optimised to facilitate 
this. A metal plate was designed with a fixed heat pad that was portable. This metal 
plate could be fixed and removed easily from the surgical set up. The fixed heat pad 
was small and electrical noise free, and so was suitable for recordings of this nature. 
Head bar clamps were also fitted to the metal plate so that the implanted head bars 




recording set up. The angle of the clamp and position of the head bar was optimised 
to ensure that imaging could occur straight away based on the location of the 
craniotomy. 
4.3.7.1.2 Electrode placement 
Following surgery, the mouse was transferred under the two-photon microscope for 
experimental recordings. The electrode angle and position were optimised to ensure 
appropriate visualisation and access to the craniotomy (Figure 4.6). A shallow 
electrode angle would not be able to access the craniotomy over the well and a deep 
angle was difficult to visualise under the microscope. In addition, the objective could 
push on the electrode if positioned wrong. An angle of ~38° was deemed optimal. The 
positioning of the whole-cell (headstage 1) and LFP electrode (headstage 2) were also 
chosen to allow recordings in close proximity to each other without collisions or 
contacts with the objective.  
 
Figure 4.6 Electrode position and angle in relation to the objective. The position 
and angle of each headstage (with the electrode) were carefully considered. Angle 
was chosen based on objective angle and well dimensions. Spacing and approach 






Urethane was used as the recording anaesthesia for two reasons. Firstly, it has been 
shown to induce minimal disruption to normal network physiology, especially 
glutamatergic signalling, which was of specific interest for experimental recordings 
(Hara and Harris, 2002; Sceniak and Maciver, 2006).  A second benefit was that it 
produced minimal pulsatile brain movements compared to other anaesthetics as it is 
not a vasodilator, and thus is commonly used for in vivo recordings (Masamoto and 
Kanno, 2012).  
4.3.8 Experimental protocols 
4.3.8.1 Series resistance 
Series resistance was measured at the start of recordings following break in and was 
measured from the current deflection recorded in response to a voltage step of a 
defined size. This was converted to a resistance measure using Ohm’s law. 
4.3.8.2 Up and down states  
This was recorded using “gap free” recording mode in current clamp, where no current 
was applied to the cell (i.e. at rest). The first three minutes were recorded using a “gap 
free” protocol following break in. Longer recordings were also made (up to 30 minutes) 
to observe other basal properties such as cyclic up and down state modulation. 
4.3.8.3 Evoked activity 
Whisker stimulation evoked a recordable synaptic response (PSP). Different 
stimulation methods and protocols were characterised, and will be described below. 
This was recorded in current clamp, with no current applied to the cell (i.e. at rest). For 
responses evoked on up and down states, the average was shown per cell from a 
stimulation period of at least 10 minutes. Comparisons of evoked responses were also 
made over time. The average response evoked on down states from the first and last 
5 minutes of the recording protocol were compared. Whilst there was some variability 
within this, stimulation recording protocols were typically 10-15 minutes long, with 
recordings shorter than 10 minutes not included in comparisons made over time. 
4.3.8.4 LFP recordings 
LFPs were also recorded using a “gap free” protocol in current clamp. This activity was 






4.3.9.1 Up and down states  
Up and down states display a network bistability, leading to voltages having a bimodal 
distribution (due to the relatively short amount of time spent between the two states). 
Therefore, a histogram of the membrane potential (Vm) typically has a bimodal 
distribution of two distinct states (up and down) which can be split. This method is 
used to define up and down states in this work and the features of these states.  
A custom MATLAB script was used to analyse up and down state properties. APs were 
filtered out of the recorded trace, with APs present exclusively on up states in these 
recordings. To do this, the AP was identified by finding the point on the trace where 
dV/dt surpassed 10 mV.ms-1. This identified possible APs, with the maximum mV then 
measured up to 1 ms after this point. If this value was larger than -50 mV, then it was 
classified as an AP. To filter out the AP, the AP threshold was identified (defined as 
the recorded mV on phase-plane plots where dV/dt surpassed 30 mV.ms-1) and all 
points greater than this threshold on the identified AP waveform were changed to be 
equal to the AP mV threshold. Following AP filtering, the traces were down sampled 
to 1 kHz. A 10 s scanning window scanned the trace in 1 s increments, with a 
histogram of the Vm calculated within this window. A bimodal distribution was fitted to 
the histogram of Vm (using fitgmdist in MATLAB for two populations) to identify the 
thresholds for up and down state detection. Two distributions were detected 
(representing up and down states) and the minimum between the two distributions 
was found. Two thirds of the up or down state peak to the local minimum distance was 
used to create a threshold for up and down states (Menkes-Caspi et al., 2015; Stern 
et al., 1997; Figure 4.7). This created a moving threshold for the trace to account for 
changes in baseline stability or changes in up and down state shape. These thresholds 
were used to detect up and down states. 
Changes past the up state threshold were counted as up states if the Vm was above 
the up state threshold for longer than 200 ms  (González-Rueda et al., 2018; Menkes-
Caspi et al., 2015), with the start and end of the up state counted as the point where 
the voltage depolarised and hyperpolarised past the down state threshold (Figure 4.7 






Figure 4.7 Thresholds for up and down state analysis. An example trace showing 
up and down states is shown on the left, with the starting Vm marked on. The 
determined up and down state thresholds are shown in red and cyan respectively. To 
the right is a histogram of Vm, with a bimodal distribution representing the mean up 
and down state Vm. Dashed lines mark the midpoint and 2/3rd points used for state 
threshold separation.  
 
 
Figure 4.8 Quantification of up state properties. A schematic showing a detected 
up state with quantified properties. Up state charge is represented by the shaded area. 
Dwell time is shown as the amount of time above the down state threshold. Mean up 
state and down state Vm were taken as the mean Vm from the bimodal Vm histogram. 
 
The mean Vm was taken as the average mV of the whole trace. The mean of up and 
down states was also calculated as the mean mV within each threshold band (Figure 
4.8), with Δ up state:down state calculated as the range between these two values. 
The dwell time of up or down states was calculated as the average up or down state 
duration from all detected states (Figure 4.8). The variance of the trace was calculated 




the up and down states. The principal frequency (the frequency identified with the 
highest spectral power) was calculated using the periodgram function within MATLAB. 
The AP firing frequency was measured as the total APs over a minute, normalised to 
APs per second (Hz). 
Cross and auto correlations between signals was performed using xcorr in MATLAB, 
used to evaluate the similarity (correlation) of two signals (cross) or the periodicity of 
one signal (auto) across time. This was done by shifting one signal across time and 
measuring the correlation at each time shift (lag) between the two signals. For auto 
correlations, this shifting was performed on a duplicate signal. The peak correlation 
and lags (s) were extracted from plots.  
Data were presented as box and dot plots. The box represents standard error of the 
mean (SEM), and within the box the square represents the mean, and the line 
represents the median.  
4.3.9.2 LFP recordings 
LFP recordings were baseline normalised and the LFP traces were compared to the 
intracellular Vm either visually or using cross and auto correlations. 
4.3.9.3 Cyclic modulation of up and down state activity 
Slow cyclic modulation of up and down state activity was visible when examining 1 Hz 
power over time. This was therefore measured using the overall power in the 1 Hz 
frequency band which was z-score normalised. Troughs in the power oscillation were 
identified and used to quantify cyclic periodicity. 
4.3.9.4 Evoked responses 
Results were analysed using custom MATLAB scripts, developed in house. Evoked 
responses were plotted as mean waveforms with shaded SEM, unless specified 
otherwise. Responses evoked on up or down states were split into two respective 
groups, calculated as up state evoked if the range was >3 mV in the 50 ms preceding 
stimulus onset (Jouhanneau et al., 2014). These responses were baseline normalised 
to the Vm period 5 ms post first stimulus onset. This 5 ms period has been shown to 
be less than the latency of the evoked response in layer II/III neurons to whisker 




The overall evoked response was averaged for comparisons. The overall evoked 
responses were quantified as total area under the curve (AUC; defined as the AUC of 
all points within the measured region, calculated using trapz in MATLAB). The evoked 
response to the first stimulus was also considered separately, to help identify individual 
response components without surround inhibition or excitation from neighbouring 
barrel stimulation (Gambino and Holtmaat, 2012). The response to the first stimulus 
was described in terms of peak and PSP, with peak referring to the rapid and large 
response at the start of the stimulation (maximum mV 0 – 40 ms following stimulus 
onset), and PSP referring to the slower and delayed depolarisation to the stimulation 
(mean mV 50 – 100 ms post stimulus onset; Figure 4.9). 
 
 
Figure 4.9 Peak and PSP components of evoked potentials. A schematic of the 
evoked response recorded in response to the first whisker stimulation. Labelled are 
the peak (fast, large amplitude response at the start of the deflection) and the PSP 
(slower after depolarisation). 
 
Statistics were performed using R software (v3.5.1) with the integrated development 
environment RStudio (v1.1.456). 
Similar to the previous results chapters, data was analysed using a generalised linear 
mixed model (GLMM). Animal number was not included due to the low number of 




conditions, cell number was incorporated into the model as a random factor, to account 
for repeated measures from the same cell for each condition compared.  
The following GLMM was used to model the data: 
𝑉𝑎𝑟𝑖𝑎𝑏𝑙𝑒 ~ 𝐷𝑟𝑢𝑔 ∗ 𝑆𝑡𝑎𝑡𝑒 + (1|𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 ) 
Variable was the experimental measure tested. Drug was compared as a main effect 
(either control or MK801 treated). State was also compared, which for this work was 
either up or down state, or “pre” or “post” (early or late in recordings). 
Each main effect was evaluated using a goodness of fit chi squared test (χ2). 
Significant results were described as (χ2 (df, n) = a, p=b*). The χ2 value was a, degrees 
of freedom was df, n was the number of recordings, and the corresponding p value (b) 
was listed with asterisks denoting level of significance when alpha <0.05. Non-
significant results were listed as a p value only. A Tukey-Kramer multiple comparison 





4.4 RESULTS: SPONTANEOUS PROPERTIES 
4.4.1 Up and down state properties following break-in 
Over the first few minutes of a cellular recording, there was an observable build-up of 
up state amplitude (Figure 4.10). This phenomenon seemed to plateau by ~2 minutes. 
This would suggest some relationship of up and down state transitions to the process 
of recording (e.g. excess K+ perfusion in the region of recording leading to local 
network depression or dialysis of the intracellular solution).  
 
 
Figure 4.10 Up state build up following whole-cell access. A recorded trace from 
a cell from the start of break in. A visible increase is seen in the size of the up states 
when comparing the start to the end of the trace. 
 
Interestingly, this same signal build up was not seen in the LFP signal in comparison 
which would add further weight to the idea that there was some wash in effect of the 
recording solution at the start of recordings (Figure 4.11 A). This can be seen clearly 
by looking at the low frequency power of each of the signals in the spectrographs 
(Figure 4.11 B). However, whilst there was not a signal build up in the LFP, the first 
minute of the LFP signal was visually different to the later time points (“noisier” with a 
larger range of frequency activity) and so this would also suggest that the perfusion of 
the intracellular solution in the extracellular space prior to recordings did have some 
effects on the local network. The cross correlation between the LFP recordings and 
the intracellular signal showed a correlation between the two signals (peak value of 
~0.2 for both; Figure 4.11 C & D; Doi et al., 2007). However, across the wash in period, 




intracellular synchrony with the network after the wash in period (lags 0.4 s to lags 
0.03s; Figure 4.11 C & D).  
Overall, it is likely that these changes in up state amplitude are due to intracellular 
dialysis of the intracellular solution, with some subtle changes in the local network from 
intracellular solution perfusion. This seems to have dissipated by the third minute of 
recordings. Therefore, it seemed appropriate to use the third minute following break in 






Figure 4.11 Up state size increases following break in in intracellular recordings 
only. A raw trace of intracellular Vm (top) and LFP (bottom) over the first three minutes 
following break in (A) (baseline normalised to 0 mV). Spectrographs of the intracellular 
Vm (top) and LFP (bottom) signals show an increase in power in low frequency bands 
in the intracellular Vm signal over time, but not in the LFP signal (B). Cross correlation 
between Vm and LFP at 1 minute (C) and 3 minutes (D) shows the peak correlation 





4.4.2 Up and down state properties of layer II/III neurons in the 
somatosensory cortex 
19 neurons, recorded from 9 animals, were analysed for up and down state properties. 
The mice used were at a mean age of 215 days (range 187-232 days), in line with the 
target experimental age for the rTg4510 mice used in studies in other chapters (~5.5 
M). The properties were analysed from the third minute following break in. 11/19 of the 
recordings were made with the use-dependent NMDAR antagonist MK801 (1 mM) in 
the intracellular solution. This has been shown to influence neuronal activity including 
up and down state properties after >5 minutes in vivo (Gambino et al., 2014; Lavzin et 
al., 2012; Smith et al., 2013).  
The mean series resistance from these recordings was 38 ± 3 MΩ (range 11 – 100 
MΩ). This was in line with similar studies, since series resistance is typically much 
larger for whole-cell recordings performed in vivo than in vitro. This is thought to be 
due to brain penetration depth, pipette contamination and physiological movement 
artifacts (Margrie et al., 2002). Recorded neurons had a mean Vm of -58 ± 2 mV, with 
a mean down state Vm -60 ± 2 mV of and a mean up state Vm of -55 ± 2 mV (Figure 
4.12 A – C). The mean downstate Vm was more depolarised than expected from other 
literature values (~-80 mV) (Brecht et al., 2003; Waters and Helmchen, 2006). Δ up 
state:down state was 5 ± 1 mV (Figure 4.12 D) which was also slightly smaller than 
expected from the literature, which can be attributed to a more depolarised down state 
Vm in this work (Chen et al., 2013; Waters and Helmchen, 2006). Mean up state dwell 
time was 0.26 ± 0.02 s (Figure 4.12 E), similar to the literature (Haider et al., 2006; 
Waters and Helmchen, 2006). The principal frequency was 0.74 ± 0.12 Hz (Figure 
4.12 F), which is a measure of the slow wave up and down state oscillation (Haider et 
al., 2006; Steriade et al., 1993c; Waters and Helmchen, 2006). The variance of the 
recordings was 8.3 ± 3.2 µV2 (Figure 4.12 G) which is similar to literature values 
(Haider et al., 2006; Waters and Helmchen, 2006). There was a low firing rate (0.0009 
± 0.0009 Hz; Figure 4.12 H) as expected from literature (Barth and Poulet, 2012; 
Brecht et al., 2003), with only one neuron firing spontaneous APs. The discrepancies 
between some of the values in this chapter compared to the literature may be 
attributable to multiple aspects of the recording procedure, such as differences in age 
of the mice (typically juvenile animals (<1M) compared to ~5.5M in this work) (Margrie 








Figure 4.12 Spontaneous up and down state properties. Box and dot plots showing 
Vm properties (mean Vm (A), mean down state Vm (B), mean up state Vm (C), Δ up 
state:down state (D)), up state dwell time (E), the principal frequency of the up down 
state oscillation (F), the variance of the signal (G) and the firing frequency at rest (H).  
 
4.4.3 Cyclic modulation of up and down state activity 
Cyclic modulation of up and down state power, akin to transitions between slow-wave 
sleep (SWS) and rapid eye movement (REM) sleep states, has been observed under 
urethane anaesthesia (Clement et al., 2008; González-Rueda et al., 2018; Pagliardini 
et al., 2012, 2013). The up and down state oscillation cycles between periods of lower 
(REM-like) and higher amplitude (SWS-like) oscillations, and this can be quantified by 




modulation has been shown to be correlated with other homeostatic process in the 
body such as breathing rate, and cycle lengths are different between mouse strains 
(Clement et al., 2008; Pagliardini et al., 2012, 2013).  
This cyclic modulation can be seen by eye when looking at the raw intracellular and 
LFP recordings over time scales of several minutes, and also at the spectrographs 
when looking at lower frequency power over time (Figure 4.13 A & B). By isolating out 
the 1 Hz frequency band, this cyclic oscillation is visible occurring over a longer time 
scale of several minutes in both the intracellular and LFP recording signals (Figure 
4.13 C). Autocorrelation of the power fluctuations from the 1 Hz z-scored signal shows 
a periodicity to this of approximately 310 seconds (range: 270 – 380 seconds), and 
that this is highly synchronous between the two signals with a cross correlation value 
of 0.7 (range: 0.52-0.81) close to 0 phase lag (range: -10 - -17 ms; Figure 4.13 D & 
E). There were only 3 cells that had recordings of a sufficient length with 
accompanying LFP recordings to measure this phenomenon. All 3 cells showed 
similar cyclic modulation behaviour. 
Whilst the mechanism underlying this modulation is unknown, it is thought to be a 
feature of a network with balanced inhibition and excitation (Renart et al., 2010) and 
could be altered in dementia models where there is dysregulation of neural circuit 
dynamics (Harris et al., 2020). This cyclic phenomenon is also likely to have an impact 
on measured and evoked activity. For example, the amplitude of up states would be 
larger in periods of high 1 Hz power. Therefore, this feature will be quantified and 







Figure 4.13 Intracellular cyclic modulation of up and down states. The top panel 
shows an intracellular recording of the Vm and an LFP recording over a period of 30 
minutes (A). These recordings have been baseline normalised to 0 mV. Spectrographs 
of the two recordings are shown in the middle (B), with the power across low 
frequencies (0 – 10 Hz) shown across time. This shows observable fluctuations in the 
low frequency power (1 Hz). This fluctuation was quantified below (C), where 1 Hz 
power was measured and z-scored to normalise. Intracellular Vm is shown in pink and 
LFP in blue. The detected cyclic periods are denoted with black circles. Auto 
correlation of the 1 Hz power from the LFP (pink) and intracellular Vm (blue) are shown 
at the bottom (D), showing high rhythmicity of each of the signals. Cross correlation 




4.5 RESULTS: EXPERIMENTAL OPTIMISATIONS 
DEVELOPING A PROTOCOL TO MEASURE PUTATIVE 
NMDAR AND AMPAR FUNCTION 
Findings presented in Chapter 2 indicate that glutamatergic receptor function may be 
altered in ~5.5M rTg4510 mice (e.g. reduced NMDA:AMPA receptor ratio). It was 
useful to try and assess this functional alteration in vivo using a behaviourally relevant 
stimulus. One benefit of the somatosensory cortex as a model system for this work is 
that whisker stimulation can be used to reliably evoke glutamatergic synaptic 
responses. Whisker stimulation would also stimulate the same layer IV to layer II/III 
synaptic pathway as the evoked responses generated in slices in Chapter 2. 
Therefore, whisker evoked activity could potentially be compared to the in vitro evoked 
activity. The whisker evoked response is a multicomponent response which can then 
be dissected for likely NMDAR and AMPAR activity based on the latency of the 
components (Armstrong-James et al., 1993; Gambino and Holtmaat, 2012; Gambino 
et al., 2014). This can be further quantified by using receptor antagonists to isolate the 
contribution of a specific receptor to the measured response. To this end, intracellular 
MK801 was used which is a use-dependent NMDA receptor antagonist.  
4.5.1  Evoked responses to whisker stimulation: experimental 
design 
4.5.1.1 How many whiskers to stimulate? 
The first experimental consideration was whether to stimulate a single whisker 
compared to all the whiskers. Whilst stimulating a single whisker would provide a 
unitary evoked response within a barrel, this would add extra levels of technical 
complexity. The barrel field corresponding to the stimulated whisker would either need 
to be identified during surgery or multiple whiskers would need to be stimulated to 
identify the principal whisker corresponding to the recorded barrel field. Therefore, it 
was decided that all whiskers would be stimulated together, producing whisker evoked 
responses in whichever barrel field recordings were made from. 
One thing to note, is that whilst it is technically easier to stimulate all whiskers, multi-
whisker evoked responses can be significantly different from single whisker evoked 




2014). For example, the intracellular response to multi-whisker stimulation or surround 
whisker stimulation compared to principal whisker stimulation has a different overall 
response shape and a more variable onset (Brecht et al., 2003; Gambino and 
Holtmaat, 2012; Jouhanneau et al., 2014; Mirabella et al., 2001; Shimegi et al., 1999). 
However, multi whisker evoked responses also have a multicomponent response and 
so are still a viable means of interrogating AMPAR- and NMDAR-mediated synaptic 
function in vivo. 
4.5.1.2 How to stimulate? 
A second consideration was how to stimulate the whiskers, with airpuff stimulation 
compared to an electrically movable metal wafer (piezo wafer). A piezo wafer converts 
electrical energy into a mechanical stimulation. This allows for precise and consistent 
stimulation as long as the whiskers are placed on the wafer in the same way. Airpuff 
stimulation uses pressurised air to stimulate the whiskers (delivered by a PicoPump 
using Nitrogen at a pressure of 10 mBar). This method can be more variable but is 
comparable to piezo stimulation. Due to the nature of electrical piezo stimulation, this 
also produced an observable electrical artifact in the Vm signal (Figure 4.14). This 
artifact could potentially mask smaller or the quicker AMPAR component of the evoked 
responses and so it was decided to use airpuff stimulation for the experimental design. 
 
 
Figure 4.14 Stimulus artifacts from piezo wafer stimulation. Large and rapid 
change in the recorded electrical potential (stimulus artifacts) were measured when 
stimulating the whiskers using a piezo wafer (A) with stimulus onset denoted with 
arrows. A blue box highlights one stimulus which when examined at a higher time 
resolution, the onset and offset of the electrical trigger can be observed with the onset 





4.5.1.3 How often to stimulate? 
Finally, a single evoked response was compared to repeated evoked responses by 
stimulating a whisker once compared to a repetitive stimulation train. A single 
stimulation should elicit a single evoked response with multiple components. However, 
the success rate of evoking a response can be variable from trial to trial (Kerr et al., 
2007; Ranjbar-Slamloo and Arabzadeh, 2019). In comparison, repeated stimulation 
would more reliably evoke a synaptic response (Barros-Zulaica et al., 2019; 
Kheradpezhouh et al., 2017). Responses may facilitate producing a “response 
envelope” which could also be used to investigate the contribution of NDMAR activity 
to evoked responses. This could also allow for exploration of whether cell responses 
are different in their facilitation or depression to multiple stimuli. But multiple 
stimulations would recruit other surround and concurrent activity from neighbouring 
connected cortical columns which needs to be considered in this analysis. However, 
when applying multiple stimuli, the first response can still also be isolated and 
analysed separately. Therefore, a multiple stimulation protocol was chosen for 
protocols. 
Different frequencies of stimulation were investigated and from the stimulation 
protocols tested (five stimulations at 2.5, 5 and 8 Hz), 5 Hz produced a clear synaptic 
response with slight overlap to allow for NMDAR activation whilst being able to identify 
individual responses (Figure 4.15). Therefore, five stimulations delivered at 5 Hz was 
chosen as the stimulation paradigm for future experimental protocols. 
 
 
Figure 4.15 Different whisker stimulation frequencies. A single trace of responses 





4.5.2 Evoked responses to whisker stimulation using the optimised 
protocol 
It was concluded that the optimal whisker stimulation protocol to evoke a robust 
frequency-modulated train of glutamatergic synaptic responses would be multiple 
whiskers bunched together and stimulated using an air puff (five stimuli at 5 Hz (100 
ms per stimulation)). Using this protocol, the evoked response was measured with or 
without 1 mM MK801 in the intracellular solution to characterise the effect of NMDAR 
antagonism on evoked synaptic responses. The average responses to all five 
stimulations and the first stimulation of the five were compared. For these protocols, 
whiskers were stimulated every 30 seconds, for recordings of a minimum length of 10 
minutes (range: 10 – 30 minutes). 
4.5.2.1 Evoked responses were modulated by up and down state activity and 
MK801 treatment 
Responses evoked by whisker stimulation on up states are reduced in amplitude 
compared to responses on down states (Ferrarese et al., 2018; Gambino and 
Holtmaat, 2012; Petersen et al., 2003; Sachdev et al., 2004). This was also observed 
in the recordings presented within this chapter, as the total evoked response to all five 
stimuli, regardless of MK801 treatment, showed a larger depolarising response when 
stimulated in down states compared to up states ((Up or down state effect: χ2 (1, 20) = 
8.59, p<0.005***; Figure 4.16 A, B, E). There was also a significant effect of MK801 
treatment on the overall response (χ2 (1, 20) = 6.55, p=0.01**), but no interaction 
between the two effects (p=0.24; Figure 4.16 A, B, E). When focusing on the response 
evoked on the first stimulation out of five, the early peak component was not 
statistically different regardless of whether it was evoked on an up or down state 
(p=0.65), with or without MK801 treatment (p=0.6) and there was no interaction 
between these two effects (p=0.68; Figure 4.16 C, D, F). However, the PSP was 
significantly different when evoked on an up state compared to a down state (χ2 (1, 20) 
= 7.7, p=0.006**), but was not statistically different between MK801 treatment groups 
(p=0.35), and there was also no interaction effect (p=0.52; Figure 4.16 C, D, G). From 
this information, evoked responses will be split into those on up vs those on down 






Figure 4.16 Up and down state evoked responses. The mean response to multiple 
whisker stimulations without MK801 (left-hand side; A & C) or with MK801 (right-hand 
side; B & D) in the intracellular solution. The coloured line represents the mean 
response, and the shaded area represents the SEM. The AUC value for these traces 
is shown in plot E. The first response of the train is highlighted in the bottom plots (C 
& D) for –MK801 and +MK801 conditions, respectively. The quantified peak (F) and 
PSP (G) components from these traces are shown below. The time-course of the 
whisker stimulation protocol is shown below each of the traces as a black line. Data 
shown is the average of 4 cells (1 animal) for the control condition and 6 cells (3 






4.5.2.2 Evoked responses were reduced over longer stimulation protocols, 
irrespective of MK801 treatment 
Whiskers were stimulated every 30 seconds for at least 10 minutes. The data 
presented above in Figure 4.16 plotted the total average evoked response, but 
differences could appear when comparing the evoked responses across time in the 
stimulation protocol. Evoked responses may run down over time or there may be 
desensitisation to the stimulation. In addition, MK801 is a use-dependent NMDAR 
antagonist and therefore could require wash in time before becoming effective. 
Therefore, it was important to compare and acknowledge these effects, and at what 
time scale these effects occurred, in the experimental design. Due to its use-
dependent actions, it would be expected that intracellular MK801 would have an 
increasing effect over time. This was measured on down state evoked responses only, 
where the effects of NMDAR antagonists have been highly characterised in 
comparison to up state responses. 
Overall, responses did not significantly differ over time (p=0.09) or with MK801 
treatment (p=0.08; Figure 4.17 A, B, E) in respect to the AUC measurement of the 
response. There was no significant effect of time on the peak (p=0.33) or PSP 
component (p=0.22), with or without MK801 treatment (peak: p=0.59, PSP: p=0.85), 
or interaction (peak: p=0.95, PSP: p=0.99) between the two effects; Figure 4.17 C, D, 
F, G).  
Whilst the response was not significantly run down over time, it is still something that 
should be considered in the future experimental protocol (especially with marginal p 
values). From this pilot study, it was also deemed important to include both control 
and MK801 treated cells separately, as it seemed the drug may already be having an 
effect at the start of the recording. Another way to mitigate response run down is to 
include a second stimulation protocol after a break to measure and compare any 
differences from the start of the first protocol. Therefore, this will be included for the 





Figure 4.17 Evoked responses compared over time. Responses from the first 5 
minutes of stimulation vs last 5 minutes shown in pink and green respectively. Cells 
recorded with MK801 in the intracellular solution are shown on the right-hand side (B 
& D), and cells without are shown on the left-hand side (A & C). The AUC value for 
these traces is shown in plot E. The first response of the train is highlighted in the 
bottom plots (C & D). The quantified peak (F) and PSP (G) components from these 
traces are shown below. The whisker stimulation protocol is shown below the average 
traces as a black line. Data shown is the average of 4 cells (1 animal) for the control 




4.5.2.3 Comparison of evoked responses measured using whole-cell 
recordings and LFP recordings with the application of MK801  
Simultaneous LFP recordings were made to whole-cell recordings during whisker 
stimulation from 3 cells. These recordings were made with MK801 in the intracellular 
electrode, allowing comparisons of the effect of MK801 over time at the single cell 
level and how that compared to the LFP recordings. Evoked responses on down states 
were compared to the evoked responses detected in the LFP.  
The LFP recordings showed detectable evoked responses (Figure 4.18 B, D, F), with 
2 out of 3 of the recordings showing clear on and off responses to the whisker 
stimulation (Figure 4.18 B & F). These two recordings also did not appear to change 
across the ≥10 min stimulation protocol, suggesting no response run down of the 
global signal or spill over effects of MK801. The LFP recording from cell 2 showed 
variable whisker evoked responses during the first five minutes of recording (Figure 
4.18 D). Later in recordings, this response only seems to be driven by the first stimulus 
and not subsequent ones. This change over time may be a genuine feature of the 
evoked response in this animal, or perhaps may be related to technical issues with the 
recording such as decline in mouse health, anaesthesia depth, or electrode placement 
and access.  
When comparing the LFP recordings to the single cell recordings, the intracellular 
signal of cell 1 showed a clear whisker evoked potential which slightly reduced over 
time and the LFP recording also showed whisker evoked responses (Figure 4.18 A & 
B). Cell 2 showed a large evoked response to the first stimulation early in the 
recordings in the intracellular signal, but this is lost later in the recordings with a similar 
pattern seen in the LFP recording (Figure 4.18 C & D). The third cell showed a small 
evoked response to the first stimulus with a variable response afterward, whereas the 
LFP recordings showed a clear evoked response to whisker stimulation that does not 
change over time (Figure 4.18 E & F). Overall, this information suggests that whisker 
evoked responses can be variable both at the single cell and network level and 
emphasises the need to ensure whisker stimulation is consistent and even. From 
these 3 cells, it seems that excess MK801 in the extracellular space typically does not 
have an effect on the LFP. Although with only 2/3 LFP recordings showing no change 






Figure 4.18 Different types of response to whisker stimulation with MK801 
application. Comparison of whole cell evoked responses (A, C, E) and 
simultaneously recorded LFP responses (B, D, F) to whisker stimulation. Responses 
shown are average responses of individual cells or from the LFP from the first 5 
minutes of the whisker stimulation protocol compared to the last 5 minutes. All three 
cells had the addition of the use dependent NMDAR antagonist MK801 to the 





4.6 FINALISED RECORDING PROTOCOL 
From these pilot experiments, an experimental protocol was designed to measure in 
vivo properties of glutamatergic synaptic transmission in the rTg4510 model (Figure 
4.19). A three minute “gap free” recording period at the start was used to allow for 
changes in up and down state properties following initial break-in and dialysis of the 
cell (Section 4.4.1). Following this, whisker stimulation would be delivered (five 
stimulations at 5 Hz) over a period of 15 minutes. Multiple whisker stimulations at a 5 
Hz frequency appeared to produce an optimal response envelope to investigate 
NMDAR-mediated activity in this response (Section 4.5.1.3). Evoked responses would 
be analysed separately when evoked on an up or down state as this appeared to 
significantly alter the evoked response (Section 4.5.2.1). This work also showed a 
need to include a control recording dataset without MK801, even though MK801 is a 
use-dependent drug, as MK801 appeared to alter the evoked shape of responses from 
early on in recordings (Section 4.5.2.2 & 4.5.2.3). Further “gap free” and whisker 
stimulation periods were also included in the protocol to allow for a time course 
comparison to measure changes in spontaneous or evoked responses if needed (e.g. 
due to loss of access to the cell, plasticity induced changes from whisker stimulation, 
run down of the response, MK801 efficacy). Cyclic activity would also be included to 
examine genotype effects on this measure and determine whether this activity has an 
impact on evoked responses. 
 
 
Figure 4.19 Optimised recording protocol. Spontaneous activity (no current 
injection or whisker stimulation, “gap free”) is shown in blue. Whisker stimulation 
periods are shown in red. Current step injections is shown in purple, which could be 
used to measure excitability and AP properties. Series resistance (measured by 





Simultaneous LFP recordings provided valuable information about the spontaneous 
and evoked activity. However, these recordings were time consuming and increased 
the likelihood of damage to the craniotomy, reducing the number of cellular recordings 
that could be performed in a session. Therefore, LFP recordings were not included in 
the experimental design for the rTg4510 model. 
4.7 CONCLUSIONS 
In vivo two-photon targeted whole-cell recordings are a very powerful tool to dissect 
the in vivo whole-cell properties of single cells including subthreshold changes, and it 
can be combined with other techniques such as LFP recordings to provide a larger 
idea of the network state. The experimental protocol designed and optimised in this 
chapter was used in Chapter 5 to examine spontaneous and evoked properties in the 




5 IN VIVO TWO-PHOTON TARGETED WHOLE-CELL 
PATCH CLAMP ELECTROPHYSIOLOGY IN THE 
SOMATOSENSORY CORTEX OF ~5.5 MONTH OLD 
RTG4510 AND WILDTYPE MICE REVEALED ABNORMAL 
WHISKER-EVOKED RESPONSES 
5.1 INTRODUCTION 
It was established in Chapter 2 (in vitro functional synaptic assessment in the rTg4510 
mice) that there was an imbalance in the NMDA:AMPA receptor ratio at ~5.5 months 
(5.5M) of age in the rTg4510 mice. In addition, work from Chapter 3 (synaptosome 
protein expression assay in the rTg4510 mice) found a significant reduction in NMDA 
receptor (NMDAR) and AMPA receptor (AMPAR) expression at ~5.5M of age in the 
rTg4510 mice. It is likely that these identified synaptic deficits could contribute to 
alterations of synaptic processing of neural information in the brain, for example in 
synaptically-driven responses (Lebedeva et al., 2019). To assess if this was the case, 
in vivo whole-cell patch clamp recordings were used to directly assess spontaneous 
synaptic function and synaptic responses to sensory stimulation in the rTg4510 mice 
at ~5.5M of age under urethane anaesthesia. This allowed direct quantification of 
subthreshold properties, alongside measurement of network activity. Whisker 
stimulation evokes a multi-component response that has been suggested to be mostly 
AMPAR- and NMDAR-mediated, providing a tool to investigate glutamatergic receptor 
function (Armstrong-James et al., 1993; Gambino et al., 2014; Lebedeva et al., 2019). 
To isolate the different receptor mediated components of synaptic responses, 
recordings were made with or without the NMDAR antagonist, MK801. All recordings 
were performed under urethane anaesthesia, which induced a synchronous slow wave 
oscillation (up and down states) which also provided a measure of network activity 
akin to that of slow wave sleep. The anaesthetised state helped to isolate evoked 
synaptic activity by reducing the highly variable barrage of other local and global 
activity associated with awake states.  
5.1.1 Whole-cell in vivo alterations in tauopathy 
There is currently only one paper that uses in vivo whole-cell patch clamp recordings 




Specifically, Menkes-Caspi et al., 2015, investigated network oscillation dysfunction 
(specifically up and down state properties) in rTg4510 mice and wildtype littermate 
controls at 3.5 and 5.5M of age in the frontal cortex. In this study, 5.5M rTg4510 mice 
had a lower principal frequency than wildtype littermate controls, equating to fewer up 
states. Spontaneous firing was also reduced in the rTg4510 mice. However, these 
recordings were made under ketamine-xylazine anaesthesia, with ketamine being an 
NMDAR antagonist (Anis et al., 1983; MacDonald et al., 1987). In vivo administration 
of ketamine during up and down state recordings has been shown to reduce up state 
duration significantly (Steriade et al., 1993a).Therefore, it is possible that some of the 
changes observed by Menkes-Caspi et al., 2015, were related to a reduction in 
NMDAR function from the use of ketamine in combination with effects from tau 
overexpression. The work in this chapter should help substantiate the role of tauopathy 
in slow wave oscillation dysfunction. 
5.1.2 The role of NMDAR function in vivo 
NMDAR function is hypothesised to play a role in the generation and maintenance of 
slow wave oscillations and sensory-evoked responses in the somatosensory cortex. 
Therefore, the work presented in this chapter, in which neurons were recorded in the 
presence of an NMDAR antagonist, should detect alterations in oscillatory and evoked 
activity.  
Slow wave oscillations (up and down states) are thought to be generated intrinsically, 
driven by dynamic fluctuations of excitation and inhibition. Antagonists targeting 
excitatory NMDARs, blocked the generation of up states in pyramidal neurons in vitro 
(Cossart et al., 2003; Woodward and Pava, 2009). However, whole-cell recordings in 
vivo with NMDAR antagonists have shown no change in up and down state properties. 
This includes, but is not limited to, up and down state frequency, amplitude, Δ up down 
state or up state dwell time (Chen et al., 2013; Palmer et al., 2014; Smith et al., 2013). 
However, other intrinsic properties were altered including a reduction in action 
potential (AP) frequency (Palmer et al., 2014; Smith et al., 2013). 
In some of these studies, evoked activity was also altered, leading to 
neurophysiological dysfunction in sensory processing (Chen et al., 2013; Palmer et 
al., 2014; Smith et al., 2013). The evoked activity to whisker stimulation in the 




NMDAR antagonists in vivo reducing the slower postsynaptic potential (PSP) 
component of this response (Gambino and Holtmaat, 2012; Gambino et al., 2014). 
From this, it is likely that application of MK801 (a use dependent NMDAR antagonist) 
during recordings alters whisker evoked responses but not up and down state 
properties. The work presented in this chapter clarifies tauopathy-mediated changes 
in the functional properties of single cells in vivo in the rTg4510 mice, specifically with 
and without the presence of NMDAR-mediated activity. 
5.2 AIMS 
Following the putative glutamatergic receptor dysfunction measured in Chapter 2, and 
the reduced glutamatergic receptor expression witnessed in Chapter 3, it was prudent 
to determine whether this dysfunction manifested itself in vivo in the rTg4510 model in 
both passive and stimulated conditions. Therefore, up and down state properties and 
slower cyclic modulation activity was measured in the rTg4510 and wildtype littermate 
mice in layer II/III neurons in the somatosensory cortex as a measure of spontaneous 
activity. These recordings were made in the same region used to measure 
glutamatergic receptor function in Chapter 2 and glutamatergic receptor expression in 
Chapter 3. This allowed for some comparisons to be made between the results of 
these chapters. In addition, the stimulation protocol established in Chapter 4 evoked 
glutamatergic receptor mediated responses and thus was used in this chapter to 
investigate glutamatergic receptor activity. The passive and stimulated properties 
were compared to responses with intracellular MK801 application, an NMDAR 
antagonist, allowing the isolation of NMDAR activity in the passive and stimulated 
activity. Together, this should help characterise glutamatergic receptor activity in 
passive and evoked activity and determine how the altered glutamatergic phenotype 
manifested in the intact network in the rTg4510 mice. 
5.3 METHODS 
5.3.1 Ethical Approval 
Studies were approved by the University of Bristol Animal Welfare and Ethical Review 
Body. All procedures, including Schedule 1 procedures, were performed in 
accordance with the UK Animal (Scientific Procedures) Act 1986 and its subsequent 




animals used for scientific purposes. All studies described are performed on adult 
mice, kept on a 12:12 light/dark cycle and granted ad libitum access to food and water.  
5.3.2 Animals 
5.3.2.1 rTg4510 mice 
The experiments in this chapter used the rTg4510 (TG) mouse model of tauopathy 
with wildtype (WT) littermate controls, with or without the presence of both the 
tetracycline transactivator and the tau P301L transgene, respectively. Male TG mice 
and WT littermate controls of 4-5 months of age were bred at ENVIGO (Oxon, UK) 
and provided by Eli Lilly & Company. Animals were transferred to a vivarium at the 
University of Bristol and were habituated to their new environment for at least two 
weeks prior to experiments. Experiments were performed blind with respect to 
genotype. 
5.3.3 Surgical details 
In total, 15 WT animals (22 - 25 weeks of age, mean 23.5 weeks) and 15 TG animals 
(22 - 25 weeks, mean 23.5 weeks) underwent surgery for acute recordings. The 
surgical methodology is described in brief below. For further information on the 
surgical methods, refer to Chapter 4.  
All surgeries began approximately between 12:00 and 13:30 hours with surgeries 
taking approximately 1:30-2:30 hours in length. Animals were weighed before surgery 
began to ensure correct urethane anaesthetic doses were given. Between genotypes, 
the mice were significantly different in weight (WT mean 34.1 g ± 0.7 g, TG mean 28.8 
g ± 0.2 g; Mann-Whitney U t-test, t 2,29 = -6.43, p<0.005***). This has been seen within 
the literature in the model (Yue et al., 2011), and did not impact the total normalised 
urethane dose given (1.5-2mg/kg). 
At the start of the procedure, animals were anaesthetised using 3-4% gaseous 
isoflurane for induction. The head of the mouse was shaved, and the mouse was 
transferred to the stereotaxic frame (secured within the frame using stereotactic ear 
bars) under 1.5-2% gaseous isoflurane for anaesthetic maintenance. Eye drops, 
betadine and lidocaine was applied to the skin. Anaesthetic depth was checked by 
lack of toe pinch reflex and rhythmic slow breathing, and body temperature was 
monitored using a rectal temperature probe controlled thermostatically via a heat pad. 




marked out for the somatosensory cortex (+1.3 mm anterior-posterior and -3.4 mm 
medial-lateral from Bregma), following which the skull was scored using a needle. The 
skull was covered with a thin layer of superglue and a custom-made linear head bar 
was glued to the posterior of the skull above the cerebellum using superglue. Once 
dried, a dental cement well was formed around the edge of the skull. A craniotomy 
was performed (approximately 1mm in diameter) at the marked reference point for the 
somatosensory cortex. The piece of skull covering the brain was removed under 
submersion with aCSF (composed of (in mM) 135 NaCl, 5 KCl, 5 HEPES (Free Acid), 
1.8 CaCl2 and 1 MgCl2). The dura was then also removed from the area. Urethane 
was administered between 1.5-2mg/kg following surgery with isoflurane anaesthesia 
stopped, following which the animal was transferred to the recording set up. 
5.3.4 Recording set up & equipment 
Full details of the recording set up are specified in Chapter 4, including full 
methodology for targeting neurons for recordings. A brief overview of relevant protocol 
details is summarised below. 
Once the animal was transferred to the recording set up, the whiskers contralateral to 
the craniotomy were clumped together using Vaseline and an open-ended cone was 
placed next to the bulk of the whiskers. This cone was connected via tubing to a 
Pneumatic PicoPump (WPI, PV820), to provide whisker stimulation at ~10 mBar 
pressure using Nitrogen. 
Electrodes were fabricated using a Narishige PC-10 puller to a resistance of 4-10 MΩ 
with a long taper to limit damage when entering the brain. An intracellular solution 
composed of 135 mM K-Gluconate, 5 mM NaCl, 10 mM HEPES free acid, 0.2 mM 
EGTA, 0.3 mM GTP-Na salt, 4 mM ATP-Mg salt, 6.7 mM Biocytin, 25 µM 594 
AlexaFluor Hydrazide, with or without 1mM MK801 (NMDAR antagonist; Hello Bio) 
was used to fill the electrodes for recordings. This solution used was comparable to 
the KGluconate solution used in Chapter 2 and 4, with the addition of the AlexaFluor 
dye and MK801. Solutions with and without MK801 were interleaved between cells so 
that there would be an even number of cells recorded from both conditions. 
Cells were targeted using the shadow patch technique, visualised using two-photon 
microscopy (Kitamura et al., 2008). Layer II/III putative pyramidal neurons were 




(triangular) at the right depth from the brain surface for layer II/III (~80 - 150 µm from 
pia), and were confirmed to be likely pyramidal neurons post recording by imaging the 
structure looking for a large dendritic arbour with the presence of dendritic spines.  
Cells were recorded using whole-cell patch clamp electrophysiology. Signals were 
amplified using a Multiclamp 700A (Molecular Devices) and digitised using a CED 
Power 1401 data acquisition system (CED). Recordings were made and stored on a 
PC using Signal v5.07 software (CED). Recordings were low pass filtered at 10 kHz, 
with an output gain of 10x and sampled at 50 kHz. Liquid junction potentials were not 
compensated for (due to unknown extracellular ion concentrations), and the bridge 
was not balanced in these recordings (due to high and variable series resistance in 
these recordings to prevent extra artifacts). 
5.3.5 Electrophysiology recording protocols 
An overview of the full recording protocol is shown in Figure 4.1. In brief, following 
break in, series resistance was recorded in voltage clamp using a current step 
injection. Following this, recordings were made in current clamp “at rest” to measure 
spontaneous membrane potential properties (“gap free”; no current injection) for the 
first 3 minutes. Whisker stimulation was then delivered at 5 Hz (5 stimuli) every 30 
seconds for 15 minutes with a hyperpolarising current step at the end to measure input 
resistance changes. A quick series resistance measurement was taken in voltage 
clamp following this protocol. After this, another 5 minutes were recorded “gap free” in 
current clamp to allow comparisons of the evoked responses at the start of the 
recordings. Another set of whisker stimulations were delivered (using the same 
parameters as before) for 6 minutes. This was followed by another “gap free” recording 
epoch of 3 minutes in length. Series resistance was then measured again. Finally, 
current steps were injected to examine action potential (AP) properties, followed by a 
final series resistance measurement. After recording, the electrode was withdrawn 
slowly to attempt to form a clean reseal of the recorded neuron. The recorded cells 
were filled simultaneously with the AlexaFluor dye whilst recording the electrical 
properties. Therefore, following recordings, cells were imaged using the two-photon 
microscope (z-stack from pia to depth of filled neuron visibility, 1 s per plane, 1 µm 
steps) using a 40x objective, visualised using an excitation wavelength of 800 nm. The 




dorsal surface of the brain). This also helped to confirm neuronal recording depth (i.e. 
within layer II/III).  
5.3.6 Analysis 
Cells that depolarised above 0 mV for greater than 1 s during a protocol subsection 
(i.e. “gap free”), were excluded from that protocol but kept within previous protocols. 
Series resistance was measured at the start of recordings, recorded in voltage clamp, 
as the change in current deflection amplitude to a voltage step of 1 mV, converted to 
a resistance using Ohm’s law. Any recordings with a series resistance of over 100 MΩ 
was excluded. The series resistance exclusion criteria was much larger than that of in 
vitro recordings in Chapter 2. This was in line with similar in vivo studies, since series 
resistance is typically much greater in vivo, and this is thought to be due to brain 
penetration depth, pipette contamination and physiological movement artifacts 
(Margrie et al., 2002).  
Series resistance itself was not statistically different between genotypes or between 
MK801 conditions following exclusions (27 WT control cells (13 animals), mean 48.6 
MΩ ± 1.8 MΩ; 17 WT MK801 cells (9 animals), mean 49.8 MΩ ± 3.4 MΩ; 19 TG control 
cells (10 animals), mean 51.6 MΩ ± 3.7 MΩ; 17 TG MK801 cells (9 animals), mean 







Figure 5.1 Series resistance from all recorded cells. Measured series resistance 
from the start of cell recordings with series resistance exclusions (1 cell excluded from 
the control TG group with 109 MΩ series resistance).  
 
Recordings were analysed using custom MATLAB scripts, developed in house (see 
below for descriptions).  
5.3.6.1 Up and down states 
Up and down state analysis was performed on the third minute following break in for 
the starting analysis (due to wash in effects – see Chapter 4 for further details). Further 
comparisons were made to the later “gap free” period at 23 minutes to compare 
changes occurring across time. The analysis for up and down state extraction is 
described in brief, with further details presented in Chapter 4. 
First, APs were filtered out of the trace. This was performed by finding points along 
the trace where dV/dt exceeded 10 mV.ms-1, measuring the maximum mV 1 ms after 
this point. If this point was larger than -50 mV, then it was classified as an AP. The AP 
was then filtered out of the trace by finding the AP threshold (defined on phase-plane 
plots where dV/dt surpassed 30 mV.ms-1) and changing the mV of the AP waveform 
past threshold to equal threshold (Figure 5.2 A). AP firing rate properties were 
analysed separately. Traces were then down sampled to 1 kHz. A 10 s scanning 
window was used to scan the trace in 1 s increments to find up and down state 




was done by fitting a bimodal distribution to the histogram of Vm (using fitgmdist in 
MATLAB for two populations). The local minimum between the two distributions was 
found. Two thirds of the peak of each of the states to the local minimum distance was 
used to create a threshold for up and down states (Menkes-Caspi et al., 2015; Stern 
et al., 1997). This created a moving threshold for the trace to account for changes in 
baseline stability or changes in up and down state shape. 
Up states were then counted if the Vm was above the up state threshold for longer 
than 200 ms (González-Rueda et al., 2018; Menkes-Caspi et al., 2015), with the start 
and end of the up state counted as the point where the voltage depolarised and 
hyperpolarised past the down state threshold. 
Out of 77 recordings for “gap free” analysis, 25 recordings were excluded from a 
subset of “gap free” analysis when there was no clear split between the histogram 
distribution of the Vm, which prevented the analysis script from detecting up states. 
(Figure 5.2 C & D). This was determined by visual inspection of recordings during 
analysis, with approximately 50% detection rate as the cut off for exclusions. These 
recordings were not analysed for changes in up state properties (e.g. dwell time, mean 
Vm, Δ up state:down state, etc.) as up states could not be reliably detected. However, 
the recordings were analysed for other measures that did not require state separation 
(mean Vm, spectral analysis, variance and firing frequency). These cell recordings 
were likely to either be from a period of low 1 Hz cyclic power “rapid eye movement 
(REM)-like” or potentially other cell types (Clement et al., 2008; Pagliardini et al., 2013; 






Figure 5.2 Detected up and down states in recordings with different up and down 
state properties. Examples of exclusion categories from up and down state 
recordings. Up and down state thresholds are marked as a red and cyan lines 
respectively. Orange circles denote the start and end of a detected up state. Clear up 
and down state detection is seen with (A) and without AP filtering (B), with an example 
of an AP filtered at AP threshold in the inset of A. Partial presence of clear up and 
down states but low detection rate is shown in C, and an example of a lack of clear up 




The mean of the total Vm (regardless of up or down states) was measured, and the 
separate mean Vm of the up and down states within each threshold band was also 
measured. Δ up state:down state was calculated as the range between the two values 
calculated for mean up and down state Vm. Mean dwell time was taken as the average 
duration for up or down states. Firing frequency was the number of APs detected over 
1 minute, normalised to spikes per second (Hz). Variance was measured as the 
standard deviation (SD) of the whole Vm trace (a proxy for size and frequency of up 
and down state oscillations). Up state charge was quantified as the area under the 
curve (AUC) of all the points during an up state, baseline normalised to the Vm 
immediately preceding the up state, calculated using the trapz function in MATLAB. 
Up state frequency was calculated as the number of quantified up states divided by 
the total recording length in seconds (Hz). The principal frequency was measured as 
the frequency with the highest power on a power spectral density plot, calculated using 
the periodgram function within MATLAB. Peak power was taken as the power at the 
principal frequency. Peak bandwidth power was taken as the average power within 
principal frequency ± 0.5 Hz.  
5.3.6.2 Evoked responses to whisker stimulation 
The first whisker stimulation period (the first 15 minutes) was used for analysis. 
Whiskers were stimulated at a 5 Hz (5 stimulations, 100 ms duration) using air puff 
stimulation. Recordings were included if there was at least 6 minutes worth of 
stimulation before the Vm depolarised above 0 mV. This was to ensure there was a 
possibility of comparisons of the response over time (within 5 minute time bins). 
Recording sweeps where a cell depolarised above 0 mV were excluded, with previous 
recording sweeps (1 sweep every 30 seconds) included for the cell when the Vm was 
below 0 mV.  
The evoked responses were split into those occurring on up and those occurring on 
down states (calculated as an up state response if the range is >3 mV in the 50 ms 
preceding the stimulus, Jouhanneau et al., 2014). Evoked responses on down states 
are significantly different to those on up states, and so were compared separately 
(Gambino and Holtmaat, 2012; Gambino et al., 2014; Jouhanneau et al., 2014; 
Petersen et al., 2003). Stimulus responses were normalised to the Vm in the first 5 ms 




whisker stimulation, Jouhanneau et al., 2014; Moore & Nelson, 1998). Occasionally, 
whisker stimulations evoked APs. In these cases, APs were quantified and then 
filtered out of the evoked responses at the AP threshold using the same method used 
for the “gap free” AP filtering. 
The overall mean response on up and down states was examined over all 5 
stimulations. This response was measured from stimulation onset to 200 ms post the 
end of the last stimulus. The SD of the total response period (which would give a proxy 
of the variation of the response) and AUC (total area under the curve of the points of 
the response period) of the responses were extracted. 
The average evoked response to the first stimulus was also analysed separately, to 
measure specific components of the response whilst reducing the contamination of 
surround inhibition or excitation from other barrel field stimulation (Gambino and 
Holtmaat, 2012). Specifically, it has been suggested that the fast peak and slower PSP 
components of this response are putatively AMPAR-mediated and NMDAR-mediated 
respectively (Gambino et al., 2014). The peak was defined as the peak mV within 0 – 
40 ms of stimulus onset (Figure 5.3). The PSP was defined as the mean mV at 50 – 






Figure 5.3 Peak and PSP quantification on evoked responses. Evoked responses 
from a single cell from 0-5 minutes and 5-10 minutes of recording with intracellular 
MK801 (NMDAR antagonist) application, defined as “pre” and “post” respectively. The 
peak response was calculated as the maximum response between 0 and 40 ms from 
stimulus onset (peaks shown in circles within the left shaded area). The PSP was the 
mean response between 50-100 ms from stimulus onset (within the right shaded area). 
There was a subtle reduction on both the peak and PSP response with MK801 
application. The whisker stimulus waveform is shown below as a thick black line, and 
labelled whisker deflection.  
 
SD, AUC, peak and PSP measures were also compared across all 5 stimuli to examine 
changes in facilitation or depression by the neuron in response to multiple stimulations. 
To calculate these measures, change was compared per stimulus by either 
normalising to the baseline prior to stimulus 1 or by normalising to the baseline prior 
to the stimulus that elicited each evoked response.  
SD and AUC were also compared over time on down states within 5 minute bins. This 
was used to determine whether the recordings changed over time due to plasticity or 
evoked response rundown. 
5.3.6.3 Cyclic modulation of up and down states 
Slow cyclic modulation of up and down states was seen in recordings with changes in 
the amplitude of up and down states observable over time (Clement et al., 2008; 
Pagliardini et al., 2012, 2013; see Chapter 4 for characterisation).  This was identifiable 




modulation was measured using the overall 1 Hz power z-scored over the recorded 
whisker stimulation period to determine cyclic activity length. For these analyses, cells 
were excluded if there was not a quantifiable cycle (either due to lack of large changes 
in 1 Hz power leading to misquantification from the analysis code or due to the 
recording length not being long enough to record a whole cycle).  
This activity was examined during whisker stimulation to establish if the slow 
modulation might influence the size of evoked responses. The z-score 1 Hz power 
was compared to the evoked responses of the cell. All evoked responses of that 
neuron were split into up and down state responses, and all the evoked responses in 
either the up or down state were z-scored to normalise for changes in amplitude of 
response between cells. 
5.3.7 Statistics 
For this work, the effect of genotype on in vivo spontaneous and evoked Vm properties 
was measured with or without NMDAR antagonist application (MK801). Therefore, 
genotype (WT or TG) and MK801 treatment (Control or MK801 treated) were 
considered as fixed factors within statistical modelling. There may also be interactions 
between these two conditions, and so interaction effects were also considered (Figure 
5.4). 
The experimental unit was the “cell”, and sometimes more than one cell was recorded 
from a single animal (nested variable). Recorded cells from one animal may have a 
similar phenotype compared to cells from another animal (pseudoreplication). 
Therefore, generalised linear mixed models (GLMMs) were used to statistically model 
the main effects, including animal number as a random variable to account for this 







Figure 5.4 Overview of statistical effects and variable nesting. A schematic 
showing the two fixed effects included in analytical statistical models (genotype and 
treatment), and how animal number and cell number fit within that structure. 
 
Before modelling the data, the distribution of the data was checked so this could be 
incorporated into the model. For example, data not normally distributed would either 
need a transformation (log transformed) or to be modelled using other data 
distributions (i.e. Poisson or Gamma distributions). Specific examples where the 
distribution would have been modelled as non-gaussian or transformed would include 
spike number (count data bound at 0, Poisson distribution), and power measures 
where the data underwent a log transformation. 
For results with single data points (i.e. where there was one measure from the cell 
such as mean Vm), the GLMM had the following structure: 
𝑉𝑎𝑟𝑖𝑎𝑏𝑙𝑒 ~ 𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 ∗ 𝑀𝐾801 + (1\𝐴𝑛𝑖𝑚𝑎𝑙 𝑁𝑢𝑚𝑏𝑒𝑟) 
Consistent with the formula for statistical methods used in the previous chapters, 
variable was the tested variable, genotype and MK801 application were the two main 
effects. The interaction between the two main effects was also tested, denoted by an 









For results with repeated measures (i.e. multiple responses to a stimulus or paired 
measures within the same cell), the GLMM used had the following structure: 
𝑉𝑎𝑟𝑖𝑎𝑏𝑙𝑒 ~ 𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 ∗ 𝑀𝐾801 ∗ 𝑅𝑒𝑝𝑒𝑎𝑡𝑒𝑑 𝑀𝑒𝑎𝑠𝑢𝑟𝑒
+  (1\𝐴𝑛𝑖𝑚𝑎𝑙 𝑁𝑢𝑚𝑏𝑒𝑟|𝐶𝑒𝑙𝑙 𝑁𝑢𝑚𝑏𝑒𝑟) 
For repeated tests, the repeated measure was included as a main effect with its’ 
interaction with the two other main effects. This investigated the effect the repeated 
measure had on the measured variable (i.e. does stimulation change the response). 
As the repeated measure was applied to a single cell, the cell number needed to be 
included to account for this. As a single cell would come from a single animal (nested 
variable), this was specified as 1\Animal number|Cell number, consistent with R 
syntax. This notation reflects the hierarchy of the variable nesting, i.e. the cell was 
from a single animal. 
The interclass correlation coefficient (ICC) was measured to determine whether animal 
number had a significant effect on the data (values greater than 0.1 were included, 
quantified on a scale of 0 to 1). If not, animal number was dropped from the model. 
Values closer to 0 suggested a low effect of animal number on the measured 
variability, and values closer to 1 suggested a high effect. Similar statistical models 
were then evaluated and compared, with the model with the lowest Akaike information 
criterion (AIC) and best fit from assessment of the residuals for normality and 
heteroscedasticity chosen to model the results. Each main effect included in the 
GLMM was evaluated using goodness of fit chi (χ2) squared tests to determine 
significance. Significant results were summarised as (χ2 (df, n) = a, p=b*). The χ2 test is 
summarised as df (degrees of freedom), n (n number), test value (a), and the 
corresponding p value (b), with statistical significance denoted with asterisks when 
alpha <0.05. Results were sometimes also stated as an estimate of change with 
standard error in brackets to help signify the amount and direction of the effect. Non-
significant factors were listed with a p value only. A Tukey-Kramer multiple comparison 
adjustment was used for post hoc testing whilst controlling for multiple comparisons. 
The data was typically presented as box and dot plots, with a small square denoting 
the mean value, and the box defining ± standard error of the mean (SEM). The line 
across the box represents the median. Otherwise, data was also be presented as line 





5.4.1 Up and down state properties were not significantly different in 
TG mice, with subtle effects of NMDAR antagonism at 3 
minutes post break in 
Up and down state properties give a measure of local network activity in addition to 
intrinsic neuronal properties. Alterations in up and down states would suggest changes 
in network activity or changes in how the neuron could interact with the network, based 
on the intrinsic properties of the neuron. The up and down state properties were 
measured and compared from the third minute of recording following break in. The 
total number of animals and cells analysed for properties for mean Vm, variance, firing 
frequency, principal frequency and power and band power at principal frequency were: 
25 WT control cells (13 animals), 17 WT MK801 treated cells (9 animals), 19 TG 
control cells (10 animals), 16 TG MK801 treated cells (9 animals). For the rest of the 
properties (where up and down states were split into further sub analysis with 
exclusions of cells that were not demonstrating clear up and down states), the total 
cell and animal numbers were: 13 WT control cells (7 animals), 11 WT MK801 treated 
cells (7 animals), 16 TG control cells (9 animals), 12 TG MK801 treated cells (9 
animals). 
The mean Vm of recorded neurons was approximately -50 mV, and was not 
significantly different between genotypes (p=0.74), between treatment groups (p=0.4) 
and there were no significant interactions between the two (p=0.77; ICC=0.11; Figure 
5.5 A). This was also the case when split into up and down states, with no significant 
differences observed for mean down state (genotype p=0.18; MK801 p=0.93; 
interaction p=0.26; ICC=0; Figure 5.5 B) or up state Vm (genotype p=0.11; MK801 
p=0.92; interaction p=0.3; ICC = 0; Figure 5.5 C). The difference between up and down 
state Vm (Δ up state:down state) was ~5 mV, and this was not significantly different 
between genotypes (p=0.43), between treatment groups (p=0.29) and there were no 
significant interactions between the two factors (p=0.26; Figure 5.5 D).  
The variance of the recorded signal provided another measure of the up and down 
state properties. For example, increased frequency of up and down states with larger 
up state amplitude would increase the variability of the signal. Variance of the recorded 




treatment groups (p=0.77) and there was no significant interactions between the two 
(p=0.99; Figure 5.5 E).  
AP firing frequency in layer II/III neurons of somatosensory cortex under anaesthesia 
has been reported as low in the literature, with a suggested range of 0 to 1 Hz 
(Petersen et al., 2003). The frequency of AP firing was also low in these recordings, 
with all conditions having a mean firing rate below 0.25 Hz, with many recorded cells 
not firing APs at all during the recordings. Firing frequency was not significantly 
different between genotypes (p=0.48), between treatment groups (p=0.27) and there 





Figure 5.5 Properties related to Vm were not statistically different between 
genotype or with MK801 treatment. Properties based on Vm measures such as 
mean Vm of the whole trace (A) or the mean down state (B) or mean up state Vm (C) 
and the difference between the up state and down state Vm (Δ up state:down state) 




The amount of time spent in an up or down state may differ independently of changes 
in the frequency of these properties (i.e. a neuron that spends 1.25 s in up and down 
states equally would have a similar up state frequency as a neuron that spends 0.5 s 
in up states with 2 s in down states). However, mean down state dwell time was not 
significantly different between genotypes (p=0.82), between treatment groups 
(p=0.39) and there was no significant interactions between the two (p=0.5, ICC=0.12; 
Figure 5.6 A). Mean up state dwell time was ~1.25 s on average, and was also not 
significantly different between genotypes (p=0.48), between treatment groups 
(p=0.22) and there were no significant interactions between the two (p=0.38, ICC=0.1; 
Figure 5.6 B). 
Mean up state charge (AUC of up states) was not significantly different between 
genotypes (p=0.17; Figure 5.6 C). However, there was a significant reduction of up 
state charge with MK801 treatment (χ2 (1, 52) = 5.6, p=0.02*; ICC=0.12), even at this 
early time point in the recordings (3 minutes following break in). Post hoc statistical 
comparisons showed a significant reduction in up state charge in the WT cells from an 
average of 6244 mV.ms to 2997 mV.ms, which was not seen in the TG cells. There 






Figure 5.6 Dwell time and charge of up and down states. Dwell time of down (A) 
and up states (B), alongside normalised charge of up states (C). Statistical significant: 
GLMMs, main effects stated on the plot, with post hoc significance labelled and 






The principal frequency (calculated as the frequency peak on a power spectral density 
plot) and mean up state frequency (calculated as the number of quantified up states 
normalised to time) were similar, with the mean principal frequency being 
approximately 0.5 Hz compared to 0.4 Hz for up state frequency. This would suggest 
the main oscillation observed in the network was the slow wave up and down state 
oscillation, that oscillates between the up and down states at a frequency of between 
0.4 - 0.5 Hz. Principal frequency was not significantly different between genotypes 
(p=0.92), between treatment groups (p=0.14) and there was no significant interactions 
between the two (p=0.23, ICC=0.18; Figure 5.7 C). Mean up state frequency was also 
not significantly different between genotypes (p=0.78), between treatment groups 
(p=0.31), and there were no significant interactions between the two (p=0.71, 
ICC=0.67; Figure 5.7 D).  
Peak power (the power at the principal frequency) was not significantly different 
between genotypes (p=0.35), between treatment groups (p=0.13) and there was no 
significant interactions between the two (p=0.8, ICC=0.08; Figure 5.7 E). Peak band 
power within a 1 Hz frequency band at the principal frequency was also not 
significantly different between genotypes (p=0.42), between treatment groups 
(p=0.22) and there was no significant interactions between the two (p=0.86, ICC=0.1; 






Figure 5.7 Vm spectral frequency and power properties during up and down 
states. A power spectral density plot of the first minute of “gap free” recording for 0-
100 Hz (A) and 0 – 5 Hz (B) is shown. The line represents the mean, and shading 
represents the SEM. The principal spectral frequency (i.e. the peak of the power 
spectral density plot) (C) and the manual calculated frequency based on number of up 
states divided by length of recording time (D) are shown as box and dot plots. The 
power at the principal frequency (E) and the power within a 1 Hz band at that frequency 





5.4.2 Comparisons of up and down state properties between early 
and late periods during experimental recordings suggests 
increased MK801 efficacy and decreasing recording quality 
Paired comparisons of up and down state properties were made between the 3rd and 
23rd minute of recordings to determine whether measures changed with recording 
length or with MK801 treatment. MK801 is a use dependent NMDAR antagonist, so 
whilst effects were observed from minute 3, it is possible that further alterations could 
be observed across longer recording epochs with further neuronal activity. Other work 
suggests an effect of MK801 treatment after at least 5 minutes (Gambino et al., 2014; 
Lavzin et al., 2012; Smith et al., 2013). 
For this analysis, cells were only included in the analysis if there was a measure for 
the early (3 minutes) and late (23 minutes) time point. The total cells and animals 
compared were: 13 WT control cells (9 animals), 10 WT MK801 treated cells (7 
animals), 11 TG control cells (7 animals), 9 TG MK801 treated cells (7 animals). 
Mean Vm was significantly depolarised later in the recording session (depolarised by 
11.39 mV (4.01), χ2 (1, 83) = 8.1, p <0.005***) and this was not specific to genotype 
(p=0.16) or treatment (p=0.76; Figure 5.8 A). Mean down state Vm was significantly 
depolarised later in the recording session (11.72 (4.74), χ2 (1, 56) = 6.1, p=0.01**) and 
this was not specific to genotype (p=0.27) or treatment (p=0.90; Figure 5.8 B). Mean 
up state Vm was also significantly depolarised later in the recording session (12.279 
(4.13), χ2 (1, 56) = 8.8, p <0.005***) and this was not specific to genotype (p=0.16) or 
treatment (p=0.99; Figure 5.8 C). This suggests that there was a general (~10-20 mV) 
depolarisation of Vm over time during the recording that did not affect the size or shape 
of up and down states. Δ up state:down state was not affected by recording session 
as a main effect (p=0.51). However, there was a significant three-way interaction 
between genotype, treatment and recording session (p=0.05*; Figure 5.8 D). 
Firing frequency was not significantly different with recording time as a main effect 
(p=0.43; Figure 5.8 E). Mean variance was not affected by recording time as a main 
effect (p=0.58). However, there was a significant two-way interaction of MK801 
treatment with recording time (χ2 (1, 83) = 11.4, p<0.005***) and three-way interaction 
between genotype, treatment and recording time (χ2 (1, 83) = 16.8, p<0.005***; Figure 





Figure 5.8 Repeated measures of up and down state properties over time. 
Properties measured from the same cell (paired) early (3 minutes) or late (23 minutes) 
during ”gap free” recordings. Properties based on Vm, either mean Vm of the whole 
trace (A) or the mean down state (B) or mean up state Vm (C) and the difference 
between the up state and down state Vm (Δ up state:down state) (D) is shown. Firing 
frequency (E) and variance of the signal (F) are also shown. Circles represent a data 
point from one cell, and a line joining the same cell together. Statistical significance: 
GLMM, main effects stated on model, asterisks denote significance, p<0.05*, 





Mean up state or down state dwell time was not affected by recording duration (p=0.2 
and p=0.56 respectively). Mean up state charge was not significantly different when 
looking at individual factors (genotype, p=0.47; MK801, p=0.5; recording time, p=0.77; 
Figure 5.9 C). However, there was a significant interaction between genotype and 
recording session (χ2 (1, 56) = 5.4, p=0.02*). Overall, this would suggest that whilst the 
frequency of up and down states did not change, the charge of up states was larger in 
the TGs than the WTs. 
 
 
Figure 5.9 Repeated measures of up and down state dwell time and charge over 
time. Properties measured from the same cell (paired) early (3 minutes) or late (23 
minutes) during “gap free” recording. Dwell time of down (A) and up states (B), 
alongside normalised charge of up states (C) is shown as box and dot plots with joined 
dots. There was a significant increase of up state charge at the late time point between 
genotypes as indicated on the figure. Circles represent a data point from one cell, and 
a line joins the same cell together. Statistical significance: GLMM, main effects stated 
on model, lines indicate post hoc significance with asterisks denoting significance, 




Mean up state frequency was not affected by recording time as a main effect (p=0.11; 
Figure 5.10 A). Principal frequency was not affected by recording time as a main effect 
(p=0.76; Figure 5.10 B). Principal frequency power was not significantly different with 
recording time as a main effect (p=0.7; Figure 5.10 C). Principal frequency band power 
was not significantly different with recording time as a main effect (p=0.41; Figure 5.10 
D). There was a significant two-way interaction with MK801 treatment and recording 
time (χ2 (1, 82) =9.66, p<0.005***) and a significant three-way interaction between 
genotype, treatment and recording time (χ2 (1, 82) =6.1, p=0.01**). Specifically, band 
power was shown to be significantly lowered in the TG MK801 group between early 
and late conditions. 
 
Figure 5.10 Repeated measures over time of frequency and power properties. 
Properties measured from the same cell (paired) early (3 minutes) or late (23 minutes) 
in “gap free”. The manual calculated frequency based on number of up states divided 
by length of recording time (A) and the principal oscillating frequency (i.e. the peak 
frequency of the power spectral density plot) (B) with the power at the principal 
frequency (C) and the power within a 1 Hz band at that frequency (D) are shown. 
Circles represent a data point from one cell, and a line joins the same cell together. 
Statistical significance: GLMM, main effects stated on model, lines indicate post hoc 




5.4.3 The overall evoked response to whisker stimulation was not 
significantly different with genotype or NMDAR antagonism 
Evoked responses were measured by delivering a 5 Hz whisker stimulation (5 stimuli; 
100 ms duration) to drive cellular responses in the somatosensory cortex. The total 
number of cells included in analyses of evoked responses, unless stated otherwise, 
was: WT control 19 cells (12 animals); WT MK801 treated 14 cells (8 animals); TG 
control 15 cells (10 animals); TG MK801 treated 14 cells (9 animals). Whisker 
stimulation generally caused a depolarisation, often clearly associated with each 
separate stimulation but responses also summated with subsequent stimuli. This 
response was also different when evoked on up or down states (see Chapter 4 for 
response characterisation). The response itself was a multi-component response, 
which can be split into fast and slow mediated components, which are thought to be 
AMPAR- and NMDAR- mediated respectively. 
This evoked response for each cell was compared in several ways. Firstly, the overall 
evoked response envelope and shape was compared in response to the 5Hz 
stimulation. To do this, SD and AUC were compared as a measure of changes in the 
shape of the response, with this analysis performed on the average response from 
each cell. This was compared between treatment and genotype, split into responses 
that were evoked on an up or down state. The individual mean responses from each 







Figure 5.11 Individual evoked responses to whisker stimulation in up and down 
states. Line graphs showing the mean response in colour to whisker stimulation 
across all measured conditions evoked on down states (A-D) and up states (E-H). 
Mean evoked responses from individual cells are shown in grey. The stimulus 
waveform is shown beneath each trace in black, with upward square pulses denoting 





Figure 5.12 The total mean response to whisker stimulation evoked on an up or 
down states. Evoked neuronal responses to whisker stimulation during a down state 
(A & B) and in an up state (C & D) in WT (A & C) and TG (B & D) mice as line plots. 
Lines are the mean response across all cells within that condition, the shaded area 
represents SEM. The stimulus waveform is shown beneath each trace in black, with 






The overall response evoked on down states by 5 Hz whisker stimulation produced an 
envelope of depolarisation by the cell, as shown by an AUC greater than 0 (Figure 
5.12 A & B, Figure 5.13 A). The AUC was not statistically different between genotypes 
(p=0.85, ICC=0.32; Figure 5.13 A). NMDAR inhibition by application of MK801 also 
did not have a significant effect on this evoked response (p=0.29), and there was no 
interaction between MK801 treatment and genotype (p=0.37). In a similar manner, the 
SD of the total response was a proxy of the shape of this response, examining whether 
repeated stimulation led to a more variable evoked response. However, the SD was 
not significantly different between genotypes (p=0.39) or with MK801 treatment 
(p=0.31, ICC=0.13; Figure 5.13 B). 
The average responses evoked on up states were more hyperpolarised when 
compared to those on down states (Figure 5.12 C & D). This is reflected by the AUC, 
which shows the majority of evoked responses had AUC values of less than 0. The 
AUC of the total response on up states was not significantly different between 
genotypes (p=0.98) or with MK801 treatment (p=0.24) (Figure 5.13 C). There was also 
no significant interaction between the two factors (p=0.35). The SD of the response 
was similar to down states evoked responses ~ around 1.5 µV2. For the up state 
average responses, the SD was not significantly different between genotypes (p=0.17) 
or with MK801 treatment (p=0.1; Figure 5.13 D). There was also no significant 







Figure 5.13 SD and AUC of the average response to whisker stimulation when 
evoked on down or up states. The AUC (the sum of the trace) is shown for 
responses evoked on down (A) and up (C) states as box and dot plots. The SD 






5.4.4 The peak amplitude of the average evoked response to the first 
stimulus of the stimulus train was increased in TG mice 
The first evoked response of the stimulus train was also analysed separately as this 
response should not be affected by concurrent inhibition/excitation from surrounding 
barrel fields, along with summation of on and off responses of the cell (Brumberg et 
al., 1996; Shimegi et al., 1999; Simons, 1983). The peak and PSP components were 
measured as a proxy for measures of likely AMPAR- and NMDAR- mediated activity 
(Gambino et al., 2014). 
The peak evoked response amplitude on down states was significantly higher in the 
TG mice compared to WTs (Genotype effect 0.99(0.33), χ2 (1, 62) = 10.7, p<0.005***; 
ICC=0.11; Figure 5.14 E). Surprisingly, MK801 treatment also had a significant effect 
on peak response amplitude, reducing response amplitude (MK801 effect -0.79(0.25), 
χ2 (1, 62) = 10.4, p<0.005***). There was no significant interaction between the two 
factors (p=0.91). Down state PSP responses were not significantly different between 
genotypes (Figure 5.14 G). As expected, MK801 treatment significantly lowered PSP 
responses (MK801 effect -1.29(0.66), χ2 (1, 62) = 3.8, p=0.05*). There was not a 
significant interaction between the two factors (p=0.82). 
The responses of the neuron showed similar changes in up states to those in down 
states. The peak response amplitude on up states was significantly higher in the TG 
mice compared to WTs (Genotype effect 0.96(0.42), χ2 (1, 53) = 5.2, p=0.02*, ICC=0.23; 
Figure 5.14 F). MK801 treatment also had a significant effect on peak response 
amplitude, reducing response amplitude (MK801 effect -0.94(0.44), χ2 (1, 53) = 4.7, 
p=0.03*). There was no significant interaction between the two factors (p=0.25). The 
PSP response on up states was not significantly different between genotypes (p=0.53) 
or with MK801 treatment (p=0.08; Figure 5.14 H). There was also no significant 






Figure 5.14 Increased peak amplitude on the first stimulus response evoked on 
up or down states in rTg4510 mice, which was decreased with MK801 
application. Mean traces (line) of the first evoked response evoked on up or down 
states in WT (A & C) and TG mice (B & D) with control conditions and MK801 treated 
recordings overlaid. The shaded area denotes SEM. Box and dot plots of the peak 
amplitude (E & F) and mean PSP (G & H) on down (E & G) and up states (F & H) are 
shown below. Post hoc significance is denoted with asterisks (p<0.01 **) with 
significant effects and interactions listed on the figure calculated from a GLMM with 





5.4.5 The responses evoked on down states to all five stimuli 
revealed altered peak and PSP responses with MK801 
treatment, with an increased peak response in TG cells  
Peak, PSP and AUC of the evoked response to the stimulus train was also analysed 
per each stimulus (counted as 200 ms per stimulus from stimulus onset, the whisker 
stimulation was 100 ms long with a 100 ms interstimulus interval). These measures 
were considered as changes across the overall response per stimulus (normalised to 
the baseline prior to stimulus 1), and also normalised to the baseline just prior to the 
individual stimulus to get measures of change as a result of that stimulation 
specifically.  
When responses were normalised to the baseline for stimulus 1, there was no 
significant effect of genotype (p=0.83) or MK801 treatment (p=0.55) on the AUC when 
evoked from down states (Figure 5.15 A i & ii). The same was true for the response 
AUC when normalised to the baseline per stimulus (genotype p=0.44; MK801 p=0.17; 
Figure 5.15 A iii & vi). Stimulation on down states evoked significantly larger AUC 
responses compared to stimulus 1 when normalised to the baseline at the start of the 
stimulation 1 (Stimulation effect χ2 (4, 310) = 66.1, p<0.005***; Stimulus 2-5 p<0.005***; 
ICC = 0.74). When baseline normalised per stimulus, stimulation also had a significant 
effect on evoked AUC responses (χ2 (4, 310) = 26.8, p<0.005***), with stimulation on 
down states evoking significantly smaller AUC responses to stimulus 4 and 5 than to 
stimulus 1 – 3 (Stimulus 4 -9147(3723), p=0.02*; Stimulus 5 -12665(3723), p<0.005***, 
ICC = 0.1). This would suggest that response size decreases with repeated stimulation 
at 5 Hz stimulation frequencies. Taken together with the normalised data, this 
suggests that the first two responses significantly increase in normalised size and then 
the response plateaus. 
For peak amplitude, there was no significant effect of genotype (p=0.08) or MK801 
treatment (p=0.07) on peak amplitude response when normalised to stimulation 1 
baseline (Figure 5.15 B i & ii). There was also no significant effect of overall stimulation 
(p=0.31). However, the peak amplitude response to stimulation 2 was significantly 
larger than stimulus 1 (1.06(0.55), p=0.05*). There was also a significant two-way 
interaction between stimulation number and genotype (χ2 (4, 310) = 11.9, p=0.02; 




stimulation 5, p<0.005***). There was a significant effect of genotype (χ2 (1, 310) = 9.2, 
p<0.005***) and MK801 treatment (χ2 (1, 310) = 6.8, p=0.009**) on the peak amplitude 
of evoked responses when normalised to the start of each stimulation (Figure 5.15 A 
iii & iv). Stimulus also had a significant effect on peak amplitude (χ2 (4, 310) = 67.7, 
p<0.005***), with peak amplitude being significantly lower on subsequent stimulations 
following stimulation 1 (Stimulus 2 0.41(0.09), p<0.005***; Stimulus 3 1.5(0.6), 
p=0.01**; Stimulus 4 1.2(0.41), p<0.005***; Stimulus 5 1.2(0.39), p<0.005***). There 
was also a two-way interaction between genotype and stimulus (χ2 (4, 310) = 11.9, 
p=0.02*). Overall, the peak amplitude of the response appears was larger in the TG 
cells, and lower with MK801 treatment. Peak amplitude also reduces over subsequent 
stimulations, suggesting the peak response depresses to stimulation at 5 Hz 
frequencies. 
For PSP responses normalised to the start of stimulation 1, there was no significant 
effect of genotype (p=0.8) or MK801 treatment (p=0.15) (Figure 5.15 C i & ii). There 
was a significant effect of stimulation on PSP response (χ2 (4, 310) = 29.4, p<0.005***), 
with stimulations 2-4 evoking significantly larger PSP responses compared to 
stimulation 1 (stimulation 2, p<0.005***; stimulation 3, p<0.005***, stimulation 4, 
p=0.02*). PSP responses normalised per stimulation to the stimulation baseline, show 
no significant effects of genotype (p=0.6), but a significant effect of MK801 treatment 
(χ2 (1, 310) = 5.1, p=0.02*) (Figure 5.15 C iii & vi). There was a significant effect of 
stimulation number on PSP responses (χ2 (4, 310) = 35.4, p<0.005***), with a significant 
reduction in PSP stimulation 3 – 5 compared to stimulation 1 and 2 (stimulation 3 -
1.6(0.6), p<0.005***; stimulation 4 -2.3(0.6), p<0.005***; stimulation 5 -2.5(0.6), 
p<0.005***). Altogether, the evoked PSPs were larger compared to the first response 
which then plateaus. This response was not different between genotypes, but there 






Figure 5.15 Measures from responses evoked on down states to all five stimuli. 
The mean average AUC (A), peak amplitude (B) and PSP (C) responses represented 
as a line with shaded SEM. Responses were either baseline normalised to stimulus 1 
(i - ii) or per stimulus (iii – vi) for down state evoked responses. Statistical significance: 
GLMM, main effects stated in text, post hoc significance was denoted with asterisks, 






5.4.6 The responses evoked on up states to all five stimuli revealed 
altered peak and PSP responses with MK801 treatment, with an 
increased peak response in TG cells similar to responses 
evoked in down states  
There was no significant effect of genotype (p=0.99) or MK801 (p=0.45) on up state 
AUC responses normalised to the start of stimulation 1 (Figure 5.16 A i & ii). 
Stimulation also significantly increased the up AUC response (χ2 (4, 265) = 11.8, 
p=0.02*). There was no significant effect of genotype (p=0.98) or MK801 treatment 
(p=0.16) on evoked AUC responses on up states normalised per stimulation (Figure 
5.16 A iii & vi). Stimulations significantly increased the evoked AUC response (χ2 (4, 265) 
= 14.8, p<0.005***). Overall, the evoked AUC on up states was not affected by 
genotype or MK801 treatment. The response pattern suggests facilitation on 
stimulation 2, with a return to starting levels afterwards. 
There was no significant effect of genotype (p=0.16) or MK801 treatment (p=0.24) on 
up state stimulation peak amplitude normalised to the baseline at the start of stimulus 
1 (Figure 5.16 B i & ii). There was a significant effect of stimulation on the evoked 
responses (χ2 (4, 265) = 11.2, p=0.02*), with stimulus 3-5 being significantly lower than 
stimulus 1 (stimulus 3, p=0.01**; stimulus 4, p =0.02*; stimulus 5, p=0.006**). There 
was also a significant two-way interaction between genotype and stimulus number 
(χ2 (4, 265) = 9.6, p=0.05*;). There was also a significant three-way interaction between 
genotype, MK801 treatment and stimulus number (χ2 (4, 265) = 9.6, p=0.05*). There was 
a significant effect of genotype (χ2 (1, 265) = 11.7, p<0.005***) and MK801 (χ2 (1, 265) = 
8.5, p<0.005***) on the peak amplitude across all five stimulations evoked on up states 
when normalised to the baseline of the specific stimulus (Figure 5.16 B iii & vi). From 
this, this suggests TG responses were significantly higher compared to WT responses 
and the amplitude was reduced with MK801 treatment.  There was a significant effect 
of stimulations changing the evoked response (χ2 (4, 265) = 32.6, p<0.005***) with a 
significant reduction in amplitude of the response from stimulus 3 – 5 compared to 
stimulus 1 (stimulus 3, p<0.005***; stimulus 4, p<0.005***; stimulus 5, p<0.005***). 
There were also significant two-way interactions between genotype and stimulus 
number (χ2 (4, 265) = 15.8, p<0.005***), and MK801 treatment and stimulus numbers 




responses is altered with genotype and MK801 treatment, and this response also 
changes over stimulations. 
There was no significant effect of genotype (p=0.54) or MK801 treatment (p=0.08) on 
evoked up state PSP responses normalised to the baseline prior the first stimulus 
(Figure 5.16 C i & ii). There was a significant effect of stimulations on the evoked PSP 
response (χ2 (4, 265) = 25.2, p<0.005***). There was no significant effect of genotype on 
PSP responses evoked on up states, normalised to the start of each stimulation 
(Figure 5.16 C iii & vi). However, there was a significant effect of MK801 treatment 
(χ2 (1, 265)  = 5.4, p=0.02*) and a significant effect of stimulations on the evoked PSP 
responses (χ2 (4, 265) = 18.2, p<0.005***). Overall, stimulation changes the PSP 
response, and MK801 appears to have a subtle effect on reducing PSP response size 
on up states. 
 
Figure 5.16 Measures from responses evoked on up states to all five stimuli. The 
mean average AUC (A), peak amplitude (B) and PSP (C) responses with shaded 
SEM. Responses were either baseline normalised to stimulus 1 (i - ii) or per stimulus 
(iii – vi) for up state evoked responses. Statistical significance: GLMM, main effects 
stated within the main text, symbols denoted post hoc significance: p<0.05 * between 





5.4.7 The AUC of average evoked responses to whisker stimulation 
over time lowers with MK801 treatment after 10-15 minutes 
The analyses described above were performed on the mean response across the 
whole stimulation period. As there was a possibility that changes may occur over time 
when stimulating, either due to MK801 use dependent antagonism or by plasticity 
induced changes, the responses were also compared over time. This specific analysis 
compared SD and AUC of the overall response on down states across the 15 minute 
stimulation period in 5 minute bins (Figure 5.17).   
There was no significant effect of genotype (p=0.5), MK801 (p=0.43) or time (p=0.37) 
on the AUC of the response (Figure 5.18). However, there was a significant interaction 
between MK801 and time group (χ2 (2, 138) = 6, p=0.05*). Specifically, the evoked 
response at 10-15 minutes was significantly lower in the MK801 treatment group point 
(-10246(54108), p=0.04*) compared to control conditions. There was no significant 
effect of genotype (p=0.18), MK801 (p=0.72) or time (p=0.19) on the SD of the signal 






Figure 5.17 Stimulus response over time evoked on down states. Mean traces of 
the evoked response in down states within 5 minute bins. Data shown from WT (A, C 
& E) and TG (B, D & F), with or without MK801 treatment at 0-5 minutes (A & B), 5-
10 minutes (C & D) and 10-15 minutes (E & F). The mean trace is shown as a thick 
line and the SEM is the shaded area. The timecourse of the 5 Hz airpuff whisker 
stimulus is plotted (in black) beneath each set of traces, with upward square pulses 







Figure 5.18 The AUC of the average stimulus responses over time evoked on 
down states. Box and connected dot plots of AUC of the responses in 5 minute bins 
for WT (A & C), TG (B & D) with MK801 (C & D) and without MK801 (A & B). Lines 
connect the same cell. The mean result is also shown as a thick black line. Significant 
effects are stated on the figure, with post hoc significance indicated at the 10-15 minute 






Figure 5.19 The SD of the average stimulus responses over time evoked on 
down states. Box and connected dot plots of SD of the responses in 5 minute bins 
for WT (A & C), TG (B & D) with MK801 (C & D) and without MK801 (A & B). Lines 






5.4.8 Cyclic modulation on up and down states was not statistically 
different between genotypes, but did alter the evoked response 
size on up states  
The cyclic amplitude modulation of up and down states, discussed in Chapter 4, was 
quantified by measuring 1 Hz power changes over time (Figure 5.20 A). This cyclic 
modulation was quantified as periodicity, counted as the mean cycle length. This was 
measured in: 11 WT animals (15 control cells), 7 WT animals (11 cells treated with 
MK801), 9 TG animals (13 control cells), 8 TG animals (10 cells treated with MK801). 
Periodicity was not significantly different between genotypes (p = 0.67), or with MK801 
treatment (p=0.96), and there was no significant interaction between the two factors 
(p=0.55, ICC=0.14; Figure 5.20 B).  
 
 
Figure 5.20 Cyclic modulation of up and down states in WT and TG cells. Cyclic 
modulation of up and down states can be seen in the intracellular Vm, and can be 
quantified as the 1 Hz power of the oscillation, z-score normalised (A). This periodicity 
can then be quantified, highlighted as orange circles per cycle (A). Mean cycle length 
in seconds (periodicity) is shown as box and dot plots for all groups (B). 
 
Evoked response size (peak amplitude) was also compared to the cyclic phase 
modulation. As up and down states themselves can alter evoked response size, 
cyclic phase could also alter response size. There was no linear relationship 
between evoked response and the cyclic phase in either WT or TG cells, with or 




there was a weak negative relationship when cells were stimulated during up states 
(WT Control, Pearson’s rank -0.3, p<0.005 ***; WT MK801, Pearson’s rank -0.4, 
p=0.01**; Figure 5.21 E & G; Table 5.1). This suggests that during points of larger up 
states (higher 1 Hz power z-score), there was a smaller evoked response. In TG 
cells, a relationship between cyclic phase and evoked responses on up states was 
only seen in the control group. In contrast to the WT cells, this revealed a weak 
positive relationship (Pearson’s rank = 0.17, p = 0.02*; Figure 5.21 F; Table 5.1). No 
linear relationship was observable in the TG MK801 group to responses evoked on 
up states (Figure 5.21 H; Table 5.1). 
 
Table 5.1 Summary statistics of correlations between cyclic activity and 
response size amplitude evoked from up or down states. A table showing the 
summary statistics (F value, Pearson’s r and p values) for each of the groups, split into 
up and down state responses. 
Group Down state Up state 
WT Control F1,562 1.14, r = 0.045, p = 0.29 F1,75 9.19, r = -0.33, p <0.005 *** 
WT MK801 F1,413 0.49, r = 0.035, p = 0.48 F1,43 6.83, r = -0.37, p = 0.01 ** 
TG Control F1,331 0.18, r = 0.024, p = 0.67 F1,175 5.17, r = 0.17, p = 0.02 * 






Figure 5.21 Correlations between cyclic phase and evoked responses to whisker 
stimulation. Cyclic activity phase (based on 1 Hz power normalised by z-score per 
cell) and how that affects evoked response amplitude (z-score normalised per cell). 
Scatter plots with lines of best fit for WT (A, C, E, G) and TG (B, D, F, H) cells with (C, 





In vivo whole-cell recordings were made from layer II/III somatosensory pyramidal 
neurons in ~5.5M rTg4510 mice and wildtype littermate controls, to reveal significant 
effects of genotype on evoked activity with some subtle effects of genotype on 
spontaneous activity. Specifically, the early fast component of whisker deflection 
evoked responses (peak) was significantly higher in rTg4510 mice than in wildtype 
littermate counterparts. The application of MK801 had effects on several components 
of whisker evoked activity (reduction in peak and PSP of evoked responses) and on 
spontaneous properties (reductions in up state charge). 
5.5.1 Dysfunction of spontaneous and evoked activity in the rTg4510 
model 
5.5.2 Subtle spontaneous dysfunction in the rTg4510 model 
There were observed alterations in spontaneous activity, with significant increases in 
up state charge and power later in the recording time, but not earlier (Figure 5.9 & 
Figure 5.10). Measures of charge and power are almost synonymous, as larger charge 
would equate to an increase in up state power, and so it is unsurprising that both are 
increased. This result however was surprising, as it would perhaps be expected that 
charge and power would reduce over recording time if the quality of recordings 
decreased (potentially related to changes in series resistance and cell health as seen 
by depolarising recordings over time, Figure 5.8). This effect could potentially be 
related to a persistent effect of intracellular solution perfusion into the extracellular 
space at 3 minutes following break-in but not at 23 minutes which suppresses the 
network at this earlier time point. Acute injection of soluble tau has been shown to 
reduce the power of different oscillatory bands in vivo (Ahnaou et al., 2017), which is 
in contrast with the results in this chapter. However, the rTg4510 model is a model of 
chronic tauopathy and so the effect of acute vs chronic incubation of tau is likely to be 
different. Overall, the up state frequency and duration was similar between genotypes 
(Figure 5.6 & Figure 5.7). Up state initiation within layer II/III is driven from deeper 
cortical layers with additional thalamic modulation (Beltramo et al., 2013; Neske, 
2016). Deeper cortical layers have less pathological tau burden, with the thalamus 




may be less likely to be disrupted leading to a lack of dysfunction in the frequency of 
these oscillations. 
Interestingly, significant reductions in spontaneous activity in the somatosensory 
cortex in rTg4510 mice at 4-5.5M has been reported, visualised by recording AP-
mediated Ca2+ transients (Busche et al., 2019; Jackson et al., 2017). However, the 
work in this chapter and in Chapter 2 would suggest that basal synaptic activity in the 
model is relatively unimpaired. Whole-cell recordings provide a direct measure of the 
electrophysiological properties of the cell, whereas Ca2+ imaging relies on changes in 
Ca2+ to provide a proxy of neuronal activity. GCaMP Ca2+ transients are driven by AP 
activity, and typically this is bursts of AP activity rather than a single AP. Within layer 
II/III, all cells show subthreshold activity, but very few fire spontaneous APs, 
particularly under anaesthesia (Petersen et al., 2003). The activity measured by Ca2+ 
imaging best reflects highly coordinated excitatory synaptic input plus inhibitory 
modulation eliciting an AP which occurs in a relatively low number of cells. Therefore, 
these studies were measuring different types of activity in comparison to the work in 
this study. Another possible explanation for the discrepancies between the different 
studies could be related to the number of cells sampled with the two methodologies. 
Two-photon imaging typically allows the experimenter to visualise hundreds of cells at 
a time, whereas the work in this chapter only measured a couple of neurons per 
animal, perhaps missing regional effects. However, this is unlikely to be the case as 
the reduction in spontaneous Ca2+ activity was significantly large in the imaging 
studies, and it would be unlikely that this study recorded from the only neurons that 
were unaffected.  
Menkes-Caspi et al., 2015, also performed in vivo whole-cell recordings in the rTg4510 
model at 5.5M in the frontal cortex. This study found reductions in the principal 
frequency (i.e. a reduction in the number of up states) and reductions in spontaneous 
firing in rTg4510 mice. These changes were not seen in the present study, but this 
could be due to a number of reasons including differences in anaesthetic (ketamine-
xylazine used in Menkes-Caspi vs urethane in this work) to differences in regional 




5.5.3 Increased peak evoked responses to whisker stimulation in the 
rTg4510 model 
In response to whisker stimulations, the peak amplitude of evoked responses was 
significantly higher in rTg4510 mice compared to wildtypes (Figure 5.14). This was 
reduced with MK801, suggesting it is modulated in part by NMDAR activity. 
Interestingly, the whisker evoked response was otherwise similar between genotypes 
(Figure 5.13 & Figure 5.14). Together this would suggest abnormal increased NMDAR 
activity at the start of the response in the rTg4510 model, but normal PSP activity 
thereafter. Evoked Ca2+ activity in response to whisker stimulation in the rTg4510 
model at 5.5M was significantly reduced in another study, with a low number of 
neurons responding to stimulation regardless of genotype (Jackson et al., 2017). A 
strength of using whole-cell recordings is that it allows one to measure subthreshold 
changes, whereas Ca2+ imaging requires action potentials to mediate somatic Ca2+ 
transients. With evoked peak responses being larger in the rTg4510 mice within this 
study, it is surprising that evoked Ca2+ transients were not increased in Jackson et al., 
2017. However, the evoked responses in this work were still easily subthreshold 
responses in most cases. This could suggest alterations in ion channels that regulate 
Ca2+ activity in the model, such as voltage gated Ca2+ channels which may lead to 
reduced Ca2+-mediated activity or intrinsic changes that may impair the conversion of 
synaptic input to APs (i.e. hypoexcitable). However, work in Chapter 2 hinted at a 
subtle hyperexcitable phenotype in these cells so it is more likely to be the former.  
The evoked response pattern itself appears to faithfully represent the multiple 
delivered stimuli (Figure 5.15 & Figure 5.16). Evoked activity to 5 Hz whisker 
stimulation in the somatosensory cortex in the literature shows a similar facilitation 
over the first two responses followed by a depression of further responses 
(Kheradpezhouh et al., 2017). Whilst the AUC and PSP were similar between 
genotypes, the peak amplitude was increased, potentially leading to atypical transfer 
of information (Figure 5.15 & Figure 5.16). With an increased peak amplitude of 
responses, this may lead to an increased likelihood of evoking an AP and thus 
increase downstream synaptic release, altering encoding of the signal.  
Changes in inhibition within the local (i.e. principal whisker) and surround barrels may 




Local inhibition governs some of the whisker evoked dynamics with IPSPs measured 
10-20ms following stimulus onset (Moore and Nelson, 1998) and inhibition also 
modulates the amplitude of responses on up vs down states (Sachdev et al., 2004). 
In addition, stimulation of multiple whiskers leads to altered responses of the cell 
compared to stimulation of a single whisker that is specific to the barrel where the cell 
was recorded from (Brumberg et al., 1996; Gambino and Holtmaat, 2012; Shimegi et 
al., 1999; Simons, 1983). For example, suppression of lateral inhibition from 
surrounding whiskers facilitated the induction of plasticity and increased the evoked 
response in neighbouring barrels (Gambino and Holtmaat, 2012). Therefore, 
alterations in local and surround inhibition could lead to changes in evoked responses, 
including the facilitation of plasticity induced changes, and is another possible 
mechanism of dysfunction in rTg4510 mice at 5.5M.  
In response to whisker stimulation, responses evoked on down states produced a 
large envelope of depolarisation, whereas responses evoked on up states elicited a 
response of reduced amplitude which eventually led to a hyperpolarising response of 
the cell (Figure 5.14). The balance of excitatory and inhibitory conductance plus 
changes in the reversal potential of the evoked response in the two states has been 
suggested to dictate the size and shape of evoked PSP responses, with increased 
inhibitory conductance and activity during up states (Sachdev et al., 2004). Slow cyclic 
modulation of up and down states did not seem to alter response dynamics on down 
states. However, for responses evoked on up states there appeared to be altered 
response dynamics between genotypes. Whereas larger up states produced smaller 
evoked responses in wildtype mice, the inverse was true in the rTg4510 mice i.e. 
bigger up states, bigger amplitude responses (Figure 5.21). MK801 did not modulate 
response size between these phases and so it is unlikely to be related to NMDAR 
signalling. However, these were very weak correlations and so caution should be 
taken with these interpretations. If this were the case, one could hypothesise that 
increased responses in up states would lead the cell closer to AP threshold and could 
be related to changes in inhibitory conductance. Controlling the amplitude of these 
responses would likely be important for regulating synaptic processing. For example, 
induction of LTP in vivo is different during up and down states (González-Rueda et al., 




In the rTg4510 model, neurons containing neurofibrillary tangles have been shown to 
integrate into functional networks with few functional impairments (Kuchibhotla et al., 
2014). Whilst the peak responses was altered, other measures were similar and so 
the same could be said for the results in this chapter from the somatosensory circuit. 
Overall, the envelope (AUC) of the neuronal response was similar to wildtype 
responses, suggesting that whisker-based somatosensation could conceivably be 
unimpaired in the rTg4510 model at the 5.5M age point (Figure 5.13). Perhaps certain 
neuronal subtypes or circuits are preserved, albeit with more variable or 
hyperexcitable responses, whilst others are preferentially vulnerable to disruption by 
tauopathy. This has been seen in other work where head direction cell function was 
preserved, whereas grid cell functionality within the same region were impaired (Ridler 
et al., 2019). It would be interesting to see if behaviours dependent on whisker-based 
somatosensation were also altered (which could be attributed to the increased peak 
evoked response) or not (perhaps due to no change in AUC of evoked responses) in 
the rTg4510 model. 
5.5.4 The effects of MK801 on spontaneous and evoked activity 
MK801 is a use-dependent NMDAR antagonist, with application protocols having a 
long wash in time or using stimulation protocols to lead to blockade of the channel 
(Halliwell et al., 1989; Huettner and Bean, 1988; Wong et al., 1986). Application of 
MK801 via the intracellular solution in whole-cell recordings in vivo has been shown 
to have a wash in time of >5 minutes without the use of NMDAR stimulating protocols 
(Gambino et al., 2014; Lavzin et al., 2012; Smith et al., 2013). Strikingly, MK801 effects 
were seen early in the recordings within this chapter, with a significant reduction in up-
state charge seen from 3 minutes (Figure 5.6). However, performing targeted patch 
clamp recordings using the ‘shadow patching’ method results in large amounts of 
intracellular solution being applied to the surface of the cell to enable visualisation. 
NMDARs expressed by the recorded call may be blocked even before break-in, and 
other cells in the local area may also have a partial NMDAR block. Therefore, some 
of the observed effects could be attributed to widespread NMDAR antagonism in the 
local area. Consequently, there is a possibility that MK801-mediated effects in this 





When compared to spontaneous activity recorded from later time points, changes in 
variance and power of up and down states were seen with MK801 treatment (Figure 
5.8 & Figure 5.10). These properties are inherently linked, as changes in the variability 
of the signal would lead to changes in oscillatory power. Studies have reported that 
there are no differences with in vivo MK801 application on up and down state 
properties such as frequency and dwell time (Palmer et al., 2014; Smith et al., 2013) 
which was also seen within this work. Up and down states are thought to be driven by 
local network activity and synchronised synaptic activity and therefore it is perhaps 
unsurprising that there were no changes to frequency or dwell time. Measures that are 
unrelated to the frequency of the oscillation, but instead measure the shape of how 
the cell responds such as charge or power, do appear to be different with the 
application of MK801. This suggests that NMDAR activity does not alter up state 
frequency or length, but helps shape the envelope of up states in vivo. Spontaneous 
firing frequency was also decreased with intracellular NMDAR antagonist application 
in other studies (Palmer et al., 2014; Smith et al., 2013), which was not seen in this 
work. However, spontaneous AP firing frequency is very low under urethane 
anaesthesia in the somatosensory cortex (Petersen et al., 2003), and so this could be 
due to a low sample of neurons that were actively firing APs. 
Intracellular application of MK801 in vivo has been shown to reduce the slow PSP 
component of evoked whisker stimulation in layer II/III of the somatosensory cortex 
(Gambino et al., 2014). The PSP component was also decreased by application of 
MK801 in this work (Figure 5.14). However, the study by Gambino et al., 2014 also 
observed no change in peak amplitude. This is in direct contrast to the work in this 
chapter, which saw a significant reduction in peak amplitude with MK801 application, 
regardless of whether the response was evoked on an up or down state and was seen 
across multiple stimulations. Other work has observed reductions in the total evoked 
responses including early and late components (Lavzin et al., 2012), and so it is 
possible that this discrepancy is due to alterations in recording conditions or animal 
age (3-4 weeks vs ~5.5M) compared to the Gambino et al., 2014 study. It is also 
possible that these multi-whisker evoked responses cannot be as cleanly differentiated 
into AMPAR and NMDAR components as multi-whisker stimulation would drive a 
barrage of excitatory and inhibitory activity in comparison to the single-whisker evoked 




There was an observable time effect in the evoked response with MK801 application, 
with a significant reduction in AUC seen by 10-15 minutes (total wash in time of 13-18 
minutes; Figure 5.18). However, reductions in the peak amplitude and PSP were 
observed in the overall average evoked responses compared to no change in AUC in 
the average evoked response. As MK801 is use-dependent, perhaps there are 
different pools of NMDA receptors that are active in different components of the 
evoked responses which are blocked differentially. 
5.6 CONCLUSIONS 
Overall, this work reveals a role of NMDARs in shaping up states, whilst confirming no 
change in other up state properties as seen in previous works. Interestingly, these 
properties were not altered in the rTg4510 mice, although other spontaneous 
properties were changed. Overall area of evoked responses in the rTg4510 mice were 
not changed, but the peak subcomponent of this response was significantly increased. 
NMDARs appear to play a role in mediating this peak, with inhibition reducing the 
response in rTg4510 mice to the level of the wildtype response. The synaptic 
population involved in the evoked activity may have differential expression of NMDARs 
in comparison to the local synaptic population, as a compensatory mechanisms in 
response to restructuring and loss of local synaptic connections occurring at this age 
in the rTg4510 mice. Therefore, whilst there is normal function of NMDARs in 
spontaneous activity, there may be abnormal function in evoked responses, 
suggesting a role of NMDAR dysfunction in behaviourally relevant circuit disruption in 
the rTg4510 model. This could be related to differential vulnerability of synaptic 
populations that contribute to this form of activity. In neurodegenerative diseases, this 
could reflect the preservation of some synaptic pathways, and therefore behaviours, 




6 GENERAL DISCUSSION 
6.1 OVERVIEW 
The work within this thesis provides an insight into alterations in glutamatergic synaptic 
and neuronal physiology at an early neurodegenerative phase in tauopathy. Some of 
these measures were also characterised at a more advanced pathological stage to 
highlight how physiology may change with the progression of pathology.  
6.2 KEY FINDINGS: GLUTAMATERGIC RECEPTOR 
IMBALANCE AND LOSS DURING PRODROMAL 
TAUOPATHY 
At the 5-6M age point in rTg4510 mice, previous literature has eluded to an aberrant 
synaptic plasticity phenotype in which synapse density was maintained, with increased 
spine turnover masking the loss of putative mature dendritic spines with the 
replacement of immature filopodia spines (Jackson et al., 2017, 2020; Kopeikina et 
al., 2013a). In addition, it has been suggested that tau pathogenesis induces a loss of 
glutamatergic receptor localisation to the spine with a corresponding loss of function 
(Hoover et al., 2010; Suzuki and Kimura, 2017). Even at this earlier neurodegenerative 
phase of tauopathy in the rTg4510 model, I detected a significant reduction in the 
regional expression of the post-synaptic marker PSD95 and AMPA receptor (AMPAR) 
subunits in rTg4510 mice in Chapter 3. Given this global reduction in AMPAR subunit 
expression, I would have expected a reduction in spontaneous excitatory post-
synaptic current (sEPSC) frequency or an increased NMDA:AMPA receptor ratio when 
in fact the opposite was true, as determined by in vitro functional assessment in 
Chapter 2. 
It is possible that the increased proportion of new, filopodia spines that has been 
previously observed in the rTg4510 model contain silent synapses (i.e. NMDA receptor 
(NMDAR) only) which are not coupled to a pre-synapse, which could explain the 
presumed reduction in NMDAR function in contrast to the limited change in regional 
NMDAR expression seen in Chapters 2 and 3, respectively (Isaac et al., 1995; 
Jackson et al., 2017; Kopeikina et al., 2013a). One could speculate that because of a 
significant reduction in PSD95 and AMPAR expression, filopodia cannot be stabilised 




these processes (Chen et al., 2015b; Granger et al., 2013; Henley and Wilkinson, 
2013). rTg4510 neurons were also shown to have a subtle hyperexcitable phenotype 
in Chapter 2 at ~5.5M (decreased capacitance and depolarised Vm). This may be an 
intrinsic neuronal mechanism to compensate for a loss of putative AMPAR-mediated 
sEPSC activity, which could be clarified by measuring miniature EPSCs. Taking into 
account the increased dendritic restructuring that was also seen in the rTg4510 model 
in Chapter 3, it would seem that there are multiple aberrant plasticity mechanisms 
occurring in the early neurodegenerative phases of tauopathy, to likely compensate 
for loss of synaptic inputs and loss of receptor trafficking to the synapse. 
6.3 KEY FINDINGS: ALTERED ENCODING OF EVOKED 
ACTIVITY IN VIVO DURING PRODROMAL TAUOPATHY 
Strikingly, these somewhat conflicting deficits seen in vitro manifested in vivo as 
increased peak synaptic responses evoked by whisker simulation in ~5.5M rTg4510 
mice, shown in Chapter 5. These responses were sensitive to the NMDAR antagonist 
MK801, while features of spontaneous network activity were seemingly unimpaired. 
This would suggest increased evoked NMDAR activity, contradicting what I would 
have expected from the in vitro assessment of glutamatergic synaptic function. 
However, the in vivo responses were evoked by simultaneous stimulation of multiple 
whiskers, which would drive a barrage of excitatory and inhibitory activity, compared 
to the in vitro assessment in which layer IV to layer II/III glutamatergic synapses were 
selectively driven within an individual barrel field. Therefore, these responses could be 
interpreted as the global response to incoming sensory information by the cell, where 
there is a culmination of tauopathy-induced differences in synaptic and neuronal 
function within an intact network. For example, this could be a product of increased 
proximal dendritic branching with more NMDAR rich, filopodia-like synapses that when 
stimulated facilitates the evoked response. In addition, horizontal transcolumnar inputs 
synapse differentially with apical regions of the dendritic arbor of layer II/III pyramidal 
neurons in comparison to the basal dendritic layer IV inputs studied in vitro (Feldmeyer 
et al., 2002; Lübke et al., 2000). Therefore, the observed dendritic reshaping may skew 
the balance of sensory integration towards horizontal inputs which would be stimulated 




glutamatergic receptor expression and function seems to manifest as increased peak 
evoked activity in this assay, likely altering synaptic encoding of sensory information. 
To my knowledge, no other studies have used in vivo whole-cell recordings to 
investigate synaptically-driven evoked activity within a dementia model. This work 
highlights the importance of quantifying subthreshold dynamics to understand how 
changes in synaptic and intrinsic neuronal properties contribute to aberrant cellular 
processing of information. For example, if another in vivo electrophysiology technique 
such as extracellular single unit recordings had been used, these more subtle 
subthreshold deficits might not have been apparent, as this stimulation paradigm 
infrequently evokes action potentials.  
6.4 KEY FINDINGS: FURTHER GLUTAMATERGIC 
SYNAPTIC DYSFUNCTION WITH THE PROGRESSION 
OF NEURODEGENERATIVE TAUOPATHY 
Between 5.5M and 7.5M of age in the rTg4510 model, it has been evidenced that there 
is progressive atrophy of the cortex and hippocampus (Blackmore et al., 2017; 
Ramsden et al., 2005; SantaCruz et al., 2005; Spires et al., 2006; Yue et al., 2011). 
Therefore, when comparing between the ~5.5M and ~7.5M age groups in this work, it 
is likely that some of the differences seen are due to progressive neurodegeneration 
within the somatosensory cortex. Within the somatosensory cortex, NMDAR 
expression was significantly reduced (reduced GluN1 subunit expression) with further 
reductions of PSD95 and AMPAR subunit expression in rTg4510 mice at 7.5M, shown 
in Chapter 3. Given the role NMDARs play in synaptic plasticity, one could hypothesise 
that the reduction in NMDAR expression would relate to a reduction in synaptic 
plasticity, including the formation and stabilisation of new dendritic spines. Within the 
rTg4510 model at more advanced stages of neurodegeneration, there are large 
reductions in synapse density and synaptic markers which would fit with this idea 
(Crimins et al., 2011, 2012; Jackson et al., 2017; Kopeikina et al., 2013a). Functional 
assessment of synapses in Chapter 2 suggested that putative synaptic AMPAR-
mediated currents (sEPSCs) were reduced in frequency with a balanced NMDA:AMPA 
receptor ratio at ~7.5M in the rTg4510 model, which is contrary to the dysfunction seen 
at the ~5.5M age point in this model. With the significant loss of regional NMDAR 




converse would have been expected.  It is also very possible that different synaptic 
pathways or synapses are differentially affected, such as thalamocortical synapses 
compared to layer IV synapses. Measuring receptor expression at a finer resolution 
using histological techniques, and perhaps examining glutamatergic receptor 
expression at individual synapses using techniques such as super-resolution imaging, 
would resolve whether local receptor expression and localisation at the synapse is 
altered. Differences in local expression and synaptic localisation may cause this 
imbalance of function and global expression, with impairments in synaptic receptor 
localisation already shown in cultured rTg4510 neurons (Hoover et al., 2010).  
6.5 IMPLICATIONS FOR UNDERSTANDING TAUOPATHY-
MEDIATED DYSFUNCTION  
This work has highlighted the importance of the synapse in maintaining function in 
tauopathy-mediated neurodegeneration. The synapse plays a vital role in neuronal 
communication and underpins evoked network activity. Even with the dramatic 
reductions of glutamatergic receptor expression, there was maintained synaptic and 
network activity early in the neurodegenerative process (~5.5M age point). Between 
early and later neurodegenerative phases, there were diverging alterations in 
glutamatergic receptor expression and function, and further characterisation of how 
this leads to or predicts synaptic degeneration seems like a critical and unanswered 
question.  
Measuring neuronal and synaptic function in models of tauopathy is fundamental to 
deconstructing mechanisms of aberrant function prior to degeneration, with this type 
of intracellular electrophysiological characterisation not possible in humans. For 
example, whilst I saw reductions in AMPAR subunit expression in the rTg4510 mice, 
this did not manifest as a reduction in putative AMPAR-mediated function in vitro. Of 
course, different methodologies were used to generate these findings, and comparing 
single cell data to regional protein expression is not exact. Therefore, whilst it is 
important to understand pathology-driven molecular changes within the brain, this may 
not manifest in the expected functional disruption. In fact, the characterisation of 
NMDAR function in vitro suggested reduced NMDAR activity in ~5.5M rTg4510 mice, 
while there was an increase in evoked synaptic activity which had a large NMDAR-




using reduced systems such as brain slices may not always translate to the in vivo 
setting, in which diverse sources of excitatory and inhibitory innervation remain intact. 
Therefore, care should be taken to understand what changes are pathogenic, which 
are compensatory, and how these changes manifest in vivo. 
6.6 LIMITATIONS OF THE WORK 
6.6.1 Single cell portrayal of a global phenomenon? 
Global measures such as reductions in cell density, or total pathological burden within 
a region, are examples of neuropathological diagnostic criteria used to assess the 
impact of tauopathy post-mortem, inferring a causal link between this and behavioural 
change (Irwin, 2016; Kishi et al., 2015; Lao et al., 2019). However, this generally 
assumes a similar expression of pathology within the population of measured cells 
within a region. Within this population, there is a large variability between the 
pathological state of each cell with different cells being further along the 
neurodegenerative process, and some never undergoing neurodegeneration (Crimins 
et al., 2011, 2012; Rocher et al., 2010). Some cell types, such as excitatory neurons, 
have also been highlighted as particularly vulnerable compared to others (Fu et al., 
2018, 2019). Therefore, it is truly important to understand synaptic and neuronal 
dysfunction at a single cell level, which enables the analysis of cell-to-cell variability in 
expression of tauopathy-driven neurophysiological phenotypes. 
The majority of my recordings were performed early in the neurodegenerative phase 
of tauopathy in the rTg4510 model, and so the number of atrophic cells should be low 
at this disease stage (Blackmore et al., 2017; Crimins et al., 2011; Ramsden et al., 
2005; SantaCruz et al., 2005). However, even at this stage, two recorded cells may 
have very different cellular phenotypes with different pathological burdens. Using 
visualised whole-cell patch clamp recordings can also lead to targeting healthier cells 
for recording. However, care was taken to avoid this bias in this work as exclusion 
criteria was based on technique related measures such as series resistance and not 
cell health measures such as membrane potential (unless severely depolarised).  
Trying to ascribe a defined functional change observed from one cellular subset to a 
whole network when each cell harbours differing phenotypes is difficult. I have 
identified various glutamatergic receptor dysfunctions within a subset of cells in layer 




alterations that could drive altered behavioural phenotypes? In tauopathies, some 
behaviours or networks have a larger tolerance to cell loss before showing alterations 
and so these alterations in glutamatergic signalling could be an early or late 
pathogenic change for these specific cells within the network (Crimins et al., 2013; 
Perneczky et al., 2019; Stern, 2012). This could also be a compensatory mechanism 
by healthier cells to account for more pathogenic cells in the local network. This should 
be considered when discussing therapeutics that target identified single cell 
dysfunction, as this may inadvertently target compensatory “healthy” cells that show a 
tauopathy-induced non-pathogenic cellular phenotype.  
6.6.2 Can mice model dementia? 
Rodents  are a key model in neuroscience research, with a wide array of genetic and 
molecular tools, and broadly similar genetics and physiology, making them an ideal 
model organism to study normal and disease neurophysiology (Bryda, 2013; 
Ellenbroek and Youn, 2016). However, rodent models of dementia are limited as they 
do not fully recapitulate the causal diseases. In fact, research in rodent models of 
dementia has so far failed to yield successful drugs in the clinic for dementia, thought 
to be due in part to poor model translatability (Dawson et al., 2018; Drummond and 
Wisniewski, 2017; Mullane and Williams, 2019; Onos et al., 2016). 
Rodent models of dementia typically harbour genetic mutations from familial 
dementias, the incidence of which is dramatically less than the sporadic forms 
(Dawson et al., 2018; Götz et al., 2018). These models are qualified as good models 
based on the expression of the various pathologies that are present within the human  
disease, but as a field we are still unsure which forms of pathology are toxic or 
protective (Cowan and Mudher, 2013; D’Orange et al., 2018; Kuchibhotla et al., 2014; 
Spires-Jones et al., 2011). Within tauopathy research specifically, it is also important 
to note that mice lack full tau isoform expression found within humans (Dawson et al., 
2018; Götz et al., 2018). This can be compensated for with the expression of human 
tau isoforms within the mouse line, but this may not sufficiently recapitulate human tau 
physiology (Andorfer et al., 2003; Saito et al., 2019).  
In addition, the biggest risk factor for dementia is older age, and thus using rodent 
models with comparatively short lifespans can be a major limitation for modelling 




to be mature adults from 3M of age, with the equivalent of old age in mice being from 
18M, with mice over 24M considered to be “very old” (Flurkey et al., 2007). However, 
all of these age points are notably shorter than the lifespan of a human although there 
are equivalent age points. Within the rTg4510 model specifically, there is a rapid 
accumulation of pathology and degeneration that occurs within months, compared to 
a disease that takes years to precipitate from pathology onset. Therefore, we may be 
missing key changes that occur with aging that we are currently not emulating with this 
model. Whilst rodent models have their limitations, there is no such thing as the perfect 
model for human diseases and so rodent models are used to address specific 
experimental hypothesises that cannot currently be explored in humans. 
6.6.2.1 Limitations of the rTg4510 model of tauopathy 
rTg4510 mice overexpress the tau P301L mutation up to 13x the typical expression 
level of murine tau, with neurodegeneration first observed in the cortex and 
hippocampus at 5/6M (Ramsden et al., 2005; SantaCruz et al., 2005). This 
overexpression is considered to be highly influential in the resulting pathological 
phenotype seen (Blackmore et al., 2017). Other models that express mutant tau 
isoforms at more physiological levels show a more variable and delayed 
neurodegenerative phenotype in comparison (Andorfer et al., 2003; Gamache et al., 
2019; Koss et al., 2016; Saito et al., 2019). For this work, utilising the robust and rapid 
progression of pathology allowed for assessment of age points that were highly likely 
to be at a specific disease phase. However, this may not be as physiologically relevant 
to tauopathy as some of the other rodent models, due to this high overexpression of 
mutant tau. 
Recent work has suggested that the pronounced neurodegenerative phenotype seen 
in rTg4510 mice is not purely associated with tau overexpression, but is also linked to 
genetic disruption at the site of transgene insertion (Gamache et al., 2019; Goodwin 
et al., 2017). However, mutant tau expression within this model is repressible, and 
work using doxycycline to repress transgene expression provides an appropriate 
method to assess the contribution of off-target genetic effects. In studies using 
doxycycline treatment, early repression of tau overexpression was sufficient to prevent 
neurodegeneration and lowered tau pathology (Blackmore et al., 2017; Holton et al., 
2020; Ramsden et al., 2005; SantaCruz et al., 2005; Wang et al., 2018). In addition, 




still caused progressive tauopathy and neurodegeneration, albeit at a slightly later age 
than in the rTg4510 mice (Gamache et al., 2019). Therefore, whilst I cannot conclude 
for certain that the results I have observed are not influenced by off-target genetic 
effects, it is likely that pathological tau is the predominant driver of the observed 
phenotypes, particularly in experiments conducted at an age point known to precede 
the onset of cortical neurodegeneration in rTg4510 mice (Blackmore et al., 2017; 
Ramsden et al., 2005; SantaCruz et al., 2005).  
6.7 FUTURE DIRECTIONS 
There are still some key unanswered questions that are left to be addressed from this 
work. Whilst not exhaustive, some of the more pertinent suggestions are: 
 How does altered glutamatergic receptor function and expression 
manifest at individual synapses? 
Whilst regional synaptic marker and receptor expression were quantified, this 
could not be directly linked to the single cell recordings. In addition, synaptic 
function could only be ascertained as an aggregate value within individual 
neurons, skewed to activity from more proximal spines (Williams and Mitchell, 
2008). Post hoc immunohistochemical analysis, perhaps combined with a 
technique such as super-resolution or expansion microscopy, could be used to 
quantify synaptic glutamatergic receptor expression and localisation (Chen et 
al., 2015a). This would confirm whether lowered glutamatergic receptor 
expression and altered receptor function translates to a different receptor 
composition within the synapse. An interesting extension of this work would be 
to examine whether there was a difference in expression and localisation on 
proximal compared to distal spines as a consequence of the observed dendritic 
restructuring in the rTg4510 cells.  
 When do the observed changes in glutamatergic receptor expression and 
function first emerge in rTg4510 mice, and are they specifically driven by 
cellular or synaptic tauopathy? 
At the early neurodegenerative age point in rTg4510 mice (~5.5M), there were 
already apparent changes in glutamatergic receptor function and synaptic 
marker expression. Examining this at an earlier age would confirm when this 




marker expression is lowered before or after glutamatergic receptor alterations. 
Furthermore, the possibility that some phenotypic changes within the rTg4510 
model that are related to the off-target gene disruption cannot be ruled out 
(Gamache et al., 2019). It would be useful to confirm whether the detected 
alterations were due to the overexpression of mutant tau, which could be 
controlled for by using doxycycline treated rTg4510 mice as comparators which 
would repress pathology expression (Blackmore et al., 2017; Ramsden et al., 
2005; SantaCruz et al., 2005). 
 What is the role of pathological burden on the observed cellular 
phenotype? 
Tau pathology was detected and used to help confirm genotype in the in vitro 
electrophysiology characterisation. However, the amount of tau pathology in 
the local vicinity of recorded neurons was not directly quantified. There may be 
differing functional phenotypes observed with variations of the local 
pathological burden. Also, none of the recorded cells co-expressed markers of 
tau pathology (MC-1) and so using other markers such as Thioflavin-S which 
bind to a different tau structure would help confirm this result. For future 
experiments, fluorescent tau markers such as Thioflavin-S could be used to 
specifically target cells with that harbor certain pathology isoforms to ensure the 
inclusion of tau positive cells (de Calignon et al., 2009; Spires-Jones et al., 
2008). An alternative way to assess single cell pathology following recordings 
would be to perform patch-seq to quantify the expression of all tau species 
expressed within the neuron (Cadwell et al., 2016; Fuzik et al., 2016). 
 What is the impact of altered functional encoding on behavioural output? 
The in vivo whole-cell recordings revealed altered functional encoding of 
whisker-evoked responses in the rTg4510 model. It would be interesting to see 
if this affected sensory discrimination for example, by performing awake 
recordings with the presentation of different textured materials. Another way to 
examine this would be to measure whether this pathway was capable of 
undergoing plasticity induced changes such as LTP, particularly as 
glutamatergic receptor function and mobility is vital for plasticity mechanisms. 
This could be investigated in vitro, or in vivo using whisker stimulation (Bartram 




these behavioural outputs were altered, an extension of this work could then be 
to use an NMDAR antagonist for example, to attempt to normalise aberrant 
activity. 
6.8 FINAL CONCLUSIONS 
The work presented in this thesis has provided novel insights into physiological 
dysfunction at early and more advanced neurodegenerative phases of tauopathy. In 
the somatosensory cortex of rTg4510 mice, there are clear but discrepant deficits in 
glutamatergic receptor expression and function, that precipitate as altered functional 
responses to sensory stimulation early in the neurodegenerative process. 
Furthermore, with the progression of pathology and neurodegeneration, novel deficits 
emerge whilst others disappear suggesting transient alterations in glutamatergic 
receptor function may be critical to help preserve function at these earlier disease 
phases in tauopathy. Targeting these mechanisms may provide an opportunity for 
prolonging symptomatic decline and therapeutic recovery prior to overt cell loss in 
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